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The Keap1-Nrf2 pathway has been identified as a key regulator of the cytoprotective 
response of cells when exposed to oxidative stress. The induction of detoxification 
gene products by increasing the activity of the transcription factor nuclear factor 
erythroid 2-related factor 2 (Nrf2) can be used as a chemopreventive approach to 
cancer treatment. Natural and synthetic agents can disrupt the interaction between 
the substrate adaptor protein Kelch-like ECH-associated protein 1 (Keap1) and 
Nrf2, which allows nuclear Nrf2 translocation and accumulation. The aim of this 
project was to characterize the behaviour of direct and indirect Nrf2 inducer 
molecules by applying several biological methods that were specifically optimised or 
developed for the Keap1-Nrf2 pathway. Potential inhibitors of the Keap1-Nrf2 
complex were screened using a cellular NQO1 induction assay and an in vitro 
fluorescence polarisation (FP) assay for direct inhibitors. A novel in vitro Förster 
resonance energy transfer (FRET) assay was developed as an additional screening 
tool to identify Keap1 binding partners. Further biological evaluation was conducted 
with the most promising molecules using western blotting analysis and a new 
intracellular Nrf2 staining method for flow cytometry. The natural product and 
indirect Nrf2 inducer sulforaphane was used as a reference compound (NQO1 CD = 
0.4 µM). From a library of Michael acceptor-containing cyclohexadienone 
analogues, a 3-chlorophenyl compound (6.49) was identified as a potent inducer 
(NQO1 CD = 1 µM). Stearoyl-capped Nrf2-derived peptides were potent inhibitors of 
the direct Keap1-Nrf2 protein-protein interaction and showed promising cell 
penetrating properties. Direct inhibitor small molecules included two bis-
sulphonamide derivatives (7A4, NQO1 CD = 8 µM and 7B1, NQO1 CD = 4 µM) and 
a 1,2,3-triazole derivative (7C55, NQO1 CD = 0.6 µM) with FP IC50 values in the 
nano- to micromolar range. The selectivity of the compounds was assessed by 
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ABC – ATP-binding cassette 
AhR – Aryl hydrocarbon receptor 
Akt – Alpha serine or threonine-protein kinase 
α-MEM – Alpha modified eagle medium 
AOS – Antioxidant 
APS – Ammonium persulfate 
ARE – Antioxidant Response Element 
Arg – Arginine 
ARNT– AhR nuclear translocator 
ATCC – American Type Culture Collection 
ATP – Adenosine triphosphate 
Asp – Aspartate 
BHA – Butylated hydroxyanisole 
Bmax – Maximum number of binding sites 
BP – Band Pass 
BRCA1/BRCA2 – Breast cancer type 1/2 susceptibility protein 
BSA – Bovine serum albumine 
BTB – Broad complex Tramtrack Bric-a-brac  
bZIP – Basic Leucine Zipper Domain 
CD – Concentration to double the NQO1 enzymatic activity 
CDDO – 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid 
cDNA – Complementary deoxyribonucleic acid 
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CER – Cytoplasmic extraction reagent 
CNC – Cap ‘n’ collar 
Cpds – Compounds 
CUL3 – Cullin 3 
CYP1A1 – Cytochrome P450, family 1, subfamily A, polypeptide 1 
DAPI – 4',6-diamidino-2-phenylindole 
DAS – Diallyl sulfides 
DGR – Double glycine repeat 
DMEM – Dulbecco's modified eagle medium 
DMF – N,N’-dimethylformamide 
DMSO – Dimethyl sulfoxide 
DNA – Deoxyribonucleic acid 
DSF – Differential scanning fluorimetry 
DTT – Dithiothreitol 
ECACC – European Collection of Cell Culture 
eCFP – Enhanced cyan fluorescent protein 
ECL – Enhanced chemiluminescence 
EDTA – Ethylenedinitrilotetracetatic acid 
EGCG – Epigallocatechin-3-gallate 
ELISA – Enzyme-linked immune assay 
EMEM – Eagle minimal essential medium 
EMSA – Electrophorectic mobility shift assay 
ERK – Extracellular-signal-regulated kinase 
eYFP – Enhanced yellow fluorescent protein 
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FAD – Flavin adenine dinucleotide disodium salt hydrate 
FBS – Fetal bovine serum 
FD – Fold difference or fold change 
FDA – Food and drug administration 
FE – FRET efficiency 
2D-FIDA – Two-dimensional fluorescence intensity distribution analysis  
FITC – Fluorescein isothiocyanate 
FP – Fluorescence polarisation 
FRET – Förster resonance energy transfer 
FSC – Forward scattered light 
G – Gravitational force 
GFP – Green fluorescent protein 
Glu – Glutamate 
GSH – Glutathione 
GST – Glutathione S-transferase 
G6P – Glucose-6-phosphate 
G6PD – Glucose-6-phosphate dehydrogenase 
HEK293 – Human embryonic kidney cells 293 
HeLa – Henrietta Lacks 
His – Histadine 
HO-1 – Hemeoxygenase 1 
HPLC – High-performance liquid chromatography 
HRP – Horseradish peroxidase 
Hsp90 – Heat shock protein 90 
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HTS – High throughput screening 
IC50 – Inhibition constant 
IMAC – Immobilised metal ion affinity chromatography 
IPTG – Isopropylthio-β-D-galactosidase 
ITC – Isothermal calorimetry 
ITCs – Isothiocyanates 
IVR – Intervening region 
JNK – Jun N-terminal kinase 
Kan – Kanamycin 
Kd – Dissociation constant 
Keap1 – Kelch-like ECH associated protein 1  
LB – Luria Bertani 
MAPK – Mitogen-Activated Protein Kinase 
MCF-7 – Michigan Cancer Foundation-7 
 (n)MFI – (normalised) median fluorescence intensity 
mRNA – Messenger ribonucleic acid 
MTT – Thiazolyl blue tetrazolium Bromide  
MWCO – Molecular weight cut off 
NER – Nuclear extraction reagent 
NMR – Nuclear Magnetic Resonance 
NADP(H) – Nicotinamide adenine dinucleotide phosphate 
NQO1 – NAD(P)H:quinone oxidoreductase 1 
Nrf2 – Nuclear transcription factor erythroid 2p45 (NF-E2)-related factor 
PAH – Polycyclic aromatic hydrocarbons 
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PBS – Phosphate buffered saline 
PCR – Polymerase chain reaction 
PFA – Paraformaldehyde 
Pfu – Pyrococcus furiosus 
PKC – Protein kinase C 
PPI – Protein-protein interaction  
PI3 – Phosphatidylinositol-4,5-bisphosphate 3-kinase 
RNS – Reactive nitrogen species 
ROS – Reactive oxygen species 
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RT – Room temperature 
SAR – Structure-activity relationship 
SDS – Sodium dodecyl sulphate 
SDS-PAGE – Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SE – Sensitised emission 
shRNA – Short hairpin ribonucleic acid  
siRNA – Short interference ribonucleic acid 
SPR – Surface plasmon resonance 
SRB – Sulforhodamine B 
SSC – Side scattered light 
TAT – Transactivator of transcription 
TBE – Tris-Borate-EDTA buffer 
tBHQ – tert-Butylhydroquinone  
TCA – Trichloroacetic acid 
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TCDD – 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
TEMED – N,N,N',N'-tetramethylethylene diamine 
TEV – Tobacco Etch Virus 
Tm – Melting temperature 
TMB – Tetramethylbenzidine 
Tris – Tris(hydroxymethyl)aminomethane 
TS – Tris sodium 
Tween®-20 – Polyethylene glycol sorbitan monolaurate 
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1.1 Cancer statistics 
 
Cancer is one of the key causes of world-wide mortality and was responsible for 
more than one in four deaths in the UK in 2011 1. Moreover, every two minutes in 
the UK somebody receives the diagnosis of cancer 2. As a result of improvements in 
public awareness and screening methods, the overall mortality rate is decreasing 1. 
However, the incidence rates have risen by 43% in females and 23% in males since 
the mid-1970s 3. For example, the frequency of people diagnosed with cancers of 
the kidney, liver, skin, oral and womb have increased. These cancers could be 
associated with lifestyle habits, such as smoking and high alcohol, salt and fat 
intake 4; poor lifestyle factors were related to 34% of cancers in 2010 in the UK 5. A 
study from 2012 6 predicted that the worldwide cancer incidence rate will rise from 
12.7 million new cases in 2008 to 22.2 million by 2030. The cost of cancer care in 
the EU has been estimated to be 23.2 billion euros in 2009 alone 7. Considering the 
widespread impact of this disease on individuals, their families and on society, there 
is a large research effort targeted at finding effective treatments.  
 
1.2 Current cancer treatments 
 
The choice of cancer therapy often depends on the type of cancer that is diagnosed, 
with surgery, chemotherapy and radiotherapy being the most common treatments 8. 
Surgery can be used as a preventive measure to remove pre-cancerous tissue such 
as a mole that is changing in appearance or a polyp found in the colon 9. Moreover, 
a mastectomy may prevent the development of breast cancer in women with 
inherited mutations in BRCA1 or BRCA2 genes 9. Exploratory surgery can also be 
applied as a tool to diagnose or stage cancer 9. Curative surgery is often used to 
remove cancerous tissue as well as normal tissue to minimise the risk of cancer 
relapse and is often practiced alongside chemo- or radiotherapy 9. Chemotherapy 
was first used in the 1940s by administration of nitrogen mustards and antifolate 
drugs to treat Hodgkin’s lymphoma 10. However, modern chemotherapy has 
developed over the years into the use of different classes of cytotoxic drugs such as 
alkylating agents, antimetabolites, anthracyclines, topoisomerase inhibitors, mitotic 
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small molecules such as glutathione (GSH) are responsible for the conjugation of 
polar groups to the phase I activated metabolites 26. Phase II enzymes are 
associated with the detoxification of xenobiotics by increasing their hydrophilic 
character and by preparing them for excretion via ATP-binding cassette (ABC) drug 
transporters found in the kidney, liver and intestine (phase III) 25. Several blocking 
agents were found to increase the detoxification of pro-carcinogens by up-regulating 
the expression of phase II enzymes 27. At the genetic level, the antioxidant response 
element (ARE) is a DNA sequence (5′-TGACNNNGC-3′) 28 that lies upstream of the 
promoter region of several phase II gene products, including GSTs, NQO1, UGT 
and HO-1 27. The transcription of ARE-driven genes is largely controlled by the 
transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2) and its regulator 
protein Kelch-like ECH-associated protein 1 (Keap1) 27, 29.  
 
1.4 Keap1 – Nrf2 pathway 
 
The nuclear factor erythroid 2-related factor 2 (Nrf2) (66 kDa) is a basic leucine 
zipper (bZip) transcription factor that is a member of the cap ‘n’ collar (CNC) family 
30. The basic leucine zipper domain is a DNA binding domain that is able to bind to 
AREs that are positioned in the upstream regulatory regions of cytoprotective 
genes. The bZip domain is part of the Neh1 domain of Nrf2. The transcription factor 
contains five other highly conserved domains, Neh2 – Neh6 (Figure 1.4). The Neh2 
domain binds to the Kelch domain of Kelch-like ECH-associated protein 1 (Keap1) 
via high affinity motif ETGE and weaker affinity motif DLG, both Neh1 and Neh3 
domains are responsible for the heterodimerisation with small musculoaponeurotic 
(Maf) proteins, the domains Neh3 - Neh5 recruit different co-activators for the 
activation of transcription 31-32 and the Neh6 domain mediates the degradation of 
Nrf2 via a redox insensitive mechanism 33. Recently, it was found that Nrf2 protein 
levels are regulated by two β-transducin repeat-containing protein (β-TrCP) binding 
sites in the Nrf2-Neh6 domain 34. Chowdry et al. 34 demonstrated a decrease in 
β-TrCP mediated ubiquitination of Nrf2 upon deletion of either recognition motif. 
Moreover, glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase, 
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Table 1.1: Genes regulated by Nrf2 in mouse liver, lung and small intestine. Adapted from 44.  
 
 
Biochemical Function Name Symbol 
Antioxidant: GSH synthesis  
and inactivation of ROS 
Cystine transporter Slc7a11 
Glutamate cysteine ligase  
catalytic subunit 
Gclc 
Glutamate cysteine ligase  
modifier subunit 
Gclm 
Glutathione peroxidase 2 Gpx2 
Glutathione reductase 1 Gsr1 
Peroxiredoxin 1 and 6 Prxd1/6 
Antioxidant: protein thiol homeostasis Sulfiredoxin 1 Srx1 
Thioredoxin 1 Txn1 
Thioredoxin interacting protein Txnip 
Thioredoxin reductase 1 TrxR1 
NADPH regeneration enzymes Glucose-6-phosphate 
dehydrogenase 
G6pdh 
Malic enzyme 1 Me1 
6-Phosphogluconate dehydrogenase Pgd 
Metal-binding proteins Ferritin heavy and light subunit Fth/l 
Metallothionein 1 and 2 Mt1/2 
General cytoprotection against stress Heme oxygenase 1 Hmox1 
Heat shock protein 40/84/86 Hsp40/84/86 
Receptors and transcription factors Cluster of differentiation 36 CD36 
Very-low-density lipoprotein VLDL 
MafF and K protein MafF/K 
Nuclear factor-erythroid 2-like 2  
and 3 
Nrf2/3 
Arylhydrocarbon receptor Ahr 
Peroxisome proliferator-activated 
receptor gamma and delta 
PPARγ/δ 
Phase I drug oxidation/reduction 
enzymes 
Alcohol dehydrogenase 7 ADH7 
Aldehyde dehydrogenase-3 ALDH3 
Aldo-keto reductase 1B, 1C  
and 7A families 
Akr1B/1C/7A 
Carbonyl reductase 1 and 3 Cbr1/3 
Carboxyl esterase CES 




Flavin-containing mono-oxygenase 3 FMO3 
Microsomal epoxide hydrolase Eph1 
NAD(P)H:quinone oxidoreductase 1 Nqo1 
Prostaglandin reductase 1 Ptgr1 
Phase II drug-conjugating enzymes Glutathione transferase class Alpha Gsta1/2/3/4 
Glutathione transferase class Mu Gstm1/2/3/4/5/6 
Glutathione transferase class Pi Gstp1 
Glutathione transferase class Theta Gstt1/2/3 
Microsomal glutathione  
transferase 3  
MGST3 
Sulfotransferase 3A family Sult3a 
UDP-glucuronosyl transferase  
2B enzymes 
UGT2B 
Transporters Multi-drug resistance-associated 
protein 2, 3, 4, 5 and 12 
Mrp2/3/4/5/12 
Neutral amino acid transporter  mASCT1 
Solute carrier family 2, 5, 6, 39 SLC2/5/6/39 
Protein degradation α1-antitrypsin proteinase inhibitor A1AT 
26S proteasome α subunits Psma1/4/5/6 
26S proteasome β subunits Psmb1/2/3/4/5/6 
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1.5 Induction or inhibition of the Keap1-Nrf2 pathway? 
 
Studies with Nrf2-knockout and null mice have revealed the significance of this 
transcription factor in controlling ARE-mediated gene expression 27. These mutant 
mice demonstrated reduced levels of detoxification enzymes, an increased level of 
DNA adduct formation and an increased predisposition towards the development of 
tumours following exposure to carcinogens 27, 51. Moreover, the effectiveness of 
numerous chemopreventive agents is dependent on a fully functional Keap1-Nrf2 
pathway 52. Mutations in Nrf2 and/or Keap1 have been observed in certain (human) 
cancers, which were typically found in or near the DLG and/or ETGE motif in the 
Nrf2 Neh2 domain and in the Keap1 Kelch and/or IVR domain 53-55. These mutations 
may compromise the Keap1-Nrf2 PPI and result in constitutive Nrf2 activation, 
which can prime resistance towards chemotherapy and radiotherapy 56-57. Moreover, 
Nrf2 up-regulation in cancerous cells can increase the expression of drug efflux 
pumps, hence promoting chemotherapy resistance 58. The dual function of Nrf2 in 
chemoprevention and tumourigenesis presents a challenge in Nrf2 research; 
induction of Nrf2 activity may be beneficial for non-cancerous cells by protecting 
them against cellular damage, whereas inhibition of its function may contribute to 
enhancing the effectiveness of chemo- and radiotherapy 59-61. The research 
presented here only focusses on the role of Nrf2 in chemoprevention.   
 
1.6 Inducers of the Keap-Nrf2 mediated cytoprotective response 
 
The Keap1-Nrf2 pathway can be induced by numerous cellular stresses (e.g. 
oxidative stress, endoplasmic reticulum stress and shear stress) and both 
endogenous (ROS and RNS) and exogenous ARE inducer molecules 35. The 
exogenous inducers are either from natural or synthetic origin. Keap1 acts as a 
sensor protein that contains highly reactive cysteine residues. Under basal 
conditions these residues are in a reactive state (S- rather than SH) due to their low 
pKa values 40. Most ARE inducers are indirect inhibitors of the Keap1-Nrf2 PPI by 
forming covalent adducts with the sulfhydryl groups of cysteines in Keap1 via 
alkylation or oxidation processes 52. The soft electrophilic nature of these molecules 
makes them selective for reacting with soft nucleophiles (sulfhydryl groups of 
cysteine) rather than hard nucleophiles (amino and hydroxyl groups). Indirect Nrf2 
inducers react with diverse cysteine residues in Keap1 depending on their structure. 
They are generally divided into ten distinct groups based on their chemical structure 
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and interaction or reaction with cysteine sulfhydryl groups: isothiocyanates (ITCs) 
and sulfoxythiocarbamates, dithiolethiones and diallyl sulfides (DAS), Michael 
acceptors, oxidizable diphenols and quinones, vicinal dimercaptans, trivalent 
arsenicals, selenium-based compounds, polyenes, hydroperoxides and heavy 
metals and metal complexes 52. The most well-known indirect Nrf2 inducers include 
sulforaphane, oltipraz, tBHQ and CDDO and are currently undergoing clinical trials 






Figure 1.12: Chemical structure of sulforaphane 62. 
 
As it was recognised that phase II enzyme upregulation is a key step in the 
prevention of cancer initiation 63-64, Prochaska and coworkers developed a cellular 
assay to identify inducers of the phase II enzyme NQO1 in Hepa1c1c7 cells 65. 
NAD(P)H:quinone oxidoreductase-1 (NQO1) is a flavoprotein that facilitates the two-
electron reduction of quinones to hydroquinones. Hydroquinones are subsequently 
subjected to glucuronidation (addition of a glucuronic acid), which increases their 
water solubility and allows for excretion from the body 65. NQO1 is officially a phase 
I drug-metabolising enzyme according to the toxicological classification 66. However, 
due to its cytoprotective properties the enzyme will be referred to as a phase II 
enzyme in this thesis. Up-regulation of NQO1 is associated with the induction of 
other phase II enzymes including, UDP-glucuronosyltransferase (UGT) and 
glutathione S-transferases (GSTs). The NQO1 enzyme induction assay was applied 
to screen extracts from diverse cruciferous vegetables for their ability to activate the 
phase II enzyme after epidemiological evidence emerged that suggested a positive 
correlation between the consumption of vegetables and a reduction in the 
occurrence of carcinogenesis 67. Extracts from broccoli and brussel sprouts were 
found to be among the most potent inducers. Sulforaphane (Figure 1.12) was 
isolated and identified as the main compound responsible for the up-regulation of 
NQO1 68. Sulforaphane is released from disrupted plant cells by the enzyme 
myrosinase, which hydrolyses the sulforaphane precursor glucoraphanin, a 
glucosinolate 69. Sulforaphane is part of the isothiocyanate (ITC) group of chemicals 
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in which the protective effect is thought to be derived from their electrophilic nature; 
the central carbon atom can react with the sulfhydryl groups of cysteine residues in 
Keap1 to form an adduct.  
 
Evidence suggests that sulforaphane covalently modifies cysteine residues in 
Keap1, thereby allowing nuclear Nrf2 translocation 40, 70. It is proposed that 
sulforaphane modifies cysteine residue C151 in the IVR domain of Keap1, thereby 
preventing the ubiquitination of Nrf2 71. Nuclear accumulation of Nrf2 by 
sulforaphane was abolished following mutation of C151 of Keap1 to a serine residue 
71. Moreover, it has been suggested that the reaction of sulforaphane with C151 is 
reversible 70. Although sulforaphane has multiple targets and effects (apoptosis, cell 
cycle arrest, anti-angiogenesis and inhibition of metastasis) it reacts most readily 
with Keap1 at a low concentration range 72. Sulforaphane is a monofunctional 
inducer of Nrf2 because it activates phase II enzymes without involvement of the 
AhR-dependent CYP450 enzyme battery 68. Numerous case control and cohort 
studies have shown a reduction in the development of various cancers following the 
consumption of broccoli preparations 73. Consequently, the use of sulforaphane as a 
chemopreventive compound is currently under investigation in several phase II 
clinical trials 73. As sulforaphane was one of the first Nrf2 inducers to be discovered, 
it is one of the most extensively studied molecules. Hence, sulforaphane was 
chosen as a reference compound or positive control for the evaluation of other Nrf2 






Figure 1.13: Chemical structure of oltipraz 62. 
 
Oltipraz or 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Figure 1.13) is a synthetic 
dithiolethione that shares structural similarities with natural occurring dithiolethiones. 
Initially, oltipraz was brought onto the market as an anti-schistosomiasis drug 74. 
Evidence emerged that the compound exhibited cytoprotective properties by up-
regulation of phase II enzymes including, UDP-glucoronosyltransferase, glutathione 
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S-transferases, GSH and glutamate cysteine synthetase 75. Moreover, it was found 
that oltipraz is protective against the development of cancer in mammary, lung, 
hepatocellular and colon tumour models 75. Moon et al. 76 demonstrated a reduction 
in carcinogenesis of the bladder in mice, but this effect was not observed in Nrf2-
null mice, which indicates the involvement of the Keap1-Nrf2 pathway. 
Dithiolethiones such as oltipraz, are sulphur containing compounds that are 
associated with enhanced phase II enzyme levels, through their reactivity towards 
thiols 52. However, this mode of action has not yet been confirmed for oltipraz 77. 
Miao et al. 78 showed that oltipraz induced both phase I and phase II enzymes in rat 
hepatoma cells and suggested oltipraz to act as a bifunctional inducer (acting via 
the Nrf2 and AhR pathways). In addition, a study by Zhang et al. 77 demonstrated 
the production of cellular ROS by oltipraz, which may contribute to Nrf2 activation. 
Although some positive outcomes were shown, results of phase I and phase II 
clinical trials were inconclusive and associated with negative side effects including 
gastrointestinal irritation, paresthesia in fingertips and flatulence 73. Hence, 






Figure 1.14: Chemical structure of tBHQ 62. 
 
Tert-butylhydroquinone (tBHQ) (Figure 1.14), a metabolite of butylated 
hydroxyanisole (BHA) 79, is a synthetic phenolic compound that is used as a food 
preservative. Diverse studies have demonstrated the protective effect of tBHQ 
against inducers of oxidative stress including dopamine 80, alcohol 81, glutamate 82 
and hydrogen peroxide 83. Dinkova-Kostova et al. 40 showed that the cytoprotective 
activity of tBHQ is mediated through the Keap1-Nrf2 pathway. Diphenols such as 
tBHQ require bio-oxidation to electrophilic quinones containing Michael acceptor - 
groups to react with cysteine residues of Keap1, which results in nuclear Nrf2 
translocation 84 85. Michael acceptors are olefins or acetylenes conjugated to 
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electron-withdrawing groups, which are subjected to Michael addition with 
nucleophiles 52, 86. Michael acceptors are thought to react with cysteine residues of 
Keap1. Although, chemopreventive effects have been attributed to tBHQ, chronic 
exposure to the compound is associated with carcinogenicity 87. This may be due to 






Figure 1.15: Chemical structures of CDDO, CDDO-Me and CDDO-Im 62.  
 
The synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid 
(CDDO) (Figure 1.15), is derived from naturally occurring oleonolic acid and 
displays various anti-inflammatory and anti-cancer activities 88. CDDO was found to 
up-regulate phase II enzymes, which was shown to be dependent on the 
involvement of Nrf2 89. Moreover, the CDDO structure is one of the most potent Nrf2 
inducers 90 (Table 1.2).  
 
Table 1.2: The NQO1 induction potencies of synthetic triterpenoids in Hepa1c1c7 cells 89 
(CD value, Section 1.8.1.1).  
  





Dinkova-Kostova et al. 89 demonstrated the reactivity of CDDO towards cysteine 
residues of Keap1. The analogues CDDO-Me and CDDO-Im also showed the ability 
to activate the Keap1-Nrf2 pathway 91. Several phase I clinical trials have been 
conducted with CDDO-Me and revealed promising anti-cancer effects 92. However, 




1.6.5 Other indirect Nrf2 inducers 
 
Phenolic compounds are found in many types of plants and are another important 
group of Nrf2 indirect inducers. Well-known examples are quercetin, 
epigallocatechin-3-gallate (EGCG), curcumin, resveratrol and flavonoids (flavones, 
flavonols, flavanones, flavanols, chalcones, anthocyanins, and isoflavones) 86. 
Quercetin, EGCG, resveratrol and flavonoids are polyphenols; they can be oxidised 
to quinones, which contain Michael acceptors 52, 94. Curcumin contains two Michael 
acceptors and is able to induce the expression of Nrf2 regulated gene products 94. 
Recently, dimethyl fumarate (DMF), a novel compound for the treatment of multiple 
sclerosis (approved by the FDA in 2013), has been reported to induce nuclear Nrf2 
translocation 95. DMF has been shown to modify key cysteine residues of Keap1 73 
and demonstrated to have potential as an anti-cancer drug for diverse types of 
cancer 96. Although both DMF and triterpenoids CDDO-Im and CDDO-Me are 
indirect Nrf2 inducers, a recent study found that they initiated the up-regulation of 
different Nrf2 target genes and Nrf2 independent genes 97. Moreover, in a 
carcinogen-induced model of lung cancer the triterpenoids prevented the 
progression of cancer, whereas DMF induced the growth and numbers of tumours 
97. DMF and the triterpenoids contain thiol reactive Michael acceptor sites (α,β-
unsaturated carbonyl group) that can interact with diverse cysteine residue 
containing target proteins including STAT3, PI3K/Akt, IKK, mTOR, HER2 and 
Keap1 97. The biological effect of each compound may be a result of activation of 
the Keap1-Nrf2 pathway and/or other pathways, which is dependent on the dose 
and the cellular context (dual role of Nrf2 described in Section 1.5).  
 
1.6.6 Direct inhibition of the Keap1-Nrf2 PPI  
 
An alternative strategy to avert the process of cysteine modification and its 
associated cytotoxicity is by direct inhibition of the Keap1-Nrf2 PPI. Potential 
advantages of direct Nrf2 inducers over indirect Nrf2 inducers include enhanced 
specificity of the interaction with the target, reduced off-target effects, reversibility 
due to a non-covalent interaction and the potential for relatively low cytotoxicity 98. 
Direct Nrf2 inducers include Nrf2-derived (short) peptides or small molecules that 
can compete with Nrf2 for Keap1 binding sites. These inducers have been identified 
by screening compound or fragment-based libraries or via in-silico docking studies. 
Sequences of other Keap1 interactors may also provide a basis for the development 
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of direct Nrf2 inducer molecules. P62 or sequestosome-1 targets ubiquitinated 
protein cargo for autophagy, which is a process responsible for the degradation of 
proteins 99. Evidence has emerged that p62 positively regulates Nrf2 and induces 
Nrf2 downstream target genes in response to oxidative stress 100. P62 has been 
reported to bind to the Keap1 Kelch domain via a DPSTGE motif that is similar to 
the DEETGE sequence of Nrf2, hence competing with Nrf2 for Keap1 binding sites 
100. This knowledge has been used by our group to develop peptides with 
sequences based on the p62 protein, which demonstrated increased binding 
affinities compared to peptides containing the native Nrf2 ETGE containing 
sequence in a fluorescence polarisation assay 101.  
 
1.7 Transcription factor cross-talk: Nrf2 and AhR 
 
The aryl hydrocarbon receptor (AhR), a ligand dependent transcription factor, is 
responsible for the up-regulation of genes under the control of the xenobiotic 
response element (XRE) (Figure 1.16). These genes form the AhR battery and 
encode both phase I (e.g. CYP1A1, 1A2 and 1B1) and phase II enzymes (e.g. 
NQO1, GSTA2, UGT1A1 and UGT1A6), also referred to as xenobiotic-metabolizing 
enzymes (XMEs) 102. Up-regulation of phase I enzymes such as CYP1A1 can result 
in the development of reactive metabolites and oxidative stress, which may 
eventually induce carcinogenesis 103. Examples of well-known AhR ligands are 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and polycyclic aromatic hydrocarbons 
(PAHs). Under basal conditions the AhR is sequestered by two Hsp90 proteins in 
the cytoplasm 102. Following ligand binding, the AhR dissociates from Hsp90 and 
translocates to nucleus where it interacts with ARNT (AhR nuclear translocator) 102. 
Subsequently, the AhR-ARNT hetereodimer binds to the XRE of AhR battery genes 
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The murine hepatoma cell line Hepa1c1c7 was used for this assay as its NQO1 
protein is highly inducible 109. Besides NQO1 induction, the assay can also be 
employed to estimate the cytotoxicity of potential phase II enzyme inducers. Certain 
compounds may induce phase II enzymes co-ordinately with phase I enzymes, 
which could result in carcinogenic bio-activation. The BpRc1 cell line is a variant of 
the Hepa1c1c7 cell line with a defective ARNT (aryl hydrocarbon receptor, AhR, 
nuclear translocator), thereby preventing the transcription factor AhR from 
accumulating in the nucleus 110. Monofunctional inducers are able to induce the 
NQO1 enzyme in both the Hepa1c1c7 and BpRc1 cell lines and are generally 
preferable chemopreventive agents.  
 
1.8.1.2 Luciferase reporter assays: ARE-luciferase assay 
 
The first stable ARE reporter cell line was created by Boerboom et al. 111 using the 
mouse hepatoma Hepa1c1c7 cell line. This cell line was stably transfected with a 
luciferase gene controlled by a functional ARE sequence of the human NQO1 gene. 
Wang et al. 112 reported in 2007 the generation of a stable MCF-7 - derived ARE 
reporter cell line, AREc32. The luciferase gene in this cell line is under control of 
multiple ARE copies, which showed increased activity compared to Boerboom’s 
reporter cell line containing only a single ARE 111. Nrf2 overexpression resulted in an 
increase in luciferase activity, whereas Nrf2 knockdown reduced the expression of 
the luciferase protein 112. Well-known Nrf2 inducer compounds such as 
sulforaphane and t-BHQ, were found to induce ARE-luciferase activity 112. This 
assay has been used to study numerous putative Nrf2 inducer compounds 113-114 
and was adapted by Wu et al. 115 to suit high-throughput screening (HTS).  
 
1.8.1.3 Luciferase reporter assays: Neh2- luciferase assay 
 
Inspired by the ARE- reporter cell line, Smirnova et al. 116 used the Nrf2 Neh2 
domain to develop a Neh2-luciferase reporter system. In this method the Neh2 
domain is fused to firefly luciferase (Neh2 – luciferase) and competes with 
endogenous Nrf2 for Keap1 binding sites. Nrf2 inducing compounds avert the Nrf2 
fusion protein from degradation and increase its accumulation. The intensification of 
the luciferase signal is proportional to the Nrf2 inducing capability of the compound. 
The main advantage of this assay compared to the ARE based assays is that 
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compounds can be screened for their ability to disrupt the Keap1-Nrf2 PPI directly. 
Moreover, the Neh2 – reporter assay was found to be suitable for HTS 116.  
 
1.8.1.4 PathHunter Nrf2 translocation assay 
 
The principle of the PathHunter Nrf2 translocation assay (DiscoveRx) is based on 
enzyme fragment complementation 117. A recombinant cell line contains two inactive 
β-galactosidase enzyme fragments of which one is fused to the Nrf2 protein and the 
other fragment is located in the nucleus. Upon activation of the Keap1-Nrf2 
pathway, Nrf2 translocates to the nucleus where it reconstitutes functional β-
galactosidase enzyme. A chemiluminescent galactose-derived substrate is used to 
determine enzyme activity. Well-known Nrf2 inducers CDDO and t-BHQ have been 
used as positive controls in this assay 117-118. A small molecule inhibitor, (SRS)-5, of 
the Keap1-Nrf2 PPI was found to induce Nrf2 nuclear translocation in this assay 119.  
 
1.8.1.5 EMSA and ELISA based methods 
 
Electrophoretic mobility shift assay (EMSA) and enzyme-linked immune assay 
(ELISA) based methods have been developed to study the ARE-specific binding 
affinity of Nrf2. In an Nrf2-specific EMSA, radiolabeled ARE sequences are 
incubated with nuclear extracts, before the mixture is separated using 
electrophoresis 120. The Nrf2 protein that is present in the nuclear extract will bind to 
the ARE DNA sequence, which causes a shift to a higher molecular weight on the 
polyacrylamide gel compared to the control containing only the DNA fragment 120.  
In an Nrf2-specific ELISA, the ARE DNA sequence is immobilised in the wells of a 
96-well microtitre plate. Nuclear extracts containing Nrf2 will bind to the ARE and 
can be detected by a specific Nrf2 primary antibody and a horseradish peroxidase 
(HRP)-conjugated secondary antibody 121-122. These methods can be applied to 
study the ARE-specific Nrf2 inducing abilities of various compounds. The ELISA 
method developed by Assay Biotechnology detects Nrf2 by fixing cells on a plate 
and incubating them with a specific primary antibody against Nrf2 and a HRP 
conjugated secondary antibody 123. A 3,3′,5,5′-tetramethylbenzidine (TMB) substrate 
system is used to quantify the amount of Nrf2 present. This system works via the 




1.8.1.6 Expression, transcription and translation of Nrf2 (target) genes 
 
The potency of compounds to induce the expression, transcription and translation of 
Nrf2 (target) genes can be measured using diverse methods. Real-time quantitative 
PCR is a technique that is commonly used to quantify gene expression. It is based 
on the hybridisation of a (fluorescently) labelled oligonucleotide probe that can 
intercalate with double stranded DNA 124. The nuclease cleavage of the probe by 
Taq DNA polymerase during PCR extension generates a fluorescence signal, which 
is used to detect gene amplification 124. Real-time quantitative reverse transcription 
PCR entails reverse transcription of mRNA to cDNA followed by quantitative PCR, 
which allows the measurement of real time mRNA levels 125. Western blotting is the 
most frequently used technique to assess protein expression levels 126. This method 
involves the separation of proteins based on their molecular weight using 
electrophoresis, transfer to a membrane (blotting) and incubation with labelled 
antibodies to visualise the protein of interest 126. 
 
1.8.2 In-vitro assays and techniques 
 
1.8.2.1 Fluorescence polarisation (FP) 
 
Fluorescence polarisation (FP) is a homogenous method that can be used to 
identify direct inhibitors of the Keap1-Nrf2 PPI 127. When a rapidly tumbling 
fluorescently labelled Nrf2 derived peptide is excited with polarised light, the 
emission light is depolarised, which results in a low polarisation value. Following 
binding of the fluorescent Nrf2 probe to the Keap1 Kelch domain, the tumbling of the 
complex decreases. This results in an increase in the emission of polarised light and 
consequently an increase in the polarisation value. Addition of an unlabelled 
inhibitor compound disrupts the binding of the fluorescent probe to the Keap1 Kelch 
domain, resulting in a decrease in polarisation, which can be measured. Diverse FP 
assays have been developed and successfully applied for the screening of small 
molecule inhibitors of the Keap1-Nrf2 PPI 52, 128-129. More details of this assay are 





1.8.2.2 Surface plasmon resonance (SPR) 
 
The principle of Surface Plasmon Resonance (SPR) is based on a change in 
refractive index upon association of a ligand with an immobilised binding partner. 
The degree of change can be measured over time at variable ligand concentrations, 
which enables the establishment of a binding affinity profile 130. The SPR technique 
can be used to screen for compounds that directly inhibit the Keap1-Nrf2 PPI. In 
such an assay the Nrf2 derived peptide is immobilised on a sensor chip whilst the 
Keap1 Kelch domain flows in solution over the chip 52. Upon association, the 
refractive index changes and as a result affects the angle of reflected polarised light. 
Several research groups have reported the use of this method to identify de novo 
inhibitors of the Keap1-Nrf2 PPI 52, 118, 131. More details of this assay are discussed in 
Section 3.1. 
 
1.8.2.3 Isothermal calorimetry (ITC) 
 
ITC has been used to characterise the binding interaction between Keap1 and Nrf2 
52, 55, 132. This method generates valuable information on interaction 
thermodynamics: binding affinity and binding stoichiometry, enthalpy and entropy 
and Gibbs free energy 133. The principle of this technique is based on a heat-flux 
calorimeter that determines the amount of energy needed to maintain equal 
temperatures between a reference cell, containing buffer, and a sample cell, 
containing the macromolecule in the same buffer 133. The amount of heat 
exchanged (an exothermic or endothermic reaction) upon association of the Keap1 
and Nrf2 proteins is measured as one of the components is titrated into the sample 
cell containing the protein binding partner 133. The assay can be carried out in a 
competition format in which the binding profile changes upon addition of inhibitors to 
the solution cell. More details of this assay are discussed in Section 3.1.  
 
1.8.2.4 Confocal fluorescence anisotropy 
 
This method makes use of two-dimensional fluorescence intensity distribution 
analysis (2D-FIDA) and a polarisation cube and is similar to the FP approach 134. A 
fluorescent Nrf2-derived peptide and an unlabelled Keap1 Kelch domain can be 
used to determine the binding affinity 135. IC50 values can be obtained following the 
addition of varying concentrations of unlabelled inhibitors to the protein mixture.  
42 
 
1.8.2.5 Differential scanning fluorimetry (DSF) 
 
The principle of differential binding fluorimetry (DSF) is based on the binding of a 
fluorescent dye to the hydrophobic parts of a protein. Following heating of the 
protein-dye sample, the protein unfolds and exposes buried hydrophobic regions of 
the protein that can associate with the dye, which results in a change in 
fluorescence intensity 136-137. Binding of an interacting ligand increases the stability 
of Keap1 and hence affects its denaturing temperature, resulting in modified 
fluorescence values 138. Using this technique, binding affinity profiles can be created 
for Keap1 interactors 118, 139.  
 
1.8.3 Selection of screening and evaluation methods 
 
In this project several methods have been selected for the screening and evaluation 
of inhibitors of the Keap1-Nrf2 PPI. The cellular enzymatic NQO1 induction assay 
was chosen as an initial screening method to identify putative Nrf2 inducing 
molecules. This assay is one of the most widely used methods for studying the 
potency of direct and indirect Nrf2 inducer compounds to up-regulate the phase II 
enzyme NQO1 in Hepa1c1c7 cells. Potential bifunctional inducers were also 
examined in the ARNT-deficient BpRc1 cell line, where time allowed. Direct 
disrupters of the Keap1-Nrf2 PPI were additionally screened in an FP based assay, 
which was validated previously 101. In this assay a fluorescein-labelled 7-mer Nrf2 
peptide (FITC-β-DEETGEF-OH) was used as a fluorescent probe and the Keap1 
Kelch domain as a target protein. Competition experiments were carried out with 
unlabelled peptides and small molecules to evaluate their potential for disrupting the 
fluorescent peptide – protein complex. Both NQO1 and FP screening assays were 
initially performed at fixed doses to identify potent molecules. This was followed by 
dose response assays for promising structures. An additional in vitro screening 
assay was developed based on the principle of Förster resonance energy transfer. 
In the past decade, in vitro FRET assays have been developed to study several 
PPIs 140-141. However, there was no record of a Keap1-Nrf2 specific in vitro FRET 
assay when this work was carried out. Hence, a steady state FRET assay was 
developed to identify inhibitors of the Keap1-Nrf2 PPI 142 (development and 
validation described in Chapter 3). In this assay the binding of an eCFP fluorophore 
conjugated 16-mer Nrf2 derived peptide to an eYFP fluorophore fused Keap1 Kelch 
domain generates a FRET signal.  
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This signal can be disrupted by unlabelled peptides or small molecules upon their 
addition to the protein mixture. Both fixed dose and dose response profiles were 
created to identify and examine potent compounds. The most promising molecules 
were evaluated further by western blotting analysis to study their ability to up-
regulate the expression of nuclear Nrf2 and the cytoplasmic detoxification enzymes, 
HO-1 and NQO1. Potential bifunctional compounds were also assessed for the 
induction of nuclear AhR and cytoplasmic CYP1A1 proteins using both western 
blotting technique and a bioluminescent CYP1A1 activation assay (P450-Glo 
CYP1A1, Promega). Western blotting provides good qualitative information on 
protein induction levels and to lesser extent quantitative information. However, there 
is no universally standardised method for the quantification of Nrf2 activation. The 
flow cytometry based method in Chapter 4 describes a novel Nrf2 intracellular 
staining technique, which can be applied to quantify (inducible) Nrf2 protein levels in 
cells. The main advantage of this quantification method is the ability to determine 
the Nrf2 protein expression in individual cells, whereas western blotting provides an 
average for the protein expression in a whole cell population. Potential cellular ROS 
production upon exposure to promising Nrf2 inducer molecules was measured using 
a fluorescence dye and flow cytometry. Although the cellular NQO1 induction assay 
provides an insight into compounds cytotoxicity levels, the sulforhodamine B (SRB) 
assay, which measures cellular protein content, was used as a supportive tool in the 





1.9 Project aims 
 
This project focusses on the use of Nrf2 inducers as a chemopreventive strategy in 
cancer treatment. The main aim is to characterise the behaviour of various classes 
of Nrf2 inducer compounds by: 
 
• Screening all types of Nrf2 inducers for their ability to up-regulate the phase 
II enzyme NQO1 in a cellular enzymatic assay. The NQO1 assay pioneered 
by Prochaska et al. is the most widely used method to evaluate the NQO1 
enzyme inducibility by various compounds.  
• Applying other existing cellular techniques (i.e. western blotting) to evaluate 
the ability of Nrf2 inducers to up-regulate Nrf2 and downstream target 
enzymes.  
• Developing a novel flow cytometry based assay to quantify inducible Nrf2 
protein levels in cells as an additional method to existing approaches (i.e. 
western blotting). As the flow cytometry technique relies on single-cell 
analysis rather than population analysis, the determination of Nrf2 protein 
levels is anticipated to benefit from increased reproducibility and reliability. 
• Screening of direct Nrf2 inducers for their ability to disrupt the Keap1-Nrf2 
pathway using in vitro methods including a FP assay that was previously 
developed in our group 143. 
• Developing a novel FRET based assay as another approach to screen direct 
inhibitors of the Keap1-Nrf2 PPI. This method benefits from fusing stable 
fluorophores to the interacting protein pair, which makes the assay more 





2 Materials & Methods 
2.1 Bacterial strains, culture medium & preparation of competent cells 
 
XL-1 blue bacteria were a kind gift from Dr. Colin James, UCL School of Pharmacy. 
The strain-specific genotype is: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F´ proAB lacIqZΔM15 Tn10 (Tetr)]. 
Rosetta 2 (DE3) bacteria from Novagen were supplied by MerckMillipore. The 
strain-specific genotype is: F- ompT hsdSB(rB-mB-) gal dcm (DE3) pRARE2 (CamR).   
 
Bacteria were grown in:  
- Luria-Bertani (LB) Broth (in 1 L): 10 g NaCl, 10 g tryptone and 5 g yeast 
extract. Autoclave solution, cool down to hand-warm and add appropriate antibiotics 
solution. 
- LB agar (in 1 L): 10 g NaCl, 10 g tryptone and 5 g yeast extract, 1.5 g agar. 
Autoclave solution, cool down to hand-warm and add appropriate antibiotics 
solution. 
 
Growth media was supplemented with antibiotic solution where appropriate: a final 
concentration of 12.5 µg/mL tetracycline, 20 µg/mL chloramphenicol, 30 µg/mL 
kanamycin 
 
Competent bacteria were prepared using the CaCl2 method: 0.5 mL of 10 mL 
overnight grown bacteria culture was added to 500 mL LB Broth (added tetracycline 
for XL-1 blue cells and chloramphenicol for Rosetta 2 (DE3) cells). Bacteria were 
grown until OD600nm = 0.6 and pelleted at 4°C. After the supernatant was discarded, 
cells were resuspended in 500 mL ice-cold 0.1 M CaCl2 and left to incubate on ice 
for 45 min. Cells were pelleted at 4°C and resuspended in 10 mL of 20% glycerol in 
CaCl2. Competent cells were aliquoted at 0.25 mL/vial in pre-cooled Eppendorf 
tubes before flash-freezing them in liquid nitrogen. Competency was tested by 


































































































































































2.3.1 pET28c – eYFP- TEV- Kelch plasmid 
 
The cDNA encoding the human Keap1 Kelch domain (residues 321 – 609) was 
amplified from the pET15b – human Kelch plasmid (gift from Dr. Tadayuki Tsujita, 
University of Dundee) by PCR using the forward primer 5’-
AAAAGGATCCGCGCCCAAGGTGGGCCG-3’ and reverse primer 
5’AAAAGCGGCCGCTTAGGTGACAGCCACGCCCAC-3’, introducing a BamH1 site 
at the 5’-end and a Not1 site at the 3’-end. The restriction endonuclease sites are 
shown in bold. Each oligonucleotide primer contains additional bases at the 5’ end 
to aid the binding of the restriction enzymes. Forward and reverse primers were 
purchased from Eurofins MWG Operon and HPLC purified by the manufacturer. The 
amplified product and pET28c-eYFP-TEV plasmid were digested with BamH1 and 
Not1 (NEB) (Section 2.4) and ligated (Section 2.6), creating pET28c-eYFP-TEV-
Kelch. 
 
The PCR primers for the amplification of the human Keap1 Kelch domain were 
designed using the following criteria 145-147: 
• The melting temperature (Tm) was calculated using the Wallace equation 
148:  
Tm = 64.9 + 41 * yG + zC - 16.4wA + xT + yG + zC 
Where w,x,y,z are the number of the bases A,T,G,C in the amplification sequence 
respectively. 
• The melting temperature of the primer pair is designed to be within 5 °C of 
each other. 
• The optimal annealing temperature is 5 °C below the estimated Tm. 
• The optimal primer length is between 18-22 bases. 
• Primers were designed with a maximum of 4 identical bases. 
• Primers do not have complementary sequences (palindromes) within 
themselves or with the other primer in the pair. 
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For the PCR amplification of the Keap1 Kelch cDNA, a mastermix was prepared for 
use in minimal 6x PCR reactions (50 µL/reaction): 
 
7 µL Template DNA (pET15-humanKelch) 
35 µL Pfu 10x buffer (NEB)  
3.5 µL Forward primer 
3.5 µL Reverse primer 
7 µL dNTP mix 
7 µL Pfu DNA polymerase (NEB) 
287 µL dH2O 
350 µL mastermix volume (50 µL/reaction) 
 
All reactions were cycled using a Techne TC-3000G Thermal Cycler (Bibby 
Scientific) using the conditions in Table 2.1. 
 
Table 2.1: PCR reaction scheme for amplification of the Keap1 Kelch cDNA.  
 
Step Cycles Temperature Time 
1: Initial denaturation 1 95°C 5 min 
2: Denaturation 30 95°C 45 sec 
3: Annealing 54.2°C – 67.1°C 30 sec 
4: Extension 72°C 4 min and 15 sec 
5: Extension 1 72°C 10 min 
6: PCR product NA 4°C On hold 
 
The PCR products were separated according to size by electrophoresis on a 1% 
agarose gel (Section 2.5). The desired 864 basepair PCR product was most visible 
at the highest annealing temperature of 67.1 °C and was excised from the gel. The 




2.3.2 pET28c – eCFP- TEV- Nrf2 (wild-type, E78P/F83L, E79Q, T80K and 
E82D) plasmids 
 
The Nrf2 wild-type (WT) and Nrf2 mutant DNA sequences (E78P/F83L, E79Q, T80K 
and E82D) were only 48 base pairs long and did not require PCR. They were made 
by annealing forward and reverse oligonucleotide sets (Table 2.2), introducing a 
BamH1 site at the 5’-end and a Not1 site at the 3’-end. The nucleotides which were 
mutated to generate the Nrf2 mutant peptide sequences are shown in bold within 
each oligonucleotide sequence. All oligonucleotide sets were purchased from 
Eurofins MWG Operon and HPLC purified by the manufacturer. Oligos were 
dissolved in dH2O to make up 1 mM stocks. Next, 20 µl of each oligo set was 
combined with 100 mM NaCl (final concentration) in a total volume of 100 µl and 
incubated at 100 °C for 5 min. The double stranded DNA was allowed to cool down 
to RT and stored at - 20°C. The annealed products and the pET28c-eCFP-TEV 
plasmid were digested with BamH1 and Not1 (Section 2.4) and ligated (Section 2.6) 




Table 2.2: Nrf2 primers used to generate pET28c – eCFP- TEV- Nrf2 plasmids: wild-type 
(WT), E78P/F83L, E79Q, T80K and E82D. 
 
2.4 Restriction endonuclease digestion 
 
Restriction digests were performed for both the cloning of PCR and annealed 
double stranded DNA products and for clone verification purposes. For cloning 
purposes, 1 – 2 µg plasmid DNA, 1 µL BamH1, 1 µL Not1 and 1x concentrated 
restriction NEB endonuclease buffer 4 (50 mM Potassium Acetate, 20 mM Tris-
acetate pH 7.9, 10 mM Magnesium Acetate, 1 mM DTT) made to a total volume of 
15 or 20 µL with dH2O was combined in a sterile 0.5 mL centrifuge tube. The 
mixture was incubated at 37°C for 2 h. The digested DNA was separated on a 1% 
agarose gel by electrophoresis, gel purified (Section 2.5), and used for ligation 
reactions (Section 2.6). Control restriction digests with BamH1 or Not1 were 
performed separately to ensure complete digestion by both enzymes. For clone 
verification purposes, 0.5 µg mini-prepped DNA (Section 2.7), 0.5 µL Nde1, 0.5 µL 
Not1 and 1x concentrated restriction NEB endonuclease buffer 4, made to a total 
volume of 10 µL with dH2O was combined in a sterile 0.5 mL centrifuge tube.   
Nrf2 Primer 
set # 
Nucleotide sequence (5’  3’) 
WT 1 FP GATCCGCGTTCTTCGCGCAGCTGCAGCTGGACGAAGAAACCGGTGAATTCCTGGC 
WT 1 RP GGCCGCCAGGAATTCACCGGTTTCTTCGTCCAGCTGCAGCTGCGCGAAGAACGCG 
WT Peptide 
sequence 














Ala Phe Phe Ala Gln Leu Gln Leu Asp Pro Glu Thr Gly Glu Leu Leu 
Mutant 
E79Q 
3 FP GATCCGCGTTCTTCGCGCAGCTGCAGCTGGACGAACAGACCGGTGAATTCCTGGC 
Mutant 
E79Q 





Ala Phe Phe Ala Gln Leu Gln Leu Asp Glu Gln Thr Gly Glu Phe Leu 
Mutant 
T80K 
4 FP GATCCGCGTTCTTCGCGCAGCTGCAGCTGGACGAAGAAAAAGGTGAATTCCTGGC 
Mutant 
T80K 





Ala Phe Phe Ala Gln Leu Gln Leu Asp Glu Glu Lys Gly Glu Phe Leu 
Mutant 
E82D 
5 FP GATCCGCGTTCTTCGCGCAGCTGCAGCTGGACGAAGAAACCGGTGACTTCCTGGC 
Mutant 
E82D 





Ala Phe Phe Ala Gln Leu Gln Leu Asp Glu Glu Thr Gly Asp Phe Leu 
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The mixture was incubated at 37°C for 2 h. The digested DNA was separated on a 
1% agarose gel by electrophoresis, stained with SYBR Safe (Life Technologies) and 
analysed. Control restriction digests with Nde1 or Not1 were performed separately 
to ensure complete digestion by both enzymes.    
 
2.5 Agarose gel electrophoresis and DNA purification 
 
DNA products were separated by electrophoresis through a submerged gel (1% 
(w/v) agarose, 1 x SYBR Safe (Life Technologies) in DMSO in TBE buffer). 
Samples were mixed with 1x volume gel loading dye (NEB), loaded into sample 
wells and electrophoresed at 80V for 1.5 h. The DNA was visualised using a blue 
light transilluminator gel. Agarose containing DNA fragments generated by 
restriction enzyme digestion were excised from the gel and the DNA purified using 
the Qiagen kit for DNA gel extraction according to manufacturer’s instructions.    
 
2.6 Ligation reactions 
 
The amount of insert for a 6:1 molar ratio with plasmid or vector needed for the 
ligation reactions was determined by the following equation:  
Amount of insert (ng) = x ng of vectorsize in kb of vector * 0.005 kb of insert * 6 
In a sterile 0.5 mL centrifuge tube were combined: typically 150 ng of restriction 
endonuclease digested vector, the previous calculated amount of restriction 
endonuclease digested insert, 1.5 µL T4 DNA ligase (NEB) and 1x concentrated T4 
DNA ligase buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM ATP, 10 mM DTT), 
which was made to a total volume of 15 µL with dH2O. Ligations were carried out at 






2.7 Bacterial transformation and plasmid purification 
 
70 µL of competent XL-1 blue cells were transformed with ligation products and 
incubated on ice for 45 min. The cells were heat-shocked at 42°C for 90 sec then 
returned to ice for 2 min. Following the addition of 400 µL of LB-broth, cells were 
incubated at 37 °C for 45 min whilst shaking (220 rpm). 100 µL of the cell culture 
was dispersed on LB-kan agar plates and incubated at 37 °C overnight.  
 
Colonies were picked and grown in 5 mL LB-kan medium at 37°C overnight whilst 
shaking at 220 rpm. 2.5 mL of overnight cultures were harvested by centrifugation 
and purified using the Mini-Prep spin column system (Qiagen) according to the 
manufacturer’s instructions. The purified DNA was eluted in 30 µL sterile dH2O. The 
recovery of plasmid with an insert and confirmation of no additional introduced 
mutations was verified by restriction enzyme digest analysis (Section 2.4) and DNA 
sequencing respectively, using T7 forward and reverse primers (Eurofins MWG 
Operon). Large-scale plasmid DNA preparations were generated using the Maxi-
Prep Kit (Qiagen) according to manufacturer’s instructions. Recovered plasmid DNA 
was quantified by measuring the absorbance values (OD260nm) on the NanoVue Plus 
Spectrophotometer. The concentration of DNA in the sample was calculated using 
the following equation: OD260nm x 50 ng/µg. Estimation of the purity of the plasmid 
DNA was carried out by measuring the ratio of OD260nm/OD280nm. A ratio of 1.8 - 2.0 
indicated that the sample did not contain protein.   
 
2.8 Glycerol stocks of transformed XL-1 blue or Rosetta 2 (DE3) cells 
 
A single colony of transformed cells was picked from a selective agar plate and 
used to inoculate 5 mL of LB – broth containing the appropriate antibiotic. The cell 
culture was grown at 37°C overnight whilst shaking at 220 rpm. The next day 500 
µL of cell culture was supplied with 500 µL of glycerol and mixed. The glycerol 




2.9 Protein expression, purification & storage 
 
All plasmid constructs (pET28c- eCFP-TEV-Nrf2-WT, pET28c- eCFP-TEV-Nrf2-
E78P/F83L, pET28c- eCFP-TEV-Nrf2-E79Q, pET28c- eCFP-TEV-Nrf2-T80K, 
pET28c- eCFP-TEV-Nrf2-E82D, pET28c-eYFP-TEV-Kelch, pET28c-eYFP and 
pET28c-eCFP-TEV-eYFP) were used to transform 50 µL of competent Rosetta 2 
(DE3) cells as described in Section 2.7. Transformed cells were dispersed on LB-
kan agar plates and incubated at 37°C overnight. One single colony was picked and 
grown overnight in LB-kan medium at 37°C whilst shaking at 220 rpm. 1 mL of 
overnight grown culture was added to 1 L of LB-kan and incubated at 37°C until the 
cells reached the exponential growth phase (OD600nm = 0.4-0.6). The 1 L bacterial 
culture was induced with IPTG (1 mM final concentration) and incubated at 21°C for 
16 h. Cells were pelleted (6,000 x g at 4°C for 30 min) and kept on ice for further 
purification or stored at - 80°C.  
 
Bacterial pellets were resuspended in extraction buffer (20 mM Tris-HCl pH 7.4, 150 
mM NaCl, 30 mM imidazole, 0.5 mM DTT, 0.5 mM EDTA, 5% glycerol and 50 µL 
protease inhibitor cocktail (AEBSF, bestatin, E-64, pepstatin A and 
phosphoramidon, Sigma-Aldrich) / gram of bacterial pellet and sonicated for 5 min 
on ice with 15 sec of rest between each 15 sec cycle of sonication. After the cell 
debris and insoluble proteins in the bacterial suspension were pelleted at 27,000 x g 
at 4°C for 40 min, the supernatant was filtered with a 0.22 µM filter to remove any 
remaining insoluble particles.  
 
2.10 Affinity purification of hexahistadine tagged proteins 
 
The hexahistidine tagged proteins were affinity purified using immobilised metal ion 
affinity chromatography (IMAC), which is based on the binding affinity of histadine to 
nickel ions. A range of increasing concentrations of imidazole competitively 
displaces the hexahistadine tagged proteins from the nickel loaded column.  
The filtered supernatant (Section 2.9) was then applied to a 5 ml His-Trap FF 
column (GE Healthcare Life Sciences), which was washed with 30 mL degassed 
dH2O and equilibrated with 30 mM imidiazole in purification buffer (20 mM Tris-HCl 
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pH 7.4, 0.5 M NaCl and 0.5 mM DTT). After washing the column with 50 mL of 30 
mM imidazole in purification buffer and 10 mL of 50 mM imidazole in purification 
buffer, the proteins were eluted with 10 mL of a gradient of purification buffer 
containing 100 – 300 mM imidazole. To monitor purification, samples were removed 
from each stage and subjected to SDS-PAGE (Section 2.14) followed by 
Coomassie Brilliant Blue staining (Section 2.15). The eluted proteins were 
transferred to a pre-boiled dialysis membrane (SpectrumLabs). Dialysis was carried 
out in 2 L dialysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5 mM DTT and 1 
mM EDTA, adapted from 149) at 4 °C for 16 – 24 h whilst stirring. The dialyzed 
protein elutes were concentrated to a 1 mL volume using Amicon Ultra-15 
centrifugal filter units MWCO 10K spin columns (MerckMillipore) for the eCFP-TEV-
Nrf2 (WT and mutants) and eYFP proteins and MWCO 30K spin columns for the 
eYFP-TEV-Kelch and eCFP-TEV-eYFP proteins. Aliquots of the eYFP-TEV-Kelch 
protein were supplemented with 1.0x Halt protease inhibitor cocktail (AEBSF, 
aprotinin, bestatin, E-64, leupeptin, pepstatin, EDTA, Thermo Scientific). Protein 
aliquots were supplemented with 10% glycerol to prevent ice-crystals from forming 
upon freezing. The proteins were flash-frozen in liquid nitrogen and stored at - 80°C. 
 
2.11 eYFP-TEV-Kelch protein stability 
 
eYFP-TEV-Kelch protein samples were prepared with increasing amounts of Halt 
protease inhibitor cocktail (+ 0.0x, + 0.5x, +1.0 x or +10 x concentrated). Next, the 
protein samples were either stored at 4°C, RT or 37°C. Samples were taken after 0 
days (T = 0), 3 days (T = 3), 5 days (T = 5) and 7 days (T = 7). The stability of the 
eYFP-TEV-Kelch protein samples was assessed by SDS-PAGE gel electrophoresis 
(Section 2.14).  
 
2.12 Protein quantification by intrinsic GFP absorbance 
 
All YFP-Kelch and CFP-Nrf2 or CFP-Nrf2 mutant protein concentrations were 
determined by UV/visible spectroscopy, using wavelengths of 514 nm and 435 nm 
for eYFP and eCFP respectively and the extinction coefficients 83400 M-1cm-1 
(eYFP) and 28750 M-1cm-1 (eCFP). The Beer-Lambert law was applied to calculate 
the protein concentrations:  
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A = εlc  
Where A = absorbance, ε = extinction factor (M-1cm-1), l = optical cell length (cm) 
and c = concentration (M).  
The stored protein concentrations were adjusted for the dilution factor of the 
measured solutions. 
 
2.13 Protein quantification by Bio-Rad protein assay 
 
Protein content of crude, cytoplasmic and nuclear lysate samples was measured 
using the Bio-Rad protein assay (Section 2.21). This assay is based upon the 
Bradford method for determining protein concentration 150 and was carried out 
according to the manufacturer’s protocol. A range of BSA (1 - 20 µg) was used to 
produce a standard curve. Samples were diluted where necessary and made up to 
20 µL with dH2O. Then 5 µL of the samples was transferred to a flat-bottom 96-well 
plate (NUNC) and 200 µL of 5x diluted Bio-Rad protein assay reagent was added to 
each well before measurement on a spectrophotometer plate-reader (PerkinElmer 
Envision or BMG Spectrostar) at a wavelength of 595 nm. The protein concentration 
was calculated with the BSA standard curve. 
 
2.14 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
2.14.1 Preparation of protein samples for SDS-PAGE 
 
Protein samples were prepared by mixing 5 volumes of sample with 1 volume of 6x 
SDS sample loading buffer (375 mM Tris-HCl pH 6.8, 12% SDS, 30% sucrose and 
0.012% bromphenol blue) and 100 mM DTT (final concentration). The samples 







Proteins were separated by electrophoresis using the Mini-PROTEAN Tetra Cell 
system (Bio-Rad). Two glass plates (spacer plate and short plate) were assembled 
in a casting frame. The 10% polyacrylamide gels were prepared according to Table 
2.3. Polymerisation of the resolving gel was initiated by the addition of 10% 
ammonium persulfate (APS). The resolving gel mixture was dispensed into the gap 
between the glass plates and dH2O was overlaid onto the resolving gel to prevent 
drying out of the gel surface. Following polymerisation of the resolving gel, the dH2O 
was discarded and the stacking gel mixture was overlaid onto the resolving gel.  
A comb was placed inside the stacking gel mixture. After the stacking gel had 
polymerised, the wells were rinsed with SDS running buffer (0.125 M Tris-base, 
0.626 M Glycine and 0.5% SDS) prior to loading the samples and a molecular 
weight marker (7-175 kDa, NEB). Electrophoresis was carried out at 40V – 150V for 
1 – 2 h. 
 









2.15 Detection of proteins by Coomassie blue staining 
 
Proteins separated by SDS-PAGE were visualised by Coomassie blue staining. 
Gels were rinsed with dH2O before being submerged into patented Coomassie 
stain, Instant Blue (Expedion), and incubated for 1 – 2 h at RT on a rocking 
Resolving gel Stacking gel 
dH2O 1.6 mL 1.2 mL 
1M Tris – HCl 2.5 mL (pH 8.8) 225 µL (pH 6.8) 
30% Acrylamide (Protogel) 2 mL 289 µL 
10% SDS 50 µL 17.3 µL 
N,N,N’,N’-tetramethylethane-1,2-diamine (TEMED) 5 µL 1.7 µL 
10% ammonium persulfate (APS) 500 µL 17.3 µL 
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platform. The gels were rinsed again with dH2O and dried between wetted 
cellophane membranes on a gel drier (Bio-Rad). 
 
2.16 Detection of protein by western blotting 
 
Proteins were separated by SDS-PAGE and then transferred onto a nitrocellulose 
membrane (Amersham) for western blotting analysis. Fibre pads, 3 MM paper, and 
the nitrocellulose membrane were first prepared by soaking in western transfer 
buffer (25 mM Tris, 119 mM glycine and 20% methanol). Electroblotting was carried 
out at 150 mA for 1.5 h using a Mini-Trans-Blot Electrophoretic Transfer Cell (Bio-
Rad). Following protein transfer, the nitrocellulose membrane was incubated in 
blocking buffer (1% skimmed milk powder (Marvel) in Tris-salt (TS) buffer: 10 mM 
Tris-HCl pH 7.0, 150 mM NaCl) at RT for 1 h on a rocking platform. The membrane 
was incubated with primary antibodies (Table 2.4) in blocking buffer supplemented 
with 0.1% non-ionic, non-denaturing detergent, igepal CA-630 (Sigma Aldrich) at 
4°C overnight on a rocker. The membrane was washed with 1x TS, 2x TS/0.1% 
igepal CA-630 and 1x TS buffer for 10 min each, for a total of 40 min. After washing, 
the membrane was incubated with secondary antibodies, conjugated to horseradish 
peroxidase (HRP) (Table 2.4) in blocking buffer supplemented with 0.1% igepal CA-
630 at RT for 2 h. The membrane was washed as described previous before the 
protein-bound HRP was visualised using enhanced chemiluminescence (ECL) 






Table 2.4: Overview of all antibodies used and their respective concentrations.  
 
Antibodies Clonality Manufacturer details Dilution 
Primary anti – Nrf2 Rabbit 
polyclonal 
H-300, sc-13032, SantaCruz 1:1000 
Primary anti – Nrf2 Rabbit 
monoclonal 
D1Z9C XP, Cell Signalling 1:1000 
Primary anti – NQO1 Mouse 
monoclonal 
A-5, sc-271116, SantaCruz 1:100 
Primary anti – HO-1 Rabbit 
polyclonal 
H-105, sc-10789, SantaCruz 1:1000 
Primary anti – AhR Rabbit 
polyclonal 
BML-SA210-0100, Enzo Life 
Sciences 
1:2500 
Primary anti – CYP1A1 Rabbit 
polyclonal 
H-70, sc-20772, SantaCruz 1:100 
Primary anti – Keap1 Mouse 
monoclonal 
1B4 ab119403, Abcam 1:1000 
Primary anti – GFP Rabbit 
polyclonal 
ab6556, Abcam 1:1000 
Primary anti – β-actin Rabbit 
polyclonal 
R-22, sc-130657, SantaCruz 1:250 
Secondary ECL anti– rabbit 
IgG HRP conjugated 
Donkey 
polyclonal 
NA9340, GE Healthcare 1:1000 
Secondary ECL anti– mouse 
IgG HRP conjugated 
Sheep 
polyclonal 
NA931, GE Healthcare 1:1000 
 
2.17 Förster Resonance Energy Transfer (FRET) 
 
2.17.1 Fluorescence spectra 
 
All fluorescence spectra were acquired using a single sample unit PerkinElmer LS 
55 luminescence spectrometer (5 nm slit width, 1 nm interval, 1 second integration) 
and an excitation wavelength of 435 nm. Fluorescence emission spectra were 
recorded from 400 to 600 nm. Samples were measured in cuvettes (3.5 mL volume, 
10 mm path length, Sarstedt). The samples were diluted in FRET buffer (20 mM 
Tris-HCl pH 7.4 buffer containing, 0.5 mM DTT, 100 mM NaCl, 5 mM MgCl2, 0.1 mM 
EDTA and 5% v/v glycerol) to a final volume of 3 mL. The cuvettes were sealed with 
parafilm and inverted 10 times. Fluorescence emission spectra of the FRET pair 
and eCFP-TEV-Nrf2 and eYFP-TEV-Kelch were recorded separately. All samples 





2.17.2 FRET efficiency and sensitised emission  
 
The observed decrease in donor emission at 475 nm of the donor and acceptor pair 
relative to that of the donor alone was used to calculate the efficiency of energy 
transfer (FRET efficiency or FE) between the fluorescent fusion proteins: 
FE = 1 − F
da
Fd  
Where da = donor emission in the presence of the acceptor and d = donor emission 
in the absence of the acceptor.  
 
The observed increase in acceptor emission at 527 nm of the donor and acceptor 
pair relative to that of the acceptor alone was used to calculate the sensitised 
emission (SE) of the acceptor fluorescence:  
SE = F
ad
Fa − 1 *
(εa * ca)
(εd * cd)  
Where ad = acceptor emission in the presence of the donor, a = acceptor emission 
in the absence of the donor, εa or εd = extinction coefficient of the acceptor or donor 
respectively and ca or cd = molar concentration of the acceptor or donor 
respectively. 
 
2.17.3 FRET eCFP-TEV-eYFP validation: ProTEV protease 
 
A series of 100 µL reactions were prepared in duplicate containing increasing 
amounts of ProTEV protease (Promega) (0.5, 1.0, 1.5, 2.0, 2.5, 5.0 and 10 units). 
Each reaction contained 20 µg purified eCFP-TEV-eYFP protein, 1x ProTEV buffer 
and 1 mM DTT, which was made to a total of 100 µL with dH2O. The mixture was 
vortexed and pelleted at 13,000 x g for 10 sec. A control reaction containing the 
fusion protein but no ProTEV protease was prepared in parallel. Both test and 
control reactions were incubated at 30 °C for 30 min. After incubation, 20 µL 
aliquots of the reaction mixtures were removed for SDS-PAGE analysis (2.14) and 
stored at - 20 °C. The remaining 80 µL reaction mixtures were transferred to 
cuvettes containing FRET buffer. 
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2.17.4 FRET pair: eCFP-TEV-Nrf2 and eYFP-TEV-Kelch titration 
 
Following the determination of the eCFP-TEV-Nrf2 and eYFP-TEV-Kelch protein 
concentrations, the protein mixtures were diluted as appropriate in FRET buffer. 
Final concentrations of 0.05, 0.07, 0.09, 0.11, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70 and 
0.80 µM eYFP-TEV-Kelch or unconjugated eYFP were added to a final 
concentration of 0.11 µM eCFP-TEV-Nrf2. Protein samples containing either the 
donor or acceptor were prepared separately.  
 
Emission spectra were recorded and FRET efficiencies and sensitised emissions 
were calculated for each protein combination. Binding curves were fitted by 
nonlinear regression using SigmaPlot software (ligand binding, one site saturation) 
and Kd and Bmax values were determined.  
 
In addition, the emission intensity values at 527 nm were plotted for eCFP-TEV-Nrf2 
titrated with unconjugated eYFP and for direct excitation of eYFP-TEV-Kelch. Linear 
regression was used to connect the data points and generate slope values:  
y = ax+b  
Where y represents the emission at 527 nm, a is the extent of emission increase 
upon titration of eCFP-TEV-Nrf2 with increasing concentration of unconjugated 
eYFP or as a result of the direct excitation of eYFP-TEV-Kelch and b is the emission 
at 527 nm when the concentration of unconjugated eYFP or eYFP-TEV-Kelch (x) is 
0 µM (y intercept).  
 
2.17.5 FRET buffer system optimisation: NaCl 
 
A series of solutions were made containing increasing amounts of NaCl (0, 50, 100 
and 150 mM) in the original FRET buffer (without NaCl where appropriate). Each 
mixture contained 0.11 µM eCFP-TEV-Nrf2 and 0.30 µM eYFP-TEV-Kelch. 




2.17.6 FRET pair: eCFP-TEV-Nrf2 and eYFP-TEV-Kelch validation: ProTEV 
protease       
 
A series of 100 µL reactions were prepared containing increasing amounts of 
ProTEV protease (2.5, 5.0, 7.5 and 10 units). Each reaction contained 8.9 µg eCFP-
TEV-Nr2 and 24.3 µg eYFP-TEV-Kelch, 1x ProTEV buffer, 1 mM DTT and dH2O. 
The mixture was vortexed and pelleted at 13,000 x g for 10 sec. A control reaction 
containing the fusion proteins but no ProTEV protease was prepared in parallel. The 
reactions were incubated at 30°C for 30 min. Following incubation, 20 µL aliquots of 
the reaction mixtures were removed for SDS-PAGE analysis (Section 2.14) and 
stored at - 20°C. The remaining 80 µL reaction mixtures were transferred to 
cuvettes containing FRET buffer. Fluorescence emission spectra were recorded. 
 
2.17.7 Inhibition of FRET between FRET pair: eCFP-TEV-Nrf2 and eYFP-TEV-
Kelch 
 
Vehicle (DMSO) concentration 
A series of solutions in FRET buffer were made containing increasing percentages 
of DMSO (0, 1, 5 and 10%). Each mixture contained 0.11 µM eCFP-TEV-Nrf2 and 
0.30 µM eYFP-TEV-Kelch. Fluorescence emission spectra were recorded. 
 
Nrf2 peptide inhibitor 
Solutions in FRET buffer were made containing 0.11 µM eCFP-TEV-Nrf2 and 0.30 
µM eYFP-TEV-Kelch in the presence or absence of 10 µM of an unlabelled Nrf2 
derived peptide inhibitor (in 0.1% DMSO). Fluorescence emission spectra were 
recorded. 
 
2.17.8 FRET - multi-well plate format 
 
All fluorescence spectra were acquired using a Pherastar BMG Labtech microplate 
reader (excitation filter: 430 nm, dual emission filters: 480 nm and 530 nm). The 
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samples were diluted in FRET buffer (20 mM Tris-HCl pH 7.4 buffer containing, 0.5 
mM DTT, 0.1 mM EDTA and 5% v/v glycerol) to a final volume of 100 µL.The 
untreated black 96-well microtiter plates (Corning) were covered with aluminium foil 
to protect the fluorophore-fused proteins from light and incubated at 800 rpm on a 
plate shaker for 4 min. Fluorescence emission spectra of the FRET pair and eCFP-
TEV-Nrf2 and eYFP-TEV-Kelch were recorded separately. All samples were 
measured in triplicate.  
 
2.17.9 FRET titration - multi-well plate format 
 
Following the determination of the eCFP-TEV-Nrf2 and eYFP-TEV-Kelch protein 
concentrations, the protein mixtures were diluted as appropriate in FRET buffer. 
Final concentrations of 0.01, 0.03, 0.05, 0.07, 0.09, 0.11, 0.20, 0.30, 0.40 and 0.50 
µM eYFP-TEV-Kelch were added to a final concentration of 0.11 µM  
eCFP-TEV-Nrf2 or eCFP-TEV-Nrf2 mutant proteins. Emission intensity values at 
480 nm and 530 nm were recorded and FRET efficiencies were calculated for each 
protein combination. Binding curves were fitted by nonlinear regression using 
SigmaPlot software (ligand binding, one site saturation) and Kd and Bmax values 
were determined. 
 
2.17.10 FRET competition – multi-well plate format 
 
In this multi-well plate format concentrations of 0.11 µM eCFP-TEV-Nrf2 and 0.20 
µM eYFP-TEV-Kelch were used (~ 80% of maximal FE). Assays were performed 
with increasing concentrations of peptide inhibitor (0.001 – 100 µM) at a final 
volume of 100 µL and a final DMSO concentration of 0.1% v/v. All measurements 
were carried out in triplicate. Plates were read directly after mixing the components. 
The percentage inhibition was determined using: 
 % FE = 1 − FE
vehicle −  FEinhibitor
FEvehicle *100 
Inhibition curves were fitted to a standard four-parameter logistic function using 
SigmaPlot and IC50 values were determined. 
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2.17.11 Calculation of Z′ value 
 
The suitability of this assay for high throughput screening (HTS) was assessed by 
determining the Z′ value. This parameter is used as a measure of assay 
performance, based on the maximal and minimal fluorescence intensity at 480 nm. 
The Z′ value was calculated using the equation: 
Z' = 1 −  3SDmaxFRET − 3SDminFRETmaxFRET480nm − minFRET480nm 
Where min FRET480nm = the minimal fluorescence intensity observed in the absence 
of any inhibitor, max FRET480nm = the maximal fluorescence intensity observed in 
the presence of an inhibitor, and SD = the standard deviation of the fluorescence 
emissions at 480 nm. For both minimal and maximal fluorescence signal 0.11 µM 
eCFP-TEV-Nrf2 and 0.20 µM eYFP-TEV-Kelch was pipetted into the wells. The min 
FRET480nm condition was obtained using a final concentration of 0.1% v/v DMSO 
and the max FRET480nm condition was acquired using 100 µM of the 7-mer stearic 
acid (St) conjugated peptide St-DPETGEL in a final concentration of 0.1% v/v 
DMSO. The fluorescence emission at 480 nm of both the minimal and maximal 
fluorescence signal was measured in 48 wells of a 96-well plate. Triplicate 
experiments were performed. 
 
2.18 Mammalian tissue culture and reagents 
 
Alpha Modified Eagle Medium nucleotide free (α-MEM), Dulbecco's Modified 
Eagle's medium (DMEM), foetal bovine serum (FBS), 200 mM glutamine, 
Dulbecco’s phosphate buffered saline without Ca2+/Mg2+ (DPBS-), trypsin-EDTA and 
10,000 units and 10,000 µg/ml penicillin and streptomycin were purchased from 
Invitrogen. Eagle's minimal essential medium (EMEM) was supplied by Lonza via 
VWR.   
 
The murine hepatoma Hepa1c1c7 cell line was obtained from the European 
Collection of Cell Culture (ECACC). The BpRc1 cells are a Class II variant of the 
Hepa1c1c7 cell line and were purchased from the American Type Culture Collection 
(ATCC). The human epithelial carcinoma HeLa cell line was kindly provided by 
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Istvan Kovacs (UCL Cancer Institute and Wolfson Institute for Biomedical 
Research), the human epithelial mammary gland/breast MCF-7 cell line was a gift 
from Professor Stephen Neidle (UCL School of Pharmacy) and the HEK293 cells 
were provided by Professor Anne Stephenson (UCL School of Pharmacy). The cells 
were grown as monolayers and maintained by regular passage in α-MEM 
(Hepa1c1c7 cell line) or DMEM (BpRc1, HeLa and HEK293 cell line) or EMEM 
(MCF-7 cell line) supplemented with 2 mM L-glutamine, 100 units per mL penicillin 
and 100 µg mL-1 streptomycin and 10% heat-inactivated FBS, cultured at 37°C in a 
water vapour saturated atmosphere with 5% CO2. Cells were grown in T-75 cm2 or 
T-150 cm2 tissue culture flasks (Helena Biosciences). All manipulations were 
performed in a sterile environment, with disposable plasticware and glassware 
reserved specifically for the purpose. 
 
2.19 Sub-culturing of mammalian cell lines 
 
When the mammalian cell lines appeared to be ~ 70% confluent, they required sub-
culturing. Cell lines were sub-cultured at least 2 times a week. Cell culture media 
was aspirated and the cells were gently washed with PBS, which was pre-warmed 
to 37°C. The PBS was aspirated and 1 mL (for T-75 cm2 tissue culture flasks) or 3 
mL (for T150 cm2 tissue culture flasks) of pre-warmed 0.25% trypsin-EDTA (1x) 
(Life Technologies) was added onto the cells and incubated at 37°C for 1 - 5 min. 
The tissue culture flasks were gently tapped to dislodge the cells and 5 mL (for T-75 
cm2 tissue culture flasks) or 10 mL (for T-150 cm2 tissue culture flasks) of pre-
warmed cell culture medium with FBS was added to inactivate trypsin. Cells were 
mixed by resuspension. A 20 µL sample of the cell suspension was taken and 20 µL 
of trypan blue was added (2x dilute sample). A 10 µL sample of the trypan blue 
mixture was taken and added to a haemocytometer before counting the cells in the 
counting chambers. After cell counting, an appropriate volume of the original cell 
suspension was added to a new tissue culture flask with 10 mL (for T-75 cm2 tissue 
culture flasks) or 20 mL (for T-150 cm2 tissue culture flasks) of pre-warmed cell 
culture medium. The density of cells added was 4 x 105 cells/T-75 cm2 and 8 x 105 
cells/T-150 cm2 for ~ 70% confluency after 3 days and 2 x 105 cells/T-75 cm2 and 4 
x105 cells/T-150 cm2 for ~ 70% confluency after 4 days. The flasks were incubated 
at 37°C and 5% CO2 until ~ 70% confluency after which cells were used for 
subsequent experiments or sub-cultured as above. 
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2.20 Storage & revival of mammalian cells in liquid nitrogen 
 
Mammalian cell lines that had reached a ~ 70% confluency, were used to make 
liquid nitrogen stocks. Cells were harvested using the method as described in 
Section 2.19. The cell suspension was centrifuged at 500 x g for 5 min at 4°C in a 
sterile 15 mL centrifuge tube. The supernatant was aspirated and the pellet was 
resuspended in pre-warmed PBS. Cells in the PBS suspension were counted as 
described in Section 2.19. The cell suspension was centrifuged and the supernatant 
was aspirated before adding 1 mL of serum free cell freezing media, Bambanker 
(Anachem)/1 x 106 cells. The cell suspension was transferred to cryotubes (Nunc) 
and placed in liquid nitrogen for future use.  
A vial of frozen cells was taken from the liquid nitrogen storage container and 
rapidly defrosted in a water bath at 37°C. When the cells were completely thawed, 
they were transferred to 10 mL of culture medium and centrifuged at 500 x g at 4°C 
for 5 min. The supernatant was aspirated and 1 mL of culture medium was added to 
the pellet. Cells were resuspended and transferred to a T-75 cm2 tissue culture flask 
with 10 mL pre-warmed cell culture medium. The flasks were incubated at 37°C and 
5% CO2. The following day the media was aspirated and replaced with new pre-
warmed culture medium. The cells were grown until they had reached ~ 70% 
confluency before sub-culturing. 
 
2.21 Crude, cytoplasmic and nuclear lysate fractions 
 
The cells were grown until 70% confluence before they were dissociated with 1.5 – 
3 mL trypsin for 1 – 2 min, resuspended in PBS, counted and pelleted. Crude cell 
lysates were obtained by adding 100 µL/ 4 x 106 cells RIPA buffer (100 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 1mM EDTA, 1% igepal, 0.1% SDS, 0.1% deoxycholic acid, 
10 mM DTT and 1x Halt protease inhibitor (AEBSF, aprotinin, bestatin, E-64, 
leupeptin, pepstatin, EDTA, Thermo Scientific). The mixture was incubated on ice 
for 30 min and centrifuged at 16,000 x g at 4°C for 15 min. The supernatant, 
containing the crude cell lysate, was stored at - 20°C. Nuclear and cytosolic lysate 
fractions were separated by NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(Thermo Scientific). Ice-cold 100 µL/1x106 cells CER I + 1x Halt protease inhibitor 
was added to the pellet. The tube was vortexed for 15 sec and incubated on ice for 
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10 min. Ice-cold 5.5 µL/1x106 cells CER II was added to the mixture, vortexed for 15 
sec and incubated on ice for 1 min. The suspension was then pelleted at 16,000 x g 
at 4°C for 5 min. The supernatant, containing the cytoplasmic lysate fraction, was 
transferred to a pre-chilled tube and stored at - 20°C. Next, ice-cold 50 µL/1x106 
cells NER was added to the pellet, vortexed for 15 sec and incubated on ice for 10 
min. This procedure was repeated for a total time of 40 min before the suspension 
was pelleted at 16,000 x g at 4°C for 10 min. The supernatant, containing the 
nuclear lysate fraction, was transferred to a pre-chilled tube and stored at - 20°C.   
 
2.22 NQO1 induction assays 
 
Hepa1c1c7 or BpRc1 cells were seeded in tissue-culture treated 96-well plates with 
a cell density of 2 x 104 cells/200 µL per well and incubated overnight in a 37°C 
incubator. The cells were treated with compound or vehicle (0.1% DMSO final 
concentration) and incubated for a further 24 h. The culture medium was aspirated 
and cells were lysed using 50 µL per well lysis buffer (0.1% Tween20 in 2 mM 
EDTA) and the plate shaken at RT for 15 min. An enzyme reaction was initiated by 
adding 200 µL of mixture to each well: 0.067% bovine serum albumin (BSA), 0.01% 
Tween20, 5 µM flavin adenine dinucleotide disodium salt (FAD), 1 µM glucose-6-
phosphate (G6P), 30 µM β-nicotinamide adenine dinucleotide phosphate hydrate 
(NADP), 40 units G6P dehydrogenase, 0.03% thiazolyl blue tetrazolium bromide 
(MTT) and 50 µM menadione in 25 mM Tris-HCl pH 7.5.  
After incubation at RT for 5 min, 40 µL of stop solution (10% SDS, 1.5% final 
concentration) was added to each well. The plate was shaken briefly before 
measuring the absorbance at 595 nm on a PerkinElmer EnVision or a BMG 
Pherastar plate reader. The background optical density was measured using wells 
containing tissue culture medium, lysis buffer, and enzyme and stop solutions 
without Hepa1c1c7 or BpRc1 cells. The optical density values at 595 nm were 
averaged and the background corrected ratio of optical densities was calculated:  






The concentration of compound causing a doubling of NQO1 activity (change in 
optical density) relative to the vehicle was estimated from a plot of change in optical 
density versus concentration (CD value). 
 
2.23 SRB cytotoxicity assays 
 
Hepa1c1c7 or BpRc1 cells were seeded in tissue-culture treated 96-well plates with 
a cell density of 2x104 cells/200 µL per well and incubated overnight in a 37°C 
incubator. The cells were treated with compound or vehicle (0.1% DMSO final 
concentration) and incubated for a further 24 or 48 h. The culture medium was 
aspirated and cells were fixed by adding 100 µL of ice-cold trichloroacetic acid 
(TCA, Sigma Aldrich) to each well. After incubation at 4°C for 1 h, wells were 
washed five times with 200 µL of dH2O and dried in a hot-air oven. TCA fixed cells 
were stained with 100 µL of 0.4% w/v sulphorhodamine B (SRB, Sigma Aldrich) in 
1% acetic acid at RT for 30 min. SRB was removed before the wells were washed 
five times with 200 µL of 1% acetic acid and dried in a hot-air oven. To dissolve the 
SRB dye, 100 µL of 10 mM Tris was added to each well and incubated at RT for 10 
min on a plate shaker. The optical density values at 564 nm (BMG Spectrostar plate 
reader) were averaged and the background corrected percentage viability was 
calculated: 
% Cell viability = 1 − OD564nm




2.24 CYP1A1 induction assay 
 
Hepa1c1c7 cells were seeded in tissue-culture treated 96-well plates with a cell 
density of 2x104 cells/200 µL per well and incubated overnight in a 37°C incubator. 
The cells were treated with compound or vehicle (0.1% DMSO final concentration) 
and incubated for a further 6 or 24 h. The culture medium was aspirated and cells 
were washed with PBS before addition of culture medium containing luciferin 
substrate. After cells were incubated at 37°C for 3 h, 25 µL of the culture medium 
was transferred to a white luminometer plate. Subsequently, 25 µL of luciferin 
detection reagent was added to each well and incubated at RT for 15 min in the 
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dark. CYP1A1 activity was measured using a luminescence filter with the BMG 
Pherastar plate reader. Next, the cells were fixed in 10% TCA and stained with SRB 
(Section 2.23). The percentage cell viability was calculated and used to correct the 
luminescence values on an individual well basis. 
 
2.25 Flow cytometry 
 
All flow cytometry samples were analysed on a MACSQuant Analyzer (Miltenyi 
Biotec) using MACSQuantify software. Calibration checks were performed daily. 
The MACSQuant Analyzer has 3 lasers (405 nm, 488 nm and 635 nm) and 9 
detectors: 2 for light scatter and 7 for fluorescence. MACSQuant running buffer, 
washing solution, storage solution and bleach solution were purchased from Miltenyi 
Biotec. 
 
2.25.1 Intracelllular Nrf2 staining assay 
 
Hepa1c1c7, HeLa and MCF-7 cells were seeded in tissue-culture treated T-75 cm2 
flasks and grown until 70% confluence. The cells were treated with 10 µM 
sulforaphane or other Nrf2 inducer compound for different periods of time and 
incubated at 37°C at 5% CO2 before dissociation with trypsin. Cells were pelleted 
and resuspended in PBS and used for western blotting (Section 2.16) or flow 
cytometric analysis.     
 
2.25.1.1 Standard protocol  
 
The ‘standard protocol’ was developed as an initial intracellular staining method for 
the detection of Nrf2. Unstimulated and stimulated Hepa1c1c7 cells were fixed by 
adding 40 µL 36.5 - 38% in H2O formaldehyde solution (Sigma Aldrich) to 1 mL PBS 
to obtain a final concentration of ~ 1.5 % formaldehyde. Cells were incubated at RT 
for 10 min and pelleted. After a centrifugation step, cells were resuspended in the 
residual 100 µL PBS. The cells were then permeabilised by slowly adding 900 µL of 
ice-cold 100% methanol (Sigma Aldrich) and incubated on ice for 30 min or stored 
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up to 1 week at - 80°C. Permeabilised cells were washed with 0.5 mL flow buffer 
(0.5% BSA/2 mM EDTA in PBS buffer) before blocking in 0.5 mL flow buffer at RT 
for 10 min. Subsequently, cells were stained with 5 µL of polyclonal rabbit anti-Nrf2 
primary antibody (H-300, sc-13032, SantaCruz) in 0.5 mL flow buffer and incubated 
at 4°C overnight. After primary antibody staining, cells were washed with 1 mL flow 
buffer and pelleted. Cells were then incubated with 1 uL of polyclonal goat anti-
rabbit IgG FITC conjugated secondary antibody (sc-2012, SantaCruz) or isotype 
control normal rabbit IgG (sc-3888, SantaCruz) in 0.5 mL flow buffer at RT for 1 h. 
Finally, cells were washed with 1 mL flow buffer, pelleted and resuspended in 0.3 
mL flow buffer before being analysed on a flow cytometer.  
 
2.25.1.2 Adapted standard protocol – ‘whole’ cells and isolated nuclei 
 
The ‘adapted standard protocol’ was implemented to quantify Nrf2 using flow 
cytometry after examination of a range of parameters to improve the ‘standard 
protocol’. Hepa1c1c7, HeLa and MCF-7 cells were handled as described above and 
processed as whole cells or isolated nuclei. To obtain intact nuclei, cells were 
pelleted in PBS and resuspended in 100 µL/1 x 106 cells CER I (+ Halt protease 
inhibitor) (NE-PER kit, Thermo Scientific). After incubating the mixture on ice for 10 
min, 5.5 µL/1 x 106 cells CER II (NE-PER kit, Thermo Scientific) was added and left 
on ice for 1 min. Nuclei were pelleted and resuspended in 1 mL PBS. Isolated nuclei 
were checked for their integrity by staining an aliquot of the nuclei suspension with 
trypan blue. Nuclei look round and blue, whole cells do not get stained and cell 
debris appears as blue irregular shaped particles. Cells and nuclei were fixed by 
adding 40 µL 36.5-38% in H2O formaldehyde solution (Sigma Aldrich) to 1 mL PBS 
to obtain a final concentration of ~ 1.5 % formaldehyde. Cells were incubated at RT 
for 10 min. After a centrifugation step, cells and nuclei were resuspended in the 
residual 100 µL PBS. Subsequently, 1 mL of ice-cold 100% methanol was added. 
Cells and nuclei were left to incubate on ice for 30 min or stored up to 1 week at - 
80°C. Permeabilised cells and nuclei were washed with 0.5 mL flow buffer before a 
10 min blocking step in 0.5 mL flow buffer. Next, 0.5 µL monoclonal rabbit anti-Nrf2 
primary antibody (D1Z9C) XP (Cell Signalling) was added and the cell/nuclei – 
antibody mixture was left to incubate at 4°C overnight. After a washing step in 1 mL 
flow buffer, cells and nuclei were pelleted and resuspended in 0.5 mL flow buffer. 
They were incubated with 2.5 µL polyclonal goat anti-rabbit IgG FITC conjugated 
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secondary antibody (sc-2012, SantaCruz) or isotype control normal rabbit IgG (sc-
3888, SantaCruz) in 0.5 mL flow buffer at RT for 1 h. After a washing step with 1 mL 
flow buffer, cells and nuclei were resuspended in 0.3 mL flow buffer and analysed 




Fluorochrome emission was captured for FITC conjugates using a Band Pass (BP) 
filter 525/50 and a laser excitation of 488 nm. All samples (10.000 events/sample) 
were measured with the same protocol setting 150V FSC, 300V SSC, 300V FITC.  
FITC fluorescence histograms, which graphically summarise the distribution of 
univariate data sets, were normalised by height and smoothed using predefined 
algorithms with the MACS Quantify software.  
Data was analysed by normalizing the median fluorescence intensity (MFI) to an 
internal staining control (nMFI): 
 nMFI = MFIsampleMFIinternal staining control  
The internal staining controls are cells stained with the secondary antibody only. 
nMFI is representing shifts in the population’s fluorescence intensity without being 
affected by outliers. The fold change was calculated using the nMFI of stimulated 
(S) and the nMFI of unstimulated (US) samples: 
 Fold change = nMFISnMFIUS 
 
2.25.2 ROS detection 
 
Hepa1c1c7 cells were seeded in tissue-culture treated 6-well plates with a cell 
density of 2x105 cells/2 mL per well and incubated overnight in a 37°C incubator. 
The cells were treated with compound or vehicle and incubated at 37°C for 1 h. The 
culture medium was removed and CellROX reagent diluted in culture medium was 
added and incubated at 37°C for 30 min. Culture medium was aspirated and cells 
were washed with PBS. Cells were dislodged by adding 0.25% trypsin-EDTA, 
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incubation at 37°C for 1 min and adding culture medium to neutralise the enzymatic 
reaction. The cells were pelleted and washed with PBS before they were 
resuspended in 0.5 mL PBS and analysed on a flow cytometer. The fluorescence 
emission of the CellROX deep red reagent was measured using a band-pass (BP) 
filter 655/730 and a laser excitation of 635 nm. All samples (10,000 events/sample) 
were measured with the same protocol settings 150V FSC, 300V SSC, 250V APC. 
Data was analysed using the median fluorescence intensity (MFI).      
 
2.25.3 Uptake fluorescently labelled peptides 
 
Hepa1c1c7 cells were seeded in tissue-culture treated 6-well plates with a cell 
density of 2x105 cells/2 mL per well and incubated at 37°C overnight. The cells were 
treated with 1 µM fluorescently labelled peptide (0.1% DMSO final concentration) 
and incubated at 37°C for 5, 10, 30, 60 or 120 min. The culture medium was 
removed and cells were washed twice with PBS. Cells were incubated with 0.25% 
trypsin-EDTA at 37°C for 15 min. The cells were pelleted and washed twice with 
PBS before they were resuspended in 0.3 mL PBS and analysed on a flow 
cytometer. The fluorescence emission of the FITC labelled peptides was detected 
using a BP filter 525/50 and a laser excitation of 488 nm. All samples (10,000 
events/sample) were measured with the same protocol settings 150V FSC, 300V 
SSC, 300V FITC. Data was analysed using the median fluorescence intensity (MFI).     
 
2.26 Confocal Laser Scanning Microscopy (CLMS) 
 
Confocal microscopy was used to image peptide uptake and sub-cellular distribution 
in fixed and live Hepa1c1c7 cells. A LSM 710 was used (Zeiss, Germany) with a 
Plan-Apochromat 63x/1.40 Oil DIC M27 immersion objective. The fluorescent 
labelled cells were excited with an Argon at 488 nm, a Diode at 405 nm and a 
Helium-Neon at 633 nm, all lasers were set at 2% total laser power. A number 
averaging of 4, a scan speed of 8 – 10, a bit depth of 12 and frame size of 1024 x 
1024 were used to obtain the images. The range indicator was used to indicate 
regions of over- and undersaturation. The areas with blue (undersaturation) and red 
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(oversaturation) were adjusted accordingly using the digital offset and gain. Image 
conditions were kept constant when comparing test and control samples. 
 
2.26.1 Cellular uptake of fluorescently labelled peptides in fixed cell samples 
 
Hepa1c1c7 cells were seeded on glass cover slips in tissue culture treated 6-well 
plates with a cell density of 2 x 105 cells/ 2 mL and grown at 37°C overnight. The 
cells were treated with 1 µM or 10 µM fluorescently labelled peptide (0.1% DMSO 
final concentration) and incubated at 37°C for 1 h. The culture medium was 
removed and the cells were washed twice with PBS and submerged in 1x CellMask 
plasma membrane stain (Invitrogen, Life Technologies) diluted in PBS. After 
incubation at 37°C for 5 min, the staining solution was removed and the cells were 
washed twice with PBS. The cells were fixed in 2 mL of freshly prepared 2% 
paraformaldehyde (PFA) at RT for 10 min. The cells were washed twice with PBS 
and mounted on glass microscope slides (Thermo Scientific) with mounting medium 
containing DAPI stain (Hardset, Vectashield). Prepared slides were left to dry at RT 
for 30 min before they were imaged on a confocal laser scanning microscope. 
 
2.26.2 Cellular uptake of fluorescently labelled peptides in live cell samples 
 
Hepa1c1c7 cells were seeded in glass bottom dishes (Matek) with a cell density of 
2 x 105 cells/ 2 mL and grown at 37°C overnight. The cells were treated with 1 µM or 
10 µM fluorescently labelled peptide (0.1% DMSO final concentration) and 
incubated at 37°C for 1 h. The culture medium was removed and the cells were 
washed twice with PBS. The cells were incubated with 2 mL of 5 µg/mL Hoechst 
DNA dye diluted in culture medium (in 0.1% DMSO final concentration) at 37°C for 
25 min. The Hoechst DNA dye was removed and cells were washed twice with 
PBS. The cells were submerged in 1x CellMask plasma membrane stain diluted in 
PBS. After incubation at 37°C for 3 min, the staining solution was removed and the 
cells were washed twice with PBS. The cells were replenished with fresh 2 mL 
culture medium and imaged on a confocal laser scanning microscope in a 




3 Development of a steady-state FRET-based assay to identify 
inhibitors of the Keap1-Nrf2 protein-protein interaction 
3.1 Introduction 
 
The expression of ARE driven gene products can be modulated by molecules that 
possess electrophilic properties. These compounds increase Nrf2 activity by 
modifying reactive cysteine residues within Keap1, thereby blocking the 
ubiquitination process and stabilising Nrf2. An alternative approach to modulate 
ARE activation is by direct disruption of the Keap1-Nrf2 PPI. Potential advantages 
include increased target specificity and the reversible nature of these Nrf2 inducers. 
Several studies have shown that peptides and small molecules with sequences 
based on the Nrf2 - high affinity ETGE motif (residues 79-82) are able to bind to the 
Keap1 Kelch domain, thereby perturbing the strength of the Keap1-Nrf2 PPI 52, 135, 
143, 151.  
 
The aim of this chapter is to establish a steady-state FRET assay to study the 
Keap1 – Nrf2 PPI. This assay can be used to identify and evaluate potential 
Keap1 binding partners. Furthermore, the binding behaviour of inhibitors can 
be studied.   
 
Theodor Förster was one of the founding fathers of FRET, hence the technique is 
also referred to as Förster resonance energy transfer 152. FRET is based on 
Jablonski’s theory: the non-radiative energy transfer from an excited donor 
fluorophore to an acceptor fluorophore by dipole-dipole interactions 153-154 (Figure 
3.1). This involves the direct transfer of a proportion of the donor’s excitation energy 
to the acceptor fluorophore. Energy transfer only ensues when the separating 
distance between both fluorophores is less than 10 nm (100 Å) 155. This is within the 
distance range that two conjugated fluorophores may enter when two proteins 
interact i.e. the proteins involved in the PPI interact closely and the tethered 
fluorophores are within 10 nm of each other depending on the size of the proteins 
and the locations of their C- and N-termini. Furthermore, the donor and acceptor 
fluorophores should have a significant overlap in their fluorescence spectra and a 
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and eCFP-TEV-YFP proteins respectively. The fluorescent protein conjugates have 
a Tobacco Etch Virus (TEV) recognition site between the C-terminus of the 
fluorescent tag and the N-terminus of the protein that forms a linker to allow flexible 
positioning of the fluorophore relative to the protein or peptide.   
 
3.2.2 Purification of eCFP-TEV- eYFP, eCFP-TEV- Nrf2, eYFP-TEV-Kelch and 
eYFP proteins 
 
Following transformation of Escherichia coli Rosetta 2 (DE3) with the pET28c 
plasmid constructs, the bacteria were induced with IPTG to express the eCFP-TEV-
eYFP, eCFP-TEV-Nrf2, eYFP-TEV-Kelch and eYFP proteins (Sections 2.7 and 2.9). 
The proteins were purified using immobilised metal ion affinity chromatography 
(IMAC) as described in Section 2.10. Samples of the expressed proteins were 
analysed by SDS-PAGE (Section 2.14) at each stage of the purification process, 
which was followed by visualisation of the separated proteins by Coomassie Brilliant 
Blue staining (Section 2.15). An example of the purification stages for the eCFP-
TEV-eYFP protein is shown in Figure 3.7. Lanes 1 & 2 show a predominant 
expression of the fluorescent fusion protein in the insoluble and soluble part of the 
crude cell lysate. Lanes 6 – 8 illustrate that the protein expression is even more 
prominent after IMAC. This enabled the isolation of the protein fractions for the 
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3.2.3 Validation of eCFP and eYFP fluorophores as FRET donor-acceptor 
pair 
 
The spectral overlap of eCFP and eYFP proteins makes them ideally suited to form 
a good donor-acceptor pair for FRET. Initially, we demonstrated FRET between the 
donor (eCFP) and acceptor (eYFP) fluorophores using the eCFP-TEV-eYFP 
protein. FRET should occur since the distance between the two covalently linked 
fluorophores is approximately 3.8 nm, which is within the Förster distance of 10 nm. 
As the fluorescent fusion protein contains a TEV recognition sequence, the initial 
observed FRET should decrease rapidly upon addition of functional TEV protease 
(ProTEV protease). Figure 3.9 demonstrates that excitation of the donor, eCFP, at 
425 nm results in donor emission at 475 nm and acceptor emission at 527 nm. 
Subsequently, eCFP-TEV-eYFP protein mixtures were prepared with increasing 
concentrations of ProTEV protease (0.5 – 10 units). Upon incubation of the reaction 
mixtures at 30°C for 30 min, the donor emission progressively increased as the 
acceptor emission similarly decreased. This observation suggests that FRET occurs 
when the donor, eCFP, and the acceptor, eYFP, are in close proximity (~ 3.8 nm 
apart) and is lost when the eCFP-TEV-eYFP is exposed to the proteolytic activities 
of ProTEV protease. The loss of FRET due to cleavage of the fusion protein by 
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Figure 3.9: Demonstration of (disrupted) FRET between the donor and acceptor molecules 
of the eCFP-TEV-eYFP protein construct. The solid line represents the emission spectrum of 
the eCFP-TEV-eYFP protein demonstrating FRET before addition of ProTEV protease. The 
dotted lines illustrate the decreasing FRET after addition of increasing amounts of ProTEV 
protease (0.5, 1.0, 1.5, 2.0, 2.5, 5.0 and 10 units). The arrows indicate the decrease in 
acceptor emission and coinciding increase in donor emission upon addition of increasing 
concentrations of ProTEV protease. The shown emission spectra are the mean specific 
emissions from duplicate readings in a representative experiment.  
 
The SDS-PAGE gel in Figure 3.10 demonstrates a decreasing band intensity of 
eCFP-TEV-eYFP protein (57 kDa) and a simultaneous increasing band intensity of 
the eCFP and eYFP proteins (27 kDa) with cumulative concentrations of ProTEV 
protease (48 kDa) after incubation of the reaction mixtures. When comparing the 
band intensities of the eCFP-TEV-eYFP protein and eCFP and eYFP proteins in 
lane 1 and lane 8 it is evident that the observed decrease in the fusion protein is 
due to TEV proteolysis. In addition, a weak band, representing one of the 
degradation products, is present in lane 1, which suggests a small amount of 
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Upon addition of increasing concentrations of eYFP-TEV-Kelch to eCFP-TEV-Nrf2, 
the donor emission intensities at 475 nm gradually decreased with a corresponding 
increase in acceptor emission intensities at 527 nm (Figure 3.11 A). Although the 
acceptor fluorescence was amplified by addition of increasing amounts of 
unconjugated eYFP to eCFP-TEV-Nrf2, no concurrent decrease in donor emission 
was evident (Figure 3.11 B). 
 
 
Figure 3.11: Emission spectra of 0.11 µM eCFP-TEV-Nrf2 titrated with 0.05, 0.07, 0.09, 0.11, 
0.20, 0.30, 0.40, 0.50, 0.60, 0.70 and 0.80 µM: (A) eYFP-TEV-Kelch or (B) unconjugated 
eYFP. The solid line represents the donor alone before titration and the dotted lines show 
the addition of increasing amounts of the acceptor. The arrows indicate the increase in 
acceptor emission (in A and B) and concomitant decrease in donor emission (only in A) 
upon addition of increasing concentrations of the acceptor. The shown emission spectra are 
the mean specific emissions from duplicate readings (in A and B) in representative 
experiments.  
 
Next, the eYFP emission wavelength maximum at 527 nm was plotted against the 
eYFP concentration, using linear regression, to explore the extent of acceptor 
emission increase upon titration of eCFP-TEV-Nrf2 with increasing concentrations 
of unconjugated eYFP. The emission of eYFP-TEV-Kelch, as a result of direct 
excitation, was plotted in parallel. Both datasets display a linear increase in eYFP 
emission wavelength maximum vs. concentration and comparable slope values; 
110.97 e.u (emission units)/µM for the titration of eCFP-TEV-Nrf2 with eYFP and 
118.23e.u/µM for the direct excitation of eYFP-TEV-Kelch (Figure 3.12).     
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y= 118.23x + 5.525
R2= 0.997




Figure 3.12: Emission intensities at 527 nm of 0.11 µM eCFP-TEV-Nrf2 titrated with 0.05 - 
0.80 µM unconjugated eYFP (●) and the emission of increasing concentrations eYFP-TEV-
Kelch (0.05 – 0.80 µM) upon direct excitation of the acceptor (○). Linear regression analysis 
was applied to produce the slope of both curves. The emission intensities shown are from 
representative experiments.  
 
To examine whether FRET occurred between the two fluorescent fusion proteins, 
both FRET efficiency (FE) and sensitised emission (SE) values were calculated. 
The data were fitted by non-linear regression using an equation for ligand binding: 
 
Ligand binding = Bmax* abs (x) Kd + abs (x) +  Ns * x 
 
A gradual increase in both FE and SE values was evident when increasing 
concentrations of eYFP-TEV Kelch were added to a fixed concentration of eCFP-








Figure 3.13: FRET efficiency (A) and sensitised emission (B) of 0.11 µM eCFP-TEV-Nrf2 
titrated with increasing concentrations of eYFP-TEV-Kelch (0.05 – 0.80 µM). Binding curves 
were fitted by non-linear regression: ligand binding, one site saturation + non-specific 
binding. The error bars represent the standard deviation of n = 3 independent experiments.  
 
The FRET signal started to plateau after approximately 0.30 µM eYFP-TEV-Kelch 
was added to 0.11 µM eCFP-TEV-Nrf2 (for FE: Bmax = 0.30 FE, Kd = 0.08 µM, for 
SE: Bmax = 19.85 SE, Kd = 0.05 µM). This protein ratio was consequently used in 
subsequent experiments unless mentioned otherwise. Substitution of eYFP-TEV-


























Bmax = 0.30 FE
Kd = 0.08 µM
Ns = 1.4117E-011 FE/µM
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Figure 3.14: FRET efficiency (A) and sensitised emission (B) of 0.11 µM eCFP-TEV-Nrf2 
titrated with increasing concentrations of unconjugated eYFP (0.05 – 0.80 µM). The data 
shown are from a representative experiment.  
 
Because of the spectral overlap of the absorption spectra of the donor and acceptor 
fluorophores, the acceptor fluorophore can be excited directly with light at the 
excitation wavelength of the donor (excitation crosstalk). Likewise, donor 
fluorescence can leak into the detection channel for acceptor emission (emission 
crosstalk) 155. Since the donor emission can normally be observed without acceptor 
emission bleed-through, FRET efficiency was used to determine the amount of 
FRET present in further studies.  
 
3.2.5 Buffer system optimisation 
 
Initial FRET buffer conditions (20 mM Tris-HCl pH 7.4 buffer containing, 0.5 mM 
DTT, 100 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA and 5% v/v glycerol) were adopted 
from Dr. Andreia Guimarães 168. Preliminary experiments showed that increasing 
the viscosity of the buffer with > 5% glycerol didn’t improve the FRET signal. 
Furthermore, no benefits were attributed to the MgCl2 component. Other factors 
affecting the FRET efficiency were examined by varying the NaCl concentrations in 
the buffer system. X-ray crystallography studies of the protein-protein interaction 
between the Keap1 Kelch domain and the ETGE-containing Nrf2 peptide have 
eYFP (µM)





































shown that salt bridge formation is an important component of the binding 
interaction 47. It was hypothesised that high salt concentrations in the buffer may 
screen charge-charge interactions between Glu/Asp residues in the Nrf2 peptide 
and Arg residues in the Kelch binding site. Reaction mixtures of eYFP-TEV-Kelch 
and eCFP-TEV-Nrf2 were prepared in buffers with NaCl concentrations of 0, 50, 
100 and 150 mM. Control reactions, containing either the donor or the acceptor in 
buffer supplemented with matching NaCl concentrations, were prepared in parallel. 
Emission spectra of the protein mixtures were recorded upon excitation at 425 nm 
and the FE values were calculated. Figure 3.15 demonstrates that the FE 
decreased to 0 in buffer containing 150 mM NaCl (vs. FE ~ 0.30 in buffer without 
NaCl). As a consequence, subsequent experiments were performed with FRET 
buffer containing 20 mM Tris-HCl pH 7.4, 0.5 mM DTT, 0.1 mM EDTA and 5% v/v 
glycerol with no added NaCl.  
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Figure 3.15: Demonstration of the effect of NaCl on the FRET efficiency (FE) between 
eCFP-TEV-Nrf2 and eYFP-TEV-Kelch. The FE values were plotted against increasing NaCl 







3.2.6 Validation of FRET between eYFP-TEV-Kelch and eCFP-TEV-Nrf2 
 
As both fluorescent fusion proteins possess a TEV recognition site between the 
fluorescent tag and the protein, energy transfer should be abolished upon addition 
of ProTEV protease to the protein mixture. FRET between the eYFP-TEV-Kelch and 
eCFP-TEV-Nrf2 proteins is demonstrated in Figure 3.16.  
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Figure 3.16: Demonstration of (disrupted) FRET between eCFP-TEV-Nrf2 and eYFP-TEV-
Kelch. The solid line reflects the emission spectrum of the fusion proteins demonstrating 
FRET before addition of ProTEV protease. The dotted lines show the decreasing FRET 
following addition of increasing amounts of ProTEV protease (2.5, 5.0, 7.5 and 10 units). 
The arrow indicates the decrease in acceptor emission following addition of increasing 
concentrations of ProTEV protease. The shown emission spectra are the mean specific 
emissions from duplicate readings in a representative experiment.  
 
Following incubation of the protein reaction mixture at 30°C for 30 min with ProTEV 
protease, a formation of precipitate was observed. Addition of increasing 
concentrations of ProTEV protease resulted in a decrease in acceptor emission at 
527 nm. However, the donor emission at 475 nm was not altered. Nevertheless, 
SDS-PAGE analysis demonstrates supporting evidence of cleavage of the two 
fluorescent fusion proteins by ProTEV protease. Increasing concentrations of 
ProTEV protease (0 – 10 units) reveals a concomitant decrease of eYFP-TEV-Kelch 
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3.2.8 Effect of DMSO co-solvent and an Nrf2 derived peptide inhibitor on 
FRET between eYFP-TEV-Kelch and eCFP-TEV-Nrf2 
 
DMSO is often used as a co-solvent for small molecules and peptides. To examine 
the effect of DMSO on the emission spectra, a range of increasing concentrations 
(0.1, 0.5, 1.0, 5.0 and 10% DMSO) was added to reaction mixtures of eYFP-TEV-
Kelch and eCFP-TEV-Nrf2 in buffer. Emission spectra of the protein mixtures were 
recorded upon excitation at 425 nm. Increasing DMSO concentrations were found to 
decrease the overall fluorescence intensity of the emission spectra of both fusion 
proteins (Figure 3.21). This outcome limited the use of DMSO to a concentration of 
0.1% v/v.  
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Figure 3.21: The effect of DMSO on the emission spectra of 0.11 µM eCFP-TEV-Nrf2 and 
0.30 µM eYFP-TEV-Kelch. The solid line represents the emission spectrum of the fusion 
protein pair before addition of DMSO and the dotted lines reflect the emission spectra in the 
presence of 0.1, 0.5, 1.0, 5.0 and 10% DMSO. The arrows indicate the decrease of both 
donor and acceptor emission following addition increasing concentrations of DMSO. The 
shown emission spectra are the mean specific emissions from duplicate readings in a 
representative experiment.   
 
A known Nrf2-derived peptide inhibitor (Ph-DPETGEL-OH, IC50 ~ 0.20 µM obtained 
through a fluorescence polarisation assay 170) was tested to confirm that the 
observed energy transfer between the interacting FRET pair could be inhibited. 
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Reaction mixtures of eYFP-TEV-Kelch and eCFP-TEV-Nrf2 were prepared in buffer 
with or without 10 µM of the inhibitor (in 0.1% DMSO final concentration). Control 
reactions containing either the Nrf2 donor or the Kelch acceptor conjugates were 
supplemented with the inhibitor and were prepared in parallel. Figure 3.22A shows 
that excitation of the donor at 425 nm results in donor emission at 475 nm and 
acceptor emission at 527 nm, suggesting FRET. Addition of the inhibitor to the 
protein mixture resulted in a simultaneous increase in donor emission and decrease 
in acceptor emission (Figure 3.22 B). This observation suggests that energy transfer 
can be halted by a suitable (peptide) inhibitor. 
 
 
Figure 3.22: Emission spectra of 0.11 µM eCFP-TEV-Nrf2 and 0.30 µM eYFP-TEV-Kelch in 
the absence (A) and presence (B) of 10 µM of an unlabelled Nrf2-derived peptide inhibitor. 
Shown are the emission spectra of the donor (- - -) and acceptor ( ̶   ̶   ̶ ) the sum of both 
emission spectra (·····) and the emission spectrum of the FRET pair (      ). The arrows 
indicate the increase in donor emission and coinciding decrease in acceptor emission in the 
presence of the inhibitor. The shown emission spectra are the mean specific emissions from 
duplicate readings in representative experiments.   
 
3.2.9 FRET assay adaptation to a multi-well plate format 
 
Following the development of the FRET assay using the fluorescence spectrometer, 
the assay was adapted to a multi-well plate format. It was hypothesised that the 
adaption to a micro-plate format would result in a reduction of the assay’s sensitivity 
due to the smaller volumes. Consequently, preliminary experiments were performed 
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with 10 times more protein than in the original assay (3.0 µM and 1.1 µM versus 
0.30 µM and 0.11 µM, acceptor and donor proteins respectively). The recorded 
FRET, measured immediately after mixing the fusion proteins, was found to be 
relatively stable over a 24 h period (Figure 3.23). During the optimisation phase, 
protein volumes < 10 % of the total well volume were found to negatively impact the 
reproducibility and accuracy of the assay. Additionally, the use of a multi-channel 
pipette enhanced the assays reproducibility. 



















Figure 3.23: FRET efficiency of 1.1 µM eCFP-TEV-Nrf2 and 3.0 µM eYFP-TEV-Kelch after 
0, 1.5, 3.0 and 24 h in a multi-well plate format. The error bars represent the standard 
deviation of n = 3 independent experiments. 
 
To verify the hypothesis that adaption of the FRET assay to a multi-well plate format 
would reduce its sensitivity, the concentration of the fluorescent fusion proteins was 
lowered to 0.30 µM eYFP-TEV-Kelch and 0.11 µM eCFP-TEV-Nrf2 (previously 
optimised concentrations described in Section 3.2.4). Initial experiments showed 
that lowering the protein concentrations resulted in increased sensitivity. 
Subsequently, a titration experiment was performed to determine the optimal protein 
ratio for energy transfer between the fluorescent fusion proteins. A fixed 
concentration of eCFP-TEV-Nrf2 (0.11 µM) was titrated into varying concentrations 
of eYFP-TEV-Kelch (0.01 – 0.50 µM). The titration was performed with a lower 
eYFP-TEV-Kelch starting concentration than in the original format (0.01 vs. 0.05 
µM) in order to explore the sensitivity of this assay.  
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The lower eYFP-TEV-Kelch maximum concentration (0.50 vs. 0.80 µM in the 
original format) was chosen since, signal saturation started in the original assay at 
concentrations above 0.30 µM eYFP-TEV-Kelch to 0.11 µM eCFP-TEV-Nrf2. FRET 
efficiencies were calculated upon excitation of the protein mixture at 430 nm and 
subsequent emission at 480 and 530 nm (dual emission filters). The data were fitted 
by non-linear regression using an equation for ligand binding, one site saturation + 
non-specific and are presented in Figure 3.24.The efficiency of energy transfer 
between the interacting FRET pairs was optimal using 0.30 µM and 0.11 µM 
acceptor and donor species respectively (Bmax = 0.28 FE, Kd = 0.08 µM). These 
results are consistent with earlier findings (Section 3.2.4). Subsequent multi-well 
plate assays were performed with an acceptor and donor ratio (0.20 µM and 0.11 
µM), which achieved ~ 80% of the maximal FE. This ratio was chosen so that in a 
competition assay format a small displacement of Nrf2 peptide from the Keap1 
Kelch binding site results in a relative large change in FE.  
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Bmax = 0.28 FE
Kd = 0.08 µM
Ns = 1.2054E-011 FE/µM
 
 
Figure 3.24: FRET efficiency of 0.11 µM eCFP-TEV-Nrf2 titrated with increasing 
concentrations of eYFP-TEV-Kelch (0.01, 0.03, 0.05, 0.07, 0.09, 0.11, 0.20, 0.30, 0.40 and 
0.50 µM) in a multi-well plate format. Binding curves were fitted by non-linear regression: 
ligand binding, one site saturation + non-specific. The error bars represent the standard 




3.2.10 Demonstration of the specificity of the Keap1-Nrf2 PPI in a multi-well 
plate format 
 
X-ray crystallography studies of Keap1 Kelch and Nrf2 derived peptide complexes 
have shown that 77DxETGE82 residues E79 and E82 are essential for the protein-
protein interaction; the side chains form salt bridges with R380, R415 and R483 in 
the Kelch domain 46. Residue T80 forms both inter-and intramolecular interactions 
46-47. In certain human cancers these Nrf2 residues are mutated to E79Q, E82D and 
T80K. ITC experiments demonstrated that the ETGE point mutations compromised 
Keap1 recognition, resulting in abnormal cellular accumulation of Nrf2 55. The 
biologically relevant Nrf2 mutations were used to verify the specificity of the 
interaction between the eYFP-TEV-Kelch and eCFP-TEV-Nrf2 proteins. The wild-
type pET28c-eCFP-TEV-Nrf2 plasmid construct was used as a template to generate 
proteins containing the three Nrf2 point mutations; eCFP-TEV-Nrf2-E79Q, eCFP-
TEV-Nrf2-E82D and eCFP-TEV-Nrf2-T80K (Table 3.1) (details in Section 2.3.2). 
Titration experiments were performed in which increasing concentrations of eYFP-
TEV-Kelch (0.01 – 0.50 µM) were added to a fixed concentration of the mutant 
eCFP-TEV-Nrf2 proteins (0.11 µM). All three mutant proteins demonstrated a 
reduced binding affinity for the Keap1 Kelch domain compared to the wild-type 






















Kd = > 0.1 µM
Ns = > 0.05 FE/µM
 
 
Figure 3.25: FRET efficiency of 0.11 µM eCFP-TEV-Nrf2-E79Q (●), eCFP-TEV-Nrf2-T80K 
(○) or eCFP-TEV-Nrf2-E82D (▼) titrated with increasing concentrations of eYFP-TEV-Kelch 
(0.01, 0.03, 0.05, 0.07, 0.09, 0.11, 0.20, 0.30, 0.40 and 0.50 µM) in a multi-well plate format. 
Binding curves were fitted by non-linear regression: ligand binding, one site saturation + 
non-specific. The error bars represent the standard deviation of n = 3 independent assays. 
 
Table 3.1: Dissociation constants and Bmax values for eCFP-TEV-Nrf2 fusion proteins.  
 
Protein Sequence Kd ± SE (µM) Bmax (FE) 
eCFP-WT eCFP-AFFAQLQLDEETGEFL 0.08 ± 0.02 0.28 
eCFP-E79Q eCFP-AFFAQLQLDEQTGEFL >0.1 -a 
eCFP-T80K eCFP-AFFAQLQLDEEKGEFL >0.1 -a 
eCFP-E82D eCFP-AFFAQLQLDEETGDFL >0.1 -a 
Notes: a. Not determined. 
 
3.2.11 Competition assay in a multi-well plate format 
 
To verify whether the newly developed FRET multi-well plate assay could be used 
to evaluate compounds that competitively inhibit the Keap1-Nrf2 PPI, unconjugated 
versions of the Nrf2-derived 16-mer peptide sequences in Table 1 were tested. 
Upon addition of increasing concentrations of the Nrf2-derived 16-mer peptides 
(0.001 – 100 µM) to the eCFP-TEV-Nrf2 and eYFP-TEV-Kelch protein mixture (0.11 
µM and 0.20 µM respectively), the change in FRET efficiency was used to 
determine IC50 values (Figure 3.26 and Table 3.2). The wild-type Nrf2 peptide 
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presented a dose-dependent reduction in energy transfer, whereas the three mutant 
Nrf2 peptides failed to disrupt the Keap1-Nrf2 PPI. 
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Figure 3.26: Competitive inhibition of FRET between 0.11 µM eCFP-TEV-Nrf2 and 0.20 µM 
eYFP-TEV-Kelch by increasing concentrations (0.001 – 100 µM) of unlabelled Nrf2-derived 
16-mer peptides (●: WT,○: E79Q, ▼: T80K and ∆: E82D). The data were fitted to a standard 
four-parameter logistic function. The error bars represent the standard deviation of n = 3 
independent assays. 
 
Table 3.2: IC50 values for Nrf2-derived 16-mer peptides for the interaction between eCFP-
TEV-Nrf2 and eYFP-TEV-Kelch. 
 
Peptide Sequence IC50 (µM) 
WT AFFAQLQLDEETGEFL 0.11 
E79Q AFFAQLQLDEQTGEFL -a 
T80K AFFAQLQLDEEKGEFL -a 
E82D AFFAQLQLDEETGDFL -a 






The suitability of the developed FRET assay for high throughput screening (HTS) 
was evaluated by calculation of the Z′ value 143: 
 
Z' = 1- 3SDmaxFRET-3SDminFRETmaxFRET480nm-minFRET480nm 
 
Here, the minFRET480nm is the minimal fluorescence intensity observed in the 
absence of any inhibitor and maxFRET480nm is the maximal fluorescence intensity 
observed in the presence of an inhibitor, and SD is the standard deviation of the 
fluorescence emissions at 480 nm. 
 
A Z′ value of > 0.5 is usually considered to be suitable for HTS. Competition 
experiments with 100 µM of an unlabelled peptide (St-DPETGEL, IC50 ~ 0.12 µM 
142) were performed to verify the assay performance based on the maximal and 
minimal fluorescence intensity at 480 nm (Figure 3.27) 170 (details in Section 
2.17.11). Here, the Z′ value was calculated as 0.63 ±0.07, which indicated that the 
assay was highly suitable for HTS usage.  
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Figure 3.27: Well-to-well variation of FRET between 0.11 µM eCFP-TEV-Nrf2 and 0.20 µM 
eYFP-TEV-Kelch in the absence (wells 1 – 48) and presence (wells 49 – 96) of 100 µM of an 
unlabelled Nrf2-derived inhibitor (St-DPETGEL 170). The mean and standard deviation of the 
minimal and maximal emission intensities at 480 nm was used to calculate Z′ (Section 





Direct disruption of the Keap1-Nrf2 interaction is an emerging approach to increase 
Nrf2 activity and to stimulate ARE driven gene expression. In this respect, a high-
throughput steady-state homogeneous FRET assay was devised to examine the 
binding affinity of a range of potential inhibitors of the Keap1-Nrf2 PPI. FRET was 
demonstrated between a 16-mer Nrf2 derived peptide conjugated to an eCFP 
fluorophore and the Keap1 Kelch domain conjugated to an eYFP fluorophore.  
 
The ability to calculate the absolute concentration of the eCFP and eYFP fusion 
proteins using their molar extinction coefficient and UV absorption enhances the 
accuracy of the FRET assay 140. Moreover, the spectral properties of eCFP and 
eYFP make them a fluorescent protein pair that is well-suited for FRET 157. This has 
been demonstrated with the eCFP-TEV-eYFP protein construct that contained both 
fluorophores, separated by a TEV recognition site (3.8 nm separation between both 
fluorophores). FRET was observed in a mixture containing only the eCFP and eYFP 
fusion protein, but was lost following the addition of functional TEV protease 
(Figures 3.9 and 3.10). This observation suggests that FRET can only occur when 
the donor, eCFP, and the acceptor, eYFP, are in close proximity. To verify whether 
FRET can serve as a molecular ruler for determining distances within 10 nm, TEV 
protease was added to a mixture containing the fusion proteins eCFP-TEV-Nrf2 and 
eYFP-TEV-Kelch. The addition of TEV protease to the protein mixture revealed the 
cleavage of the two fusion proteins. However, this resulted only in a decrease in 
acceptor emission and no change in donor emission (Figure 3.16). The outcome 
could have been affected by precipitate formation that was observed upon 
incubation of the protein reaction mixture with TEV protease. This precipitation 
might have interfered with fluorescence readings by reflecting the excitation and 
emission light into the detector, which could result in to fluorescence bleed-through. 
Repetition of the experiment would be desirable to confirm the use of FRET as a 
spectroscopic ruler in this context.  
 
Conjugation of the eCFP and eYFP fluorophores to proteins of interest increases 
the fusion proteins stability 171-172. However, SDS-PAGE and western blot analysis 
revealed that eYFP-TEV-Kelch presents itself as a smaller size protein band 
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(~ 54 kDa) than predicted (59 kDa) (Section 3.2.6). Moreover, in an experiment 
where TEV protease was added to the fusion protein, the Kelch degradation product 
appeared as a ~ 29 kDa protein on the SDS-PAGE gel instead of its predicted size 
of 32 kDa (Section 3.2.6). The altered electrophoretic migration might be affected by 
the amino acid composition of the protein, which can influence the SDS binding 
affinity and therefore the mobility of the protein 173. Proteolytic cleavage may also 
have been a factor affecting the apparent molecular weight of the protein. Hence, 
the degree of degradation of de novo purified eYFP-TEV-Kelch protein was 
compared to a protein sample that was purified a month earlier and stored at 4°C. 
Results indicated a more prominent presence of smaller products in the older 
protein sample, indicating degradation. However, more de novo protein sample was 
loaded compared to the older protein sample, which made direct comparison 
difficult. Additional experiments showed that eYFP-TEV-Kelch degradation products 
started to appear when the protein was stored at temperatures above 4°C or for 
prolonged periods of time (up to 7 days) (Section 3.2.7). Supplementation of the 
protein storage buffer with a protease inhibitor cocktail did retard the proteolytic 
process. Nevertheless, mass-spectrometry analysis would be desirable here to 
verify the extent of protein degradation. Overall, these observations demonstrate the 
factors that can affect protein stability and therefore the robustness of the assay. 
 
When the donor fusion protein concentration was fixed, increasing FRET was 
recorded with increasing amounts of the acceptor fusion protein, until optimum FE 
and SE values were recorded with 0.11 µM eCFP-TEV-Nrf2 and 0.30 µM eYFP-
TEV-Kelch (Figure 3.13). Comparable binding affinities were determined when a 
curve fit for ligand binding was applied to both datasets: Kd ~ 0.08 µM and Kd ~ 0.05 
µM for FE and SE datasets respectively. However, the contribution from non-
specific binding was most prominent for the calculated SE values (non-specific 
slope values: 3.17 SE/µM vs.1.41 x 10-11 FE/µM). This could be due to background 
acceptor fluorescence that results from acceptor excitation with light that was used 
to excite the donor. This crosstalk or bleed-through can generate false positives and 
may affect the accuracy of the FRET measurement when using sensitised emission. 
This overlap of absorption spectra is not relevant when observing donor emission, 




In additional titration experiments, the concentration of eYFP-TEV-Kelch was fixed 
(0.11 µM) and the amount of eCFP-TEV-Nrf2 was varied (0.05 – 0.80 µM). Based 
on previous outcomes, the hypothesis was that concentrations up to 0.11 µM eCFP-
TEV-Nrf2 would increase the FRET signal. FRET was expected to plateau upon the 
addition of > 0.11 µM of the donor protein. However, an overall decrease of the FE 
and SE values was observed upon addition of increasing concentrations of eCFP-
TEV-Nrf2 to eYFP-TEV-Kelch. The results were inconclusive and may warrant 
further investigation.   
 
To account for non-specific interactions, eCFP-TEV-Nrf2 was titrated with 
increasing amounts of unconjugated eYFP. This resulted in a linear increase in 
acceptor emission at 527 nm. The slope of the curve (110.97 e.u/µM) was 
comparable to the slope value obtained by direct excitation of increasing 
concentrations of eYFP-TEV-Kelch (118.23 e.u/µM). This suggests that the 
determined FRET between the fusion proteins was indeed due to the interaction 
between Keap1 Kelch and the 16-mer Nrf2 derived peptide and that the non-specific 
component of the interaction is negligible. Figure 3.14 shows that eCFP-TEV-Nrf2 
titration with unconjugated eYFP results in relative unaltered FE and SE values over 
the concentration range. Nevertheless, the titration with eYFP was only performed 
once and should be repeated in the multi-well plate format. 
 
The effect of ionic strength was investigated by varying salt concentrations in the 
buffer. A decrease in FRET efficiency was evident upon increasing NaCl 
concentrations (up to 150 mM NaCl). This result was consistent with our hypothesis 
that the high ionic strength of the buffer may negatively impact the electrostatic 
component of the Keap1-Nrf2 PPI and matches with results from our previously 
described FP assay 143. Maintaining buffer conditions at 20 mM Tris-HCl pH 7.4 
(without added NaCl) was considered to be of high importance.  
 
The specificity of the PPI was validated by comparing the FRET signal of the 
original fusion protein pair with eCFP conjugated constructs containing Nrf2 
mutations found in cancerous human tissue and cell lines. The Nrf2 mutations, 
E79Q, ET80K and E82D, where previously shown to exhibit a low Keap1 binding 
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affinity 55. FRET studies with eCFP conjugated versions of the mutant Nrf2 derived 
peptides confirmed this observation (Section 3.2.10). The competition aspect of the 
assay was verified with unconjugated versions of both the wild-type and mutant 16-
mer Nrf2 derived peptides. Only the wild-type Nrf2 peptide was able to perturb the 
PPI in a dose-dependent manner and restore the eCFP fluorescence emission. The 
obtained data provides an insight into structure-activity relationships and can aid in 
the design of potential inhibitors of the Keap1-Nrf2 PPI.   
 
The adaption of the FRET method to a multi-well plate format generated a robust 
and reproducible assay. Titration experiments with the fusion proteins resulted in 
identical binding affinities in both assay formats (Kd = 0.08 µM). The accuracy of the 
assay was improved in the multi-well plate format by using the same protein stock 
solution for the whole plate and by pipetting protein volumes of at least 10% of the 
total well volume with a multichannel pipette. Evidence of this improved accuracy 
can be found by comparing SD values from Figure 3.13 with Figure 3.23; error bars 
are substantially smaller in the optimised multi-well plate format.    
 
The FRET method described here is distinct from other techniques that have been 
applied previously to examine the PPI 52, 135, 143, 151. Although the use of ITC is cost-
effective and doesn’t require labelling, FRET is higher-throughput and has higher 
sensitivity 164-165, 174 Therefore, the required sample amounts are usually lower than 
for ITC. One of the main advantages of the SPR technique is the ability to monitor 
protein binding in real-time 130. However, unlike FRET, it requires sample 
immobilisation that can affect the conformation and/or activity of a protein 161. Both 
FP and FRET are fluorescence-based methods that are sensitive, homogeneous 
and adaptable to a high-throughput format. FP requires complex polarizing optics, 
whereas FRET can be measured using simple excitation and emission filters, which 
can be applied to less sophisticated plate readers 162, 175. Conjugation of the proteins 
of interest to fluorophores, makes the FRET assay more robust and time-stable than 
FP assays. Since both methods can be affected by fluorescence interference from 
inhibitors, further confirmation may be required. Subsequent screening of hit 
compounds with cell-based assays can identify biological active inhibitors. In this 
respect, a variation on the FRET technique was recently applied to the Keap1-Nrf2 
PPI in single cells 176. In this study a FRET-based methodology was combined with 
multi-photon fluorescence lifetime imaging microscopy (FLIM).  
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The FRET assay described here is a sensitive method that can be applied to 
quantify protein-protein binding and to screen Nrf2 derived peptides for the 
competitive inhibition of the interaction between Keap1 and Nrf2. Moreover, the 
assay has been applied to identify the inhibition potential of small molecules 
(Section 3.2.11). A future possibility is to adapt the developed FRET assay to a 
time-resolved (TR) FRET assay format. TR-FRET uses a long-lifetime donor 
fluorophore and a short-lifetime acceptor fluorophore combined with pulsed-laser 
excitation and time-resolved detection. The time delay can be very effective in 
reducing background fluorescence that originates from direct excitation of the 





In summary the major findings reported in this chapter are: 
 
• The fusion proteins eCFP-TEV-eYFP, eCFP-TEV-Nrf2 wild type and 
mutants, eYFP-TEV-Kelch and eYFP were successfully expressed and 
purified. 
• FRET was shown to occur when the eCFP and eYFP fluorophores were in 
close proximity of each other (< 10 nm) using the eCFP-TEV-eYFP protein 
construct. Energy transfer was halted following the addition of functional 
TEV protease, which increased the distance between the fluorophores (> 10 
nm).   
• FRET was demonstrated between eCFP-TEV-Nrf2 and eYFP-TEV-Kelch 
and was optimal using a protein ratio of 1:3 respectively. The observed 
FRET between the fusion proteins was found to be due to the interaction 
between Keap1 Kelch and the 16-mer Nrf2 derived peptide and not a result 
of non-specific interactions between the fluorescent tags (Figure 3.27). 
• FRET between eCFP-TEV-Nrf2 and eYFP-TEV-Kelch was found to be 
favoured in a buffer environment with low ionic strength. 
• Determining FRET by quantifying the decrease in donor emission is a direct 
measure of FRET efficiency and minimises the risk of spectral bleed-through 
in the eCFP fluorescence emission channel.  
• The binding affinities of various eCFP-TEV-Nrf2 fusion proteins were 
determined following titration experiments with eYFP-TEV-Kelch. The 
developed assay was found to be sufficiently sensitive to detect changes in 
binding affinity due to single amino acid substitutions in the Nrf2-derived 
peptide.  
• FRET observed between eCFP-TEV-Nrf2 and eYFP-TEV-Kelch was 
competitively inhibited by unlabelled Nrf2-derived peptides, which resulted in 
a restored eCFP fluorescence emission.   
• The developed FRET assay was successfully adapted to a multi-well plate 
format that maintained sensitivity and was found suitable for high throughput 






Figure 3.27: Schematic representation and corresponding emission spectra of the 
specific binding between eCFP-TEV-Nrf2 and eYFP-TEV-Kelch in a 1:3 ratio 




eYFPKelcheCFP Nrf21x eCFP Nrf2 + eYFP Kelch3x
1x eCFP Nrf2 + eYFP3x eCFP Nrf2 eYFP
    
Wavelength (nm)






































































































Chemoprevention by Nrf2 activation, induces the expression of downstream ARE 
regulated detoxifying proteins and enzymes. In this respect, various classes of small 
molecules and peptides have been reported to induce nuclear Nrf2 accumulation 52, 
98. The Nrf2 induction potential of these molecules can be verified by determining 
the amount of up-regulated Nrf2 protein in cells. Typically, western blotting or 
ELISAs have been used for this purpose 178-179. Flow cytometry is an evolving 
technique that has been employed in multi-parametric analysis of various cellular 
characteristics. An important aspect of this versatile technique is its ability to monitor 
protein levels in single cells using intracellular staining techniques 180-181.  
 
The aim of this chapter is to develop an Nrf2 intracellular staining method for 
flow cytometry. This method can be used to detect and quantify constitutive 
and inducible Nrf2 protein levels in different cell lines using various Nrf2 
inducer compounds.  
 
The basis of modern flow cytometry was laid by Moldavan (~ 1930) and Crosland-
Taylor (1953). Moldavan designed a capillary tube device to count individual cells 
and Crosland-Taylor developed this technique further by applying the principles of 
hydrodynamic focusing to align the cells within a fluid stream 182. This stream is 
created by a sheath flow, which is maintained at a constant pressure to ensure cells 








Figure 4.1: Schematic of the flow cytometry principle. Individual (stained) cells are 
hydrodynamic focused with sheath fluid before they intersect a laser beam. Signals are 
passed through bandpass filters and collected by optical detectors including a forward 
scatter detector (FSC), a side scatter detector (SSC) and diverse fluorescent emission 
detectors. The signals are converted to a digital form and send to a computer system.  
 
The sheath pressure should be lower than the cell sample pressure. When a low 
pressure is applied to the sample, the sample flow path is narrowed and a drag is 
created that focuses the cells, allowing them to be analysed one-by-one 
(hydrodynamic focusing). Increasing the sample pressure widens the flow path and 
reduces the focus of cells. Therefore, the sample pressure and sample 
concentration should be kept constant. As cells pass the interrogation point, they 
scatter the light (by reflection and diffraction) in different angles relative to the 
interrogation point. Light that is scattered at low angles in a forward direction 
(forward scattered light or FSC) is used to measure cell size. The light scattered at 
high angles in a sideward direction (side scattered light or SSC) is affected by the 
shape (cell and nucleus) and optical homogeneity or granularity of a cell. As 
fluorescently labelled cells flow through the laser beam, the fluorescent probes are 
excited to a higher energy state. The fluorescence emission is also measured from 
light that is emitted at high angles. The scattered light and fluorescent signals are 
collected by an optical detection system, where the signals are split by dichroic 
mirrors and filters, which direct each signal to the correct detector (Figure 4.1) 183. 
Photomultiplier tubes or PMTs are responsible for the amplification of the 
















The fluorescence emission intensity is then converted to a digital signal and is 
presented as a mean, median or mode of the entire intensity range.  
 
Flow cytometry allows the detection of proteins expressed on cell membranes 
(surface staining) or inside cells (intracellular staining) 185. In comparison with cell 
surface labelling, intracellular staining requires fixation and permeabilisation of the 
cells to allow antibodies to pass the cell membranes. This is then followed by either 
a direct or indirect staining approach. In direct staining, cells are incubated with a 
fluorophore conjugated primary antibody. Since there is only one antibody 
incubation step, there is a minimal risk of non-specific binding. However, 
fluorophore conjugated versions of specific primary antibodies are often not 
available, unless produced in-house. In indirect staining, cells are incubated with an 
unconjugated primary antibody and a fluorophore conjugated secondary antibody.  
 
In order to interpret the data there is need for control samples. Unstained controls 
are important to verify the extent of cellular background staining. Isotype controls 
are unconjugated versions of the secondary antibody and are used as a control to 
account for non-specific staining from the primary antibody 186. The level of non-
specific staining from the secondary antibody is estimated by cells stained only with 
the fluorophore conjugated secondary antibody. Furthermore, biological comparison 
controls are needed to distinguish between positive and negative signals 186. Cells 
stimulated with a known protein inducer compound can be used as a positive 
biological control sample. The level of protein induction upon stimulation can be 
best determined by using unstimulated cell samples, which serve as negative 
biological controls.   
 
Western blotting is one of the most frequently used methods to detect and quantify 
specific proteins in a sample of tissue homogenate or cell lysate. This technique 
uses electrophoresis to separate proteins, which are subsequently transferred to a 
membrane and incubated with antibodies specific to the protein of interest (Section 
2.16). Chemiluminescence is a commonly used method to visualise the target 
protein on the membrane 187. In this case the added secondary antibody is 
conjugated to horseradish peroxidase (HRP). The membrane bound HRP-
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conjugated antibody converts chemiluminescent substrates (peroxide and an 
enhanced luminol solution) into light that can be detected by a sensitive camera. 
Protein levels are then determined with densitometry, using a housekeeping gene 
(e.g. β-actin) as a loading control. Quantifying the expression of proteins using 
western blotting has several benefits over other methods: it allows for the 
determination of the size and molecular weight of the target protein and is indicative 
of the specificity of the primary antibody 188. Since the signal is amplified 
enzymatically, proteins expressed at very low levels can be visualised 189. Although 
some level of optimisation is required, western blotting is a relatively straight-
forward method. Nevertheless, there are some important disadvantages to be 
considered. Western blotting involves multiple steps, which are rather time-
consuming and can take up to two days: sample preparation, SDS-PAGE, protein 
transfer, blocking of non-specific sites, primary and secondary antibody incubation, 
multiple washing steps and development of the blot. In addition, western blotting 
requires large numbers of cells 190-191. The technique doesn’t allow for the 
separation of cells based on their responsiveness and obtains an average value for 
the protein expressed in a whole cell population (population analysis) 189. 
Consequently, repetition experiments can acquire different datasets and limit the 
statistical significance. One of the important aspects of flow cytometry is its ability to 
measure events in individual cells (single-cell analysis). This makes protein 
quantification using this method more informative and reliable 192.  
 
Over the years flow cytometry has become a widely used and applied technique in 
both the research laboratory and the clinic. Analysis of e.g. red blood cells, 
leucocytes and platelets are an important part of routine flow cytometry in the clinic. 
Cell surface staining allows for the detection and quantification of specific immune 
cell subsets and has been applied to immunophenotyping (e.g. CD4+ T cell blood 
counts in HIV patients) and cancer diagnostics (e.g. CD20+ B cell malignancies) 193. 
The development of intracellular cytokine staining permits the simultaneous 
detection of multiple cytokines in one single cell sample 194. Other applications 
involve cell cycle and DNA analysis. The use of flow cytometry for (nuclear) protein 
quantification presents another interesting application. The combination of these 
flow cytometry techniques can provide valuable information regarding various 




Although some developed protocols for nuclear protein staining have recently been 
published 195-197, there is no standard procedure for staining intracellular (nuclear) 
antigens using flow cytometry and each protocol has to be tailored to the specific 
(nuclear) protein under study. Nuclear antigens require different fixation and 
permeabilizing treatments to cytoplasmic antigens. To date, no such protocol has 
been designed for the detection and quantification of Nrf2. In this study, cells are 
treated with a known Nrf2 inducer compound before they are fixed and 
permeabilised (Figure 4.2). Subsequently, an indirect staining approach is used, 
which includes the incubation of cells with an unconjugated anti-Nrf2 primary 
antibody followed by a fluorophore conjugated secondary antibody. Since the 
induction of Nrf2 was expected to result in the accumulation of the transcription 
factor in the nucleus, the intracellular staining method was adapted to label the Nrf2 
protein in both whole cells and isolated nuclei. The level of Nrf2 protein expressed is 
determined by calculation of the median fluorescence intensity (MFI) for each 
protein-antibody complex. This chapter describes the development of a working 
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4.2 Results: set-up of a standard protocol 
 
The paragraphs below describe the different aspects that were considered whilst 
setting up a standard protocol for the intracellular staining of Nrf2.  
 
4.2.1 Stimulation conditions for Nrf2 induction 
 
To evaluate the ability of flow cytometry to determine Nrf2 protein levels inside cells, 
stimulation conditions that triggered up-regulation of the transcription factor had to 
be determined. Literature suggests that the murine hepatoma cell line Hepa1c1c7 is 
highly responsive to Nrf2 inducer compounds 198. Hence, this cell line was selected 
for the initial evaluation of this method. Sulforaphane is a natural product isolated 
from cruciferous vegetables and a known Nrf2 inducer 68. This compound up-
regulates Nrf2 by covalently modifying cysteine residues in the Keap1 protein, 
impeding ubiquitination of Nrf2 40. Sulforaphane has demonstrated the ability to 
activate the phase II enzyme NQO1 in Hepa1c1c7 cells 199. Moreover, western 
blotting experiments showed induced Nrf2 expression in Hepa1c1c7 cells stimulated 
with 10 µM sulforaphane for 1 h (Figure 4.6). Hence, cells that received this 
treatment were used as positive biological comparison controls (also referred to as 
‘stimulated sample’) in the following flow cytometry experiments.   
 
4.2.2 Instrument settings  
 
One of the important steps for the development of a protocol for intracellular staining 
is setting the PMT voltages (i.e. instrument gain) on the flow cytometer 
(MACSQuant Analyzer, Miltenyi Biotec). Here, the PMT voltages were set using an 
unstained cell sample. The FSC and SSC voltages were adjusted until the cells 
appeared in the middle of the two-dimensional dot-plot (150V FSC, 300V SSC) 
(Figure 4.3 A). The FITC voltage was set such that the unstained cells appeared in 
the 1st log decade of the fluorescence histogram (300V FITC). This voltage was 
used to measure stained cell samples. Figure 4.3 B shows the position of the 
unstained sample in relation to the isotype control (unconjugated anti-rabbit IgG), 
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4.2.3 Fixing and permeabilisation conditions 
 
Prior to intracellular staining, cells need to be fixed and permeabilised. Cells are 
fixed to maintain and stabilise the cellular structure before the cell membranes are 
permeabilised to allow antibodies to access. Formaldehyde is a commonly used 
fixative that cross-links proteins 203. Formaldehyde prevents cell clumping and 
maintains cellular scatter properties when used before a permeabilisation reagent 
188. Permeabilisation of the cells with organic solvents such as methanol precipitate 
and denature proteins, which provides access to nuclear antigens 189. Hence, the 
combination of formaldehyde and methanol was expected to suit the intracellular 
staining of the nuclear transcription factor Nrf2. Initially, cells were fixed with 1.5% 
formaldehyde and permeabilised with ice-cold methanol, which were the conditions 
adopted from 188. Methanol permeabilised cells were found to be stable to storage 
for up to a week at - 80 °C without substantial loss of staining efficiency.  
 
4.2.4 Antibody selection 
 
Since no fluorescent labelled primary anti-Nrf2 antibody was available, an indirect 
staining approach was adopted. The rabbit polyclonal anti-Nrf2 H300 (SantaCruz) 
antibody was used as an unconjugated primary antibody for initial flow cytometry 
experiments since Nrf2 expression could be demonstrated with western blotting 
using this antibody (Figure 4.6 A). The goat anti-rabbit IgG-FITC conjugated 
antibody (SantaCruz) was selected as a fluorophore conjugated secondary 
antibody. The FITC fluorochrome was chosen as there is a wide range of FITC 
labelled antibodies available. Both antibodies were titrated at a dilution range of 
1:25 – 1:500 using sulforaphane stimulated cell samples (Figure 4.5). The data 
were best separated into positive (sulforaphane stimulated) and negative signals 
(unstained) with a minimal use of antibodies using dilutions of 1:100 for the 
polyclonal primary antibody and 1:500 for the FITC conjugated secondary antibody. 
Certain antibody combinations resulted in deformity of the FITC fluorescence peaks, 
which could be due to aggregation of the antibody-protein complexes. The isotype 
control antibody, unconjugated anti-rabbit IgG (SantaCruz), was matched with the 
FITC conjugated secondary antibody and used at the same optimised dilution 
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Formaldehyde was added to the buffer to ensure fixation of the cells throughout the 
procedure. However, the cross-linking nature of formaldehyde induced FITC 
fluorescence background staining 204. The final standard protocol that was 
developed is described in Table 4.1.  
 




1 Stimulate cells with Nrf2 inducer compound 
2 Trypsinise cells 
3 Pellet cells 
4 Resuspend cells in PBS 
5 Fix cells cells in 1.5% formaldehyde for 10 min at RT 
6 Pellet cells 
7 Permeabilise cells in ice-cold methanol for 30 min on ice 
8 Wash cells in buffer 
9 Block cells in buffer for 10 min at RT 
10 Stain cells with 1:100 anti-Nrf2 H300 primary pAb overnight at 4°C 
11 Wash cells in buffer 
12 Stain cells with 1:500 anti-rabbit IgG FITC conjugated secondary pAb 
for 1 hour at RT 
13 Wash cells in buffer 
14 Analyse samples on flow cytometer 
 
4.2.6 Standard protocol 
 
The protocol was applied to stain Nrf2 in unstimulated and sulforaphane stimulated 
Hepa1c1c7 cells. Flow cytometry analysis showed no visible staining difference 
between stimulated and unstimulated samples (FD or fold difference ~ 1.2) (Figure 
4.6 B). Western blotting analysis was carried out to verify the antibody specificity of 
the polyclonal anti-Nrf2 primary antibody. Results revealed the presence of multiple 
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FITC versus PerCP conjugated secondary antibody 
Since we found that formaldehyde fixation increased the FITC auto-fluorescence 
signal (Section 4.2.5), a second fluorophore conjugated secondary antibody was 
tested. PerCP fluoresces in the red region of the spectrum and is not affected by 
formaldehyde fixation 204. However, changing the FITC conjugated secondary 
antibody to a PerCP conjugated secondary antibody resulted in a substantial 
reduction in fold change: FD ~ 3.4 for FITC versus FD ~ 2.0 for PerCP for whole cell 
samples and FD ~ 7.7 for FITC versus FD ~ 2.6 for PerCP for nuclei samples (Table 
4.2).   
 
Staining volume 
Antibody staining was originally carried out in a final volume of 500 µL. To decrease 
the amount of antibody needed, the final volume was reduced to 100 µL. However, 
this resulted in a decreased fold change: FD ~ 3.4 for 500 µL versus FD ~ 2.3 for 
100 µL for whole cell sample and FD ~ 7.7 for 500 µL versus FD ~ 4.6 for 100 µL for 
nuclei samples (Table 4.2).  
 
Formaldehyde fixation 
To test whether staining efficiency was affected by the percentage of formaldehyde, 
cells were fixed with 1.5% or 0.5% formaldehyde. The fold change was slightly 
reduced when cells were fixed with 0.5% formaldehyde: FD ~ 3.4 for 1.5% versus 
FD ~ 3.1 for 0.5% for whole cell samples and FD ~ 7.7 for 1.5% versus FD ~ 7.5 for 
0.5% for nuclei samples (Table 4.2).  
 
Other 
The buffer conditions of the Foxp3 staining buffer set (Miltenyi Biotec) are 
specifically designed for the intracellular staining of the Foxp3 transcription factor. 
To verify whether such optimised conditions for a transcription factor could enhance 
the staining of the Nrf2 transcription factor, the buffer set was compared with the 
original fixation (1.5% formaldehyde) and permeabilisation (ice-cold methanol) 
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conditions. Similar results were found for both methods (FD ~ 3.0 for whole cells) 
(Table 4.2).  
 
Table 4.2: Overview of conditions tested to optimise the standard intracellular Nrf2 staining 
protocol. Shown are fold changes from representative experiments. Abbreviations used in 
the table: whole cells (W), nuclei (N), primary antibody (1st Ab), secondary antibody (2nd Ab), 
polyclonal antibody (pAb), monoclonal antibody (mAb), overnight (o/n) and formaldehyde 
(FA).  
 




FA fixation Fold 
change 
1 W Nrf2 
pAb 
FITC 
pAb o/n 500 µL 1.5 % 1.2 
2 N Nrf2 
pAb 
FITC 
pAb o/n 500 µL 1.5 % 1.4 
3 W Nrf2 
mAb 
FITC 
pAb o/n 500 µL 1.5 % 3.4 
4 N Nrf2 
mAb 
FITC 
pAb o/n 500 µL 1.5 % 7.7 
5 W Nrf2 
mAb 
FITC 
pAb 1 h 500 µL 1.5 % 2.7 
6 N Nrf2 
mAb 
FITC 
pAb 1 h 500 µL 1.5 % 7.0 
7 W Nrf2 
mAb 
PerCP 
pAb o/n 500 µL 1.5 % 2.0 
8 N Nrf2 
mAb 
PerCP 
pAb o/n 500 µL 1.5 % 2.6 
9 W Nrf2 
mAb 
PerCP 
pAb 1 h 500 µL 1.5 % 2.0 
10 N Nrf2 
mAb 
PerCP 
pAb 1 h 500 µL 1.5 % 3.0 
11 W Nrf2 
mAb 
FITC 
pAb o/n 100 µL 1.5 % 2.3 
12 N Nrf2 
mAb 
FITC 
pAb o/n 100 µL 1.5 % 4.6 
13 W Nrf2 
mAb 
FITC 
pAb o/n 500 µL 0.5 % 3.1 
14 N Nrf2 
mAb 
FITC 
pAb o/n 500 µL 0.5 % 7.5 
15 W Nrf2 
mAb 
FITC 
pAb o/n 100 µL 0.5 % 1.4 
16 N  Nrf2 
mAb 
FITC 
pAb o/n 100 µL 0.5 % 4.2 
17 W Nrf2 
mAb 
FITC 






4.4 Results: application of the intracellular Nrf2 staining assay 
 
Following on from the evaluation of various conditions for their ability to affect 
staining efficiency, improvements were found when changing the primary anti-Nrf2 
antibody from a polyclonal to a monoclonal variant and by applying the procedure to 
isolated nuclei. As a result, the staining steps in the standard protocol (Table 4.1) 
were adapted accordingly and protocol steps were included for isolation of the 
nuclei. The adapted standard protocol is described in Table 4.3 and was applied to 
the following flow cytometry experiments.      
 
Table 4.3: Adapted standard protocol for the intracellular staining of Nrf2. Protocol steps 
describing the staining procedure were adapted from the standard protocol and indicated 
with *. Protocol steps that were added for the isolation of nuclei are indicated with **.   
 
Step Description 
1 Stimulate cells with Nrf2 inducer compound 
2 Trypsinise cells 
3 Wash cells in buffer 
4 Pellet cells 
**5 Resuspend cells in 100 µL/1x106 CER I (NE-PER kit, Thermo Scientific) and incubate 
for 10 min on ice 
**6 Add 5.5 µL/1x106 CER II (NE-PER kit, Thermo Scientific) and incubate for 1 min on ice 
**7 Pellet nuclei 
8 Resuspend nuclei in PBS (check nuclear integrity by trypan blue staining) 
9 Fix cells cells in 1.5% formaldehyde for 10 min at RT 
10 Pellet cells 
11 Permeabilise cells in ice-cold methanol for 30 min on ice 
12 Wash cells in buffer 
13 Block cells in buffer for 10 min at RT 
*14 Stain cells with 1:1000 anti-Nrf2 D1Z9C-XP primary mAb overnight at 4°C 
15 Wash cells in buffer 
*16 Stain cells with 1:200 anti-rabbit IgG FITC conjugated secondary pAb for 1 hour at RT 
17 Wash cells in buffer 
18 Analyse samples on flow cytometer 
 
To verify whether this protocol could be used to quantify Nrf2 protein levels, 
Hepa1c1c7 cells were stimulated with 10 µM sulforaphane for 1, 3, 6 and 24 h. 
Next, nuclei were isolated, fixed, permeabilised and stained according to the 
adapted standard protocol (see above). Although the protocol can also be applied to 
whole cells, an overall higher signal-to-noise ratio was achieved using nuclei. In 
parallel, similar sulforaphane stimulated nuclei were lysed and subjected to SDS-
PAGE and western blotting. Similar qualitative results were observed for flow 
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Figure 4.14: Absolute fold changes calculated for flow cytometry analysis of HeLa and MCF-
7 cells. The cells were unstimulated or stimulated with 10 µM sulforaphane for 1, 3, 6 and 24 
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A range of conditions was examined to develop a protocol and to ensure optimal 
staining levels. An important aspect of the assay development is the selection of 
antibodies. Here, a monoclonal primary anti-Nrf2 antibody was found to stain more 
efficiently than a polyclonal anti-Nrf2 antibody. Primary antibody incubation times 
were optimal overnight, but may be shortened to 1 h with minimal signal loss to 
speed-up the processing time. Western blotting analysis revealed the presence of 
more non-specific protein bands when using the polyclonal antibody compared to 
the monoclonal antibody. This finding suggests that background staining 
compromised the staining efficiency. In this respect, western blotting was indicative 
of staining efficiency and served as a supportive tool to verify antibody specificity. 
The monoclonal anti-Nrf2 antibody was raised against a synthetic linear peptide and 
thus required protein denaturation to reveal the epitope. The monoclonal antibody 
recognition of Nrf2 may have benefited from the chosen fixation and 
permeabilisation conditions. Formaldehyde stabilises antigens by forming a matrix 
of static proteins thereby preventing further cell signaling 188. Methanol dehydrates 
and permeabilises cells, which can cause protein denaturation and may enable 
enhanced antibody access to nuclear antigens 189, 191. However, these conditions 
might have impaired polyclonal antibody recognition of Nrf2. Antibody-antigen 
binding can also be affected by charge; hence recognition of charged epitopes is 
dependent on the overall charge of the antibody.  
 
To further optimise staining levels and to decrease formaldehyde induced auto-
fluorescence, the fluorophore conjugated to the secondary antibody was changed 
from a FITC label (emission at 519 nm) to a PerCP label (emission at 675 nm). The 
observed decrease in staining efficiency might have been affected by the larger size 
of the PerCP fluorophore (35 kDa) compared to the FITC fluorophore (389 Da). The 
large PerCP protein may have reduced the uptake of the antibody conjugate into 
cells and blocked specific antigen binding sites due to steric hindrance [8, 9]. 
Staining efficiency may benefit from using a different fluorophore that emits light in 
the red spectrum, but is of a similar size to FITC (e.g. Cy5).  
 
In an attempt to reduce the amount of antibody needed, the staining volume was 
reduced to 100 µL. However, experiments showed that this resulted in a decreased 
staining efficiency. An increased volume of 500 µL was needed to ensure optimal 
antibody-protein contact.  
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Results have shown that the developed method can generate both qualitative and 
quantitative data on Nrf2 protein expression levels. Intermediate protein level 
changes were apparent by both techniques (compare Figure 4.12 A with Figure 
4.12 B) and normalised fold changes correlated closely when comparing flow 
cytometry to western blotting analysis (Figure 4.12 D). However, absolute fold 
changes and error bars differed between both methods (Figure 4.12 C). Since 
western blotting uses population analysis to provide one data point, identically 
stained protein bands may arise from a diverse response rate among a cell 
population 189. This may present a risk of under or over estimation of the protein 
expression. Moreover, the outcome of identical western blotting experiments may 
differ, which might explain the larger error bars observed. Flow cytometry benefits 
from its ability to measure protein levels in single cells, which may result in improved 
reproducibility of the fold changes observed. Furthermore, this technique doesn’t 
employ enzymatic signal amplification hence no saturation can occur 197. The flow 
cytometry protocol can be completed in one day whereas two days are needed for 
western blotting. Although protein quantification with flow cytometry has multiple 
advantages to western blotting, it remains crucial to verify the specificity of the 
antibodies using qualitative western blotting 189. Furthermore, the choice of primary 
antibody was found to be the key to successful intracellular Nrf2 staining.  
 
The developed intracellular staining method allows for the detection and 
quantification of constitutive and inducible Nrf2 protein levels in various cell lines. 
The assay was shown to work in the mouse Hepa1c1c7 and human HeLa and 
MCF-7 cell lines, but can be adapted for use in other cell lines. A different Nrf2 
response profile was observed among the cell lines after stimulation with 
sulforaphane. This differential effect could be attributed to the cell line’s origin (i.e. 
murine versus human). In addition, a higher Nrf2 induction level was detected in 
MCF-7 cells compared to HeLa cells. These observations can provide valuable 
information regarding Nrf2 levels in different species and tissues.    
 
The indirect staining approach used here offers the option of prior evaluation of 
unconjugated primary antibodies via western blotting. Other potential benefits 
include: detection of the protein of interest with diverse fluorophores and detection 
of multiple proteins in one single sample (multi-parameter analysis) 197. Multi-
parameter analysis is a powerful option to study (inducible) expression levels of a 
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range of proteins involved in the Keap1-Nrf2 pathway. The developed assay has 
already been used to study the Nrf2 induction potential of various small molecules. 
Future work may include screening those compounds for their ability to induce both 
Nrf2 and downstream phase II enzyme (e.g. NQO1 or HO-1) expression levels in 
multiple cell lines using different fluorescent labelled secondary antibodies. 
Induction potentials can be studied over a wide dose-range thereby generating IC50 
values. In addition, pathway specificity of novel Nrf2 inducers may be explored by 
examining the expression levels of related transcription factors and their target 
products (e.g. AhR and CYP1A1).   
 
In various cancerous tissues mutations occur in the coding region of Keap1 and/or 
Nrf2, resulting in constitutive induction and accumulation of Nrf2 55, 208. As a result, 
malignant cells become insensitive to anti-cancer treatments. The developed flow 
cytometry assay could be used to examine the potency of Nrf2 inhibitors and Nrf2 
siRNA, which may enhance chemotherapeutic sensitivity. The effectiveness of 






In summary, the major findings in this chapter are: 
 
• Nrf2 protein induction levels can be detected and quantified reliably using 
this flow cytometry method.   
• Antibody specificity is essential for optimal intracellular Nrf2 staining 
efficiency: a monoclonal anti-Nrf2 antibody presented a larger fold change 
than a polyclonal anti-Nrf2 antibody.  
• Western blotting provides a supportive qualitative tool: i.e. verification of the 
molecular weight of the protein of interest and antibody specificity.  
• There appears to be a negative association between the extent of 
background staining detected by western blotting and intracellular Nrf2 
staining efficiency. 
• The developed intracellular Nrf2 staining method can be applied to both 
whole cells and isolated nuclei. 
• Application of this method to isolated nuclei resulted in a higher staining 
efficiency. 
• The developed intracellular Nrf2 staining approach can be applied to study 
the effect of diverse Nrf2 inducer molecules in various cell lines. 
• The indirect staining approach offers the option for multi-parameter analysis: 
the induction of other related proteins can be measured in the same sample 








The isothiocyanate, sulforaphane, is one of the first and most extensively studied 
natural Nrf2 inducers. In the Prochaska NQO1 induction assay 65, sulforaphane 
doubled the NQO1 enzymatic activity at a concentration range of 0.4 – 0.8 µM in 
Hepa1c1c7 cells 209. Moreover, sulforaphane has been shown to up-regulate other 
phase II enzymes including, heme oxygenase 1 (HO-1), glutamate cysteine 
synthetase, glutamate peroxidase (GSH), glutathione reductase, glutathione S-
transferase (GST), epoxide hydrolase, ferritin, thioredoxin and thioredoxin reductase 
and UDP-glucuronosyltransferase 1A in either cells or in vivo 69. The induction of 
phase II enzymes by sulforaphane was shown to be dependent on the presence of 
Nrf2 in Nrf2 knock-out studies 69. Several studies in mice revealed that sulforaphane 
inhibited the development of tumours upon exposure to various carcinogens, but 
this protective effect was abolished in Nrf2 knock-out mice 69, 73. Sulforaphane was 
also shown to affect the expression and activity of phase I enzymes from the 
cytochrome P450 family. In some studies sulforaphane inhibited the activity of 
and/or downregulated certain CYP enzymes, such as CYP1A1, 1A2, 2B1/2, 2E1 
and 3A4 in hepatocytes, whereas in others the isothiocyanate increased the 
expression of CYP1A1, 1A2, 2B1/2, 2C11 and 3A1 in rat lung tissue 69. Evidence 
has emerged from preclinical studies that sulforaphane induces the up-regulation of 
Nrf2 target genes differently depending on the cell or tissue type 72. This could be 
due to e.g. differences in sulforaphane metabolism, direct or indirect exposure via 
digestion or systemically and nucleotide polymorphisms in downstream target genes 
72. In addition, sulforaphane is found to have a cytoprotective effect at lower doses 
whereas higher doses are associated with apoptosis, anti-angiogenesis, anti-
histone deacetylase activity and metastasis inhibition in cancer cells 72. The effects 
at higher doses were shown to target specifically cancerous cells, while normal cells 
were unaffected 210. This effect has been partly attributed to the increased inhibitory 
effect of sulforaphane on the activity of histone deacetylase (HDAC) proteins in 
cancer cells versus normal cells, resulting in an increase in apoptosis and cell cycle 
arrest 210. In diverse types of cancer, the p53 tumour suppressor gene is mutated. 
Sulforaphane was found to offset the effects of a mutated p53, which suggest its 
beneficial effect is not restricted to non-mutated/normal cells 211.   
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These findings are of great clinical importance and advocate sulforaphane as both a 
preventive and therapeutic agent. 
  
The aim of this chapter is to characterise sulforaphane as a benchmark for the 





5.2 Results  
 
5.2.1 NQO1 assay  
 
The cell-based NQO1 assay has been used as an initial screening tool to compare 
putative Nrf2 inducer molecules with the reference compound sulforaphane. 
Preliminary experiments showed that Hepa1c1c7 cells need to be exposed to 
sulforaphane for at least 24 h before NQO1 enzyme activity can be detected. 
Hence, Hepa1c1c7 and BpRc1 cells were stimulated with sulforaphane for 24 and 
48 h before cells were lysed and an enzyme reaction mixture containing glucose-6-
phosphate (G6P), glucose-6-phosphate (G6P) dehydrogenase and NADP was 
added. This reaction generates NADPH that is used by NQO1 to transfer electrons 
to menadione. Following a colourimetric reaction, to reduce menadione to menodiol, 
which consecutively reduces MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to a formazan, NQO1 induction levels were 
determined (Figure 1.14). The compounds concentration that caused a doubling of 
NQO1 activity relative to the control was used to quantify and rank their ability to up-
regulate NQO1 (CD value or concentration that causes a two-fold increase in 
activity relative to the control).  
 
As mitochondria contain numerous redox enzymes that are able to reduce MTT, 
prior studies were conducted to confirm the specificity of the reaction. Prochaska et 
al. 65 found that the reduction of MTT is accelerated following the reduction of 
menadione by NQO1 compared to the direct reduction of MTT by NQO1. The 
requirement of menadione to reduce MTT more efficiently was verified by 
comparing the reaction with and without menadione. As hypothesised, the addition 
of menadione resulted in a significant increase in amount of reduced MTT in 
sulforaphane stimulated cells. The specificity of the assay for the NQO1-dependent 
reduction of MTT was further examined by incubating sulforaphane stimulated cells 
with dicoumarol, a competitive NQO1 inhibitor 212, before adding the enzyme 




The NOQ1 dose-response curves for sulforaphane in both the Hepa1c1c7 and 
BpRc1 cell lines are shown in Figure 5.2 A and B respectively. CD values obtained 
after 24 h of sulforaphane stimulation were ~ 0.4 µM and ~ 0.6 µM for Hepa1c1c7 
and BpRc1 cells respectively. After 48 h sulforaphane stimulation CD values of ~ 
0.2 µM and ~ 0.4 µM were obtained for the Hepa1c1c7 and BpRc1 cells 
respectively. Although CD values were reduced after a longer stimulation time, 24 h 
of stimulation was sufficient to observe an increase in NQO1 activity and to obtain a 
CD value. Moreover, increasing the stimulation time to 48 h compromises the time 
efficiency of the assay. As a result of extended assay time, fewer experiments per 
week can be executed. Hence, in the following experiments cells were stimulated 
with compounds for 24 h to measure their NQO1 induction potential.  
 
 
Figure 5.2: Dose response curves for the NQO1 assays of sulforaphane in Hepa1c1c7 (●) 
and BpRc1 (○) cells after 24 h (A) and 48 h (B) stimulation. The red line indicates a doubling 
of NQO1 activity (CD value). The error bars represent the standard deviation of n = 3 
independent experiments.     
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5.2.2 SRB cytotoxicity assay 
 
The sulforhodamine B (SRB) colourimetric assay has been widely used for toxicity 
screening of drugs and compounds. The method is based on the ability of the 
protein dye SRB to bind to the basic amino acid residues of trichloroacetic acid 
(TCA) fixed cells under mildly acidic conditions 213. The UV absorbance of the bound 
SRB recorded after a washing step is proportional to the cell number and cellular 
total protein content measured over a cellular confluency range from 1 – 200% 214. 
The SRB assay was carried out to verify the cytotoxicity of sulforaphane at 
concentrations up to 100 µM (in 0.1% DMSO final concentration) after 24 and 48 h 
of stimulation of Hepa1c1c7, BpRc1 and HeLa cells (Figure 5.3 A, B and C 
respectively). The mouse hepatoma cell lines were selected for cytotoxicity 
screening as they were used to determine whether sulforaphane was able to up-
regulate Nrf2 and downstream phase II enzymes. To compare cytotoxicity levels 
with a different tissue and species, the human HeLa cell line was used. 
Sulforaphane did not affect cell viability in either of the cell lines at concentrations 
up to 10 µM after 24 and 48 h. However, a concentration of 30 µM reduced cell 
viability by 10 – 20% and a concentration of 100 µM decreased cell viability by 80 – 
100 % in the mouse hepatoma cell lines. Sulforaphane was less cytotoxic in the 
HeLa cell line; 30% and 50% reduction in cell viability was observed at a 
concentration of 100 µM after 24 and 48 h respectively. Figure 5.3 C shows an 
overlay of the NQO1 induction potency and SRB determined cytotoxicity for 
sulforaphane treated Hepa1c1c7 cells. As a maximum NQO1 induction level was 
observed at 10 µM of sulforaphane without compromising the cell viability, all 




















Figure 5.3: Dose response curves for the SRB assays of sulforaphane in Hepa1c1c7 (●), 
BpRc1 (○) and HeLa cells (▼) after 24 h (A) and 48 h (B) stimulation. Cell viability is 
calculated as a percentage of cells treated with vehicle only (0.1% DMSO). Error bars are 
based on n = 4 replicates in a representative experiment. Graph C shows an overlay of the 
NQO1 induction potency (●) (Figure 5.2 A) and SRB determined cytotoxicity (○) (Figure 5.3 







































































5.2.3 Western Blotting 
 
Western blot experiments were carried out to demonstrate induction of nuclear Nrf2 
and the downstream cytoplasmic phase II enzymes HO-1 and NQO1 in Hepa1c1c7 
and BpRc1 cells following stimulation at a fixed concentration of 10 µM 
sulforaphane over a 24 h period. Cell samples were taken after 1, 3, 6 and 24 h of 
compound exposure and separated into cytoplasmic and nuclear protein fractions. 
The resulting cell samples were analysed by immunoblotting using either rabbit 
polyclonal anti-Nrf2 H300, rabbit polyclonal anti-HO-1 H-105 or mouse monoclonal 
anti-NQO1 antibodies (all SantaCruz). Figure 5.4 A, 5.5 A and Figure 5.6 show an 
increase in nuclear Nrf2 protein levels in both cell lines that is time dependent with 
the highest induction level observed after 1 h; the fold induction was ~ 20 in 
Hepa1c1c7 cells and ~ 15-fold in BpRc1 cells. During the time course stimulation 
studies, sulforaphane also induced the expression of the phase II enzymes HO-1 
and NQO1 (Figures 5.4 - 5.5 C and D respectively and Figure 5.6). Cytoplasmic 
protein fractions from Hepa1c1c7 and BpRc1 cells showed a peak HO-1 induction 
after 6 h (fold induction ~ 7 in Hepa1c1c7 cells and a fold induction ~ 6 in BpRc1 
cells), though up-regulation of NQO1 was only detected after 24 h. NQO1 protein 



















































 24 h time p
e shown.  
146
of nuclear 







 cells after t






th 10 µM 
 and E). 
147 
 
























Figure 5.6: Quantitative western blot results of Nrf2 and HO-1 up-regulation in sulforaphane 
treated Hepa1c1c7 (light and dark blue bars respectively) and BpRc1 cells (light and dark 
purple bars respectively). Protein induction levels were expressed as relative ratio’s (RR) 
with ß-actin as a loading control. A RR ratio of 1 corresponds to no protein induction. The 
error bars represent the standard deviation of n = 2 independent experiments.   
 
5.2.4 Intracellular Nrf2 staining – flow cytometry 
 
The up-regulation of nuclear Nrf2 as a result of treating Hepa1c1c7 cells with 
sulforaphane was quantified by the flow cytometry method developed to determine 
intracellular Nrf2 staining. The results are discussed in Chapter 3. In summary, flow 
cytometry revealed a comparable trend to western blotting for Nrf2 up-regulation 
over time, but a difference in absolute fold changes. A different time course Nrf2 
induction pattern was observed in the human cell lines HeLa and MCF-7 compared 
to the murine hepatoma cell line: a peak Nrf2 protein induction after 3 h versus a 
maximum Nrf2 induction after 1 h of sulforaphane treatment respectively.   
 
5.2.5 Pathway evaluation 
 
In this section, various methods have been used to verify the possibility that 
sulforaphane up-regulates phase II enzymes via mechanisms other than the Keap1-




Two small molecule direct inducers failed to induce the phase II enzyme NQO1 in 
the ARNT-deficient BpRc1 cell line (Sections 7.3.2 and 7.5.1). This prompted the 
examination of the involvement of the AhR pathway in upregulation of NQO1 by 
these compounds (Sections 7.3.5 and 7.5.5). Sulforaphane was used as a 
reference compound for these studies and was subjected to identical examination. 
Previous results demonstrated that sulforaphane was able to induce nuclear 
accumulation of Nrf2 in both Hepa1c1c7 and BpRc1 cells (Section 5.2.3). Moreover, 
the induction level of NQO1 and HO-1 enzymes was similar in both cell lines after 
stimulation with sulforaphane (Section 5.2.3). This suggests that up-regulation of 
phase II enzymes by sulforaphane is likely to be largely independent of the AhR 
pathway. To verify these findings, western blot analysis was performed of nuclear 
AhR and cytoplasmic CYP1A1 expression in sulforaphane treated Hepa1c1c7 cells 
(Figure 5.8 A and B respectively and Figure 5.9). The cells were stimulated with 10 
µM sulforaphane over a 24 h time period with nuclear and cytoplasmic protein 
samples taken at 1, 3, 6 and 24 h. As a positive control, cells were stimulated with 
the AhR ligand benzo(a)pyrene (BaP). An SRB assay was performed to examine 
the cytotoxicity of BaP at concentrations up to 10 µM in Hepa1c1c7 cells after 24 h 
of exposure (Figure 5.7). BaP did not affect cell viability at concentrations up to 3 
µM, but decreased cell viability at concentrations of 10 µM by 10 – 20 %. Hence, the 
following experiments were performed at a concentration of 3 µM BaP.   
BaP (µM)
















Figure 5.7: Dose response curve for the SRB assays of BaP in Hepa1c1c7 cells after 24 h 
stimulation. Cell viability is calculated as a percentage of cells treated with vehicle only. Error 
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Figure 5.9: Quantitative western blot results of AhR and CYP1A1 up-regulation in 10 µM 
sulforaphane treated Hepa1c1c7 cells (black and white bars repetitively). Protein induction 
levels were expressed as relative ratio’s (RR) with ß-actin as a loading control. A RR ratio of 
1 corresponds to no protein induction. The error bars represent the standard deviation of n = 
2 independent experiments.   
 
Next, a CYP1A1 enzyme activity assay (P450 Glo Assay, Promega) was performed 
to validate the western blot results. This luminescence cellular assay measures the 
amount of luciferin-derived (CYP1A1 specific) substrate converted by CYP1A1 
enzyme activity. In the presence of a luciferin detection reagent (Promega), the 
liberated luciferin derivative generates an amount of light that is directly proportional 
to the CYP1A1 enzymatic activity. Hepa1c1c7 cells were stimulated with 10 µM 
sulforaphane (S) for 6 and 24 h (detectable CYP1A1 enzyme on western blot) 
before the luciferin substrate was added. Cells stimulated with 3 µM BaP were used 
as a positive control (P) and the negative control (C) cells were stimulated only with 
the vehicle DMSO. Since some cell loss was expected as a result of assay 
handling, the amount of luminescence detected (RLU luciferin) was corrected for 
cell viability using the SRB assay (detail in Section 2.23) (Figure 5.10 A). Following 
the measurement of luminescence in the cell culture medium, which is 
representative of CYP1A1 activity, the cells were fixed in 10% TCA and stained with 
SRB. The percentage cell viability was calculated and used to correct the 
luminescence values on an individual well basis. Fold changes for sulforaphane and 
BaP versus the vehicle control were calculated and displayed in Figure 5.10 B. The 
positive control BaP shows to have a profound effect on CYP1A1 induction (fold 
induction ~ 42 after 6 h and ~ 51 after 24 h).  
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However, a representative western blot (Figure 5.8 C) shows that a peak induction 
is visible after 6 h. Sulforaphane demonstrates an increase in CYP1A1 activity after 
6 h (fold induction ~ 2.4) and 24 h (fold induction ~ 3.8), which is similar to western 
blotting results (Figure 5.8 B). Nevertheless, fold changes are minor compared to 
BaP.      
 
 
Figure 5.10: CYP1A1 induction measured using the P450 Glo Assay (Promega) following 
exposure of Hepa1c1c7 cells to vehicle control (C), 10 µM sulforaphane (S) or 3 µM BaP 
(P). (A): the quantity of luciferin (RLU) detected is proportional to the extent of CYP1A1 
enzyme activity. The error bars represent the standard deviation of n = 8 replicates in a 




Reactive oxygen species (ROS) can activate the Keap1-Nrf2 pathway by 
modification of cysteine residues in Keap1. As a result of the conformational change 
in Keap1, the ubiquitination process is blocked and Nrf2 is stabilised 215. This 
process allows de novo produced Nrf2 to translocate to the nucleus where it 
induces the up-regulation of phase II enzymes 216. To evaluate whether novel Nrf2 
inducers induce the expression of Nrf2 and downstream target genes via the 
production of ROS, sulforaphane was used as a negative control in a flow cytometry 
based method for detecting cellular ROS. However, it has been suggested that 
sulforaphane is able to induce ROS production in certain cell lines, including the 




































for 1 h with 10 µM of sulforaphane before the cells were incubated with CellROX 
Deep Red reagent (Life Technologies). The reagent contains a fluorogenic probe 
that is non-fluorescent when in a reduced state and fluoresces following oxidation 
by ROS (excitation/emission maxima at 644/665 nm). The fluorescent signals from 
the CellROX Deep Red dye are localised in the cytoplasm. The oxidant menadione 
is known to induce ROS production and was used as a positive control 218. The 
negative controls included cells stimulated with vehicle only: DMSO (C1) for 
sulforaphane (S) and acetonitrile (C2) for menadione (M, positive control). Cells that 
received no treatment were used as an assay blank. Figure 5.11 shows the 
measured median fluorescence intensity (MFI) that corresponds to the relative 
amount of ROS produced. Whilst the positive control, menadione, successfully 
induced ROS production, no increase is observed after stimulation of Hepa1c1c7 
cells with sulforaphane.  


















Figure 5.11: ROS production measured using the CellROX Deep Red dye after exposure of 
Hepa1c1c7 cells to 10 µM sulforaphane (S) or 50 µM menadione (M) for 1 h. As controls, 
cells were exposed to the sulforaphane vehicle, DMSO (C1) and the menadione vehicle, 
acetonitrile (C2). The amount of fluorescence (APC MFI) detected is proportional to the 
extent of ROS production. The error bars represent the standard deviation of n = 3 







The reference compound sulforaphane is one of the most extensively studied 
(indirect) Nrf2 inducers and hence was evaluated for its biological activity.  
 
Sulforaphane was found to decrease cell viability at concentrations higher than 10 
µM in mouse hepatoma cell lines after 24 and 48 h. This is consistent with the 
literature 219. Lower cytotoxicity levels were found in the human HeLa cell line. An 
increased level of cytotoxicity may be found in hepatocytes compared to other 
tissue derived cell lines as they are the primary target for metabolizing drugs 220. 
Future experiments should include the assessment of the long-term toxicity of 
sulforaphane on diverse cell lines. Hepa1c1c7 cells demonstrated after 24 h of 
exposure to sulforaphane a doubling of NQO1 activity at a concentration of ~ 0.4 
µM, which is in agreement with the literature 209. This finding was confirmed by time-
dependent western blot experiments, which demonstrated detectable NQO1 protein 
levels after 24 h of exposure to the phytochemical. Evidence emerged that 
sulforaphane is able to up-regulate other phase II enzymes such as glutamate 
cysteine synthetase, glutathione peroxidase, glutathione reductase, ferritin, GST, 
thioredoxin and thioredoxin reductase, UDP-glucuronosyltransferase 1A and HO-1 
69. Indeed, sulforaphane up-regulated HO-1 in Hepa1c1c7 cells after only 1 h and 
continued to induce expression of the protein up to 6 h. To verify whether 
sulforaphane induced the phase II enzymes via the Keap1-Nrf2 pathway, Nrf2 
nuclear accumulation was studied using western blotting and flow cytometry 
techniques. Induction of the transcription factor was maximal after as early as 1 h. 
Sulforaphane demonstrated to induce phase II enzyme NQO1 in the ARNT-deficient 
BpRc1 cell line with a similar induction potential as in Hepa1c1c7 cells. Moreover, 
western blot analysis showed up-regulation of NQO1, HO-1 and Nrf2 nuclear 
accumulation in BpRc1 cells. The time course and level of protein induction was 
analogous to the Hepa1c1c7 cell line. In the BpRc1 cell line, the AhR transcription 
factor is unable to accumulate in the nucleus, hence these results are not 
suggestive of AhR pathway involvement. Nevertheless, CYP1A1 protein and 
enzyme activity (using western blot analysis and the P450 Glo Assay respectively) 
was weakly induced in Hepa1c1c7 cells after 6 – 24 h of stimulation with 
sulforaphane. Western blot analysis indicated that AhR nuclear accumulation was 
slightly inhibited in Hepa1c1c7 cells after 1 – 3 h of exposure to sulforaphane, but 
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this inhibition reversed after 3 – 24 h (Section 5.2.5). These results suggest that the 
inhibitory effect may be transient up to 3 h. After this time, sulforaphane induces 
AhR nuclear accumulation and the transcription of AhR downstream target CYP1A1 
to some extent. Sulforaphane may up-regulate Nrf2 by intracellular ROS production; 
however, no evidence of this was found here. This suggests that phase II enzyme 
up-regulation is a result of the transcriptional activation of Nrf2 gene expression in 
response to sulforaphane. However, some studies have proposed that sulforaphane 
has an effect on the AhR pathway and its downstream target, the phase I 
bioactivating enzyme CYP1A1 69, 219. These studies suggested that sulforaphane up-
regulates CYP1A1 mRNA, protein and catalytic activity in Hepa1c1c7 cells, which 
may be mediated through direct or indirect effects on the AhR pathway. Anwar-
Mohamed et al. 219 found that CYP1A1 mRNA levels increased up to 6 h after 
compound exposure. Furthermore, they revealed that sulforaphane induced the 
AhR/ARNT/XRE complex formation in the cytosol 219. A recent study 221 suggested 
that sulforaphane is a poor agonist for the AhR as the compound modestly elevated 
CYP1A1 mRNA levels in rat liver. Moreover, the same study demonstrated that the 
isothiocyanate was able to displace bound BaP from the AhR and reduced BaP 
induced CYP1A1 activity 221. The gene promotors of Nrf2, AhR and NQO1 possess 
both ARE and XRE, which could result in potential pathway cross-talk between Nrf2 
and AhR 104 102. Shin et al. 106 suggest that Nrf2 partially regulates the expression of 
AhR and its downstream targets, i.e. CYP1A1, through interaction of Nrf2 with ARE 
in the promoter region of the AhR gene. The observed induction of AhR nuclear 
accumulation by sulforaphane could be a result of this proposed mechanism or 
alternatively, the isothiocyanate may be a weak AhR ligand. Nevertheless, the 
induction of CYP1A1 enzyme activity by sulforaphane is relative small compared to 
the high enzyme activity detected with the AhR ligand, BaP. Although a dissimilar 
time course was evident, western blotting analysis of the CYP1A1 protein showed 
similar intensity protein bands after cellular exposure to either sulforaphane or BaP. 
The inability of the western blotting technique to reveal the difference in CYP1A1 
protein levels following cellular exposure to compounds with dissimilar potency is 
likely due to the population analysis approach this method uses to acquire data-
points (Chapter 4). This highlights the importance of an additional assay to quantify 
protein induction levels.  
 
The observations discussed illustrate the rationale behind the selection of 
sulforaphane as a reference tool compound. Although, the isothiocyanate is a 
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potent inducer of Nrf2 and downstream target enzymes, i.e. HO-1 and NQO1, there 
is some indication of involvement of other pathways (i.e. ARNT-AhR). Hence, the 
biological evaluation of novel Nrf2 inducer molecules should include verification of 
their Keap1-Nrf2 pathway specificity.      
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A common feature of indirect Nrf2 inducers is their thiol reactivity. Michael acceptors 
react readily with sulfhydryl groups of cysteine residues via a conjugate addition 
(Michael-type) reaction and represent an important class of indirect Nrf2 inducer 
compounds 222. Michael acceptors are olefins or acetylic groups conjugated to 
electron-withdrawing groups including aldehydes, ketones, esters and nitro groups 
52. They are thought to induce Nrf2 activity by reacting with key cysteine residues 
(e.g. C273 and C288) in the Keap1 intervening region domain 62. At low 
concentrations Michael acceptors react with cysteine residues in Keap1, but at high 
concentrations they are capable of reacting indiscriminately; an effect that is 
associated with cytotoxicity 86, 223. However, evidence has emerged that the reaction 
between Michael acceptors and thiols can be reversible (via a retro-Michael-type 
reaction) 224, which may contribute to lowering the toxicity of these compounds in 




















Figure 6.1: Forward Michael-type reaction of a thiol with an a,b-unsaturated carbonyl 
compound (A) and reverse (retro) Michael-type reaction of an adduct to yield a thiol and an 
a,b-unsaturated carbonyl compound (B).  
 
The indirect Nrf2 inducers described in this chapter are a group of 
cyclohexadienone analogues that contain Michael acceptors 62. The core p-quinol 
(4-hydroxycyclohexadienone) structure (Figure 6.2) was elaborated to study the 
effect of various substituents on the ability of the compounds to induce Nrf2 activity 












Some phytochemicals that are found in fruit and vegetables carry Michael acceptor 
functionality and can exhibit relatively low cytotoxicity levels. In an attempt to find 
potent Nrf2 inducer molecules associated with low cytotoxicity, phytochemicals and 
analogues that contain the p-quinol core structure were synthesised. Structural 
changes to the two 4-position substituents of the core structure were introduced in 
order to explore their effects on compound activity (Figure 6.2). Furthermore, the 
reactivity of the Michael acceptor groups was adjusted by adding various electron-
withdrawing groups to the 2-position of the cyclohexadienone ring in order to 
evaluate the effects on compound reactivity and biological activity. The expected 
additive or synergistic effect of molecules containing two electron-withdrawing 
groups has previously been demonstrated with related structures and suggests that 
reaction with two closely located cysteine residues in Keap1 may contribute to their 
activity 35 52. The cyclohexadienone analogues (n = 71) were subdivided into five 
distinct groups based on their chemical structures. The structures of the five groups 
and the corresponding substituents are described in Tables 6.1 – 6.5. All 
compounds contain at least one Michael acceptor group. The compounds in Table 
6.1 with an R3 substituent contain two electron-withdrawing groups, which 
potentially increases their reactivity towards cysteine residues. All structures were 
screened for their ability to activate the Keap1-Nrf2 pathway via induction of the 
downstream target enzyme NQO1. Several promising indirect Nrf2 inducers were 
assessed further using western blotting and flow cytometry (assay development 
described in Chapter 4) to confirm Nrf2 and phase II enzyme activation.  
 
The aim of this chapter is to screen a group of cyclohexadienone analogues 
for their ability to indirectly induce Nrf2 target genes and to further 




6.2 Results – Evaluation of cyclohexadienone analogues 
 
6.2.1 NQO1 assay 
 
First, the compounds were screened at a fixed dose concentration of 1 µM for their 
ability to up-regulate the downstream Nrf2 product NQO1 in Hepa1c1c7 cells, which 
allowed the ranking of molecules based on their induction potencies 65. A fixed 
concentration of 1 µM was chosen as cytotoxicity was expected at higher 
concentrations. Cytotoxicity levels were determined on the basis of the dose that 
caused a decline in NQO1 enzyme activity 67. Compounds that demonstrated 
promising activity were further evaluated by determining their therapeutic index (TI), 
which is the ratio between the dose above which NQO1 enzymatic activity declines 
and the dose that doubles NQO1 enzymatic activity: 
TI = Toxicity concentration (µM)CD value (µM)  
In addition, dose-response experiments were performed for the most promising 
molecules. 
 
Screening of compounds 
The compounds in Table 6.1 showed promising NQO1 induction potential (CD ~ 0.5 
– 10 µM) with varying cytotoxicity (1 - ≥ 30 µM) (Table 6.1). The p-acetoxy 
substituted compound 6.2 (Figure 6.3) was one of the initial compounds based 
around the p-quinol core structure, which was active (CD ~ 1 µM), showed 
moderate cytotoxicity (≥ 10 µM) and resulted in a TI value of ~ 10. Several 
compounds were synthesised to explore the structure activity relationships in 
relation to this simple core structure. Generally, extending the alkyl chain in the 4-
position and replacing the 4-acetoxy group with a hydroxyl (e.g. 6.3, 6.4, 6.5) did not 










Figure 6.3: The structure of compound 6.2. 
 
The 4-phenyl-substituted compound 6.29 (Figure 6.4 A) was relatively potent (CD ~ 
1 µM), but showed cytotoxicity at concentrations > 1 µM (TI ~ 1). Replacing the 4-
hydroxyl group with a methoxy substituent, 6.31 (Figure 6.4 B), resulted in lower 
potency (CD ~ 2 µM) and cytotoxicity (≥ 30 µM), and a higher TI of 15. This 
suggests that the phenyl group is a good substituent at the 4-position of the core 
quinol structure with scope for further improvement of the structure.  
 
 
            
 
Figure 6.4: The structure of compounds 6.29 (A) and 6.31 (B). 
 
The favourable effect on activity of an additional electron-withdrawing group at the 
2-position of the core cyclohexadienone structure was shown previously with 
compound 6.35 (Figure 6.5 C): CD value of 0.15 µM 225. This structure is a 
monocyclic derivative of the highly potent Nrf2-inducing compound CDDO. In the 
assays conducted here it demonstrated here a comparable NQO1 induction 
potency: CD value of 0.5 µM (TI ~ 20). The effect of alternative electron withdrawing 
groups was evaluated via the related compounds 6.33 and 6.34 (Figure 6.5 A and 




6.34 CD ~ 2 µM), but they were less cytotoxic (≥ 30 µM versus ≥ 10 µM), resulting in 
a higher TIs (TI ~ 25 for 6.33).  
 
    
          
 
Figure 6.5: Structure of compounds 6.33 (A), 6.34 (B) and 6.35 (C). 
 
Combining the addition of an acetyl electron-withdrawing group at the 2-position of 
the p-quinol structure with the p-phenyl substituent resulted in the active compound 
6.46 (Figure 6.6; CD ~ 1.5 µM), which demonstrated relative low cytotoxicity levels 




Figure 6.6: The structure of compound 6.46. 
 
Introducing an electron-withdrawing group to the 3- or 4-position of the phenyl ring 
resulted in further improvement of the potency: i.e. the 4-cyanophenyl substituent, 
6.48 (Figure 6.7 A) and the 3-chlorophenyl substituent, 6.49 (Figure 6.7 B) (CD 
values of 1.7 µM and 1 µM respectively). This resulted in TI values of 5.9 for 6.48 
and 10 for 6.49. The 4-tert-butylphenyl substituent 6.54 (Figure 6.7 C) was the least 
active compound in this range (no CD value could be determined). Additional 
compounds that were synthesised and evaluated are shown in Table 6.1. 




           
 
Figure 6.7: The structures of compounds 6.48 (A), 6.49 (B) and 6.54 (C). 
 
Table 6.1: NQO1 (in the Hepa1c1c7 cell line) results for group 1 of the cyclohexadienone 
analogues. 
 






6.1 Me OOH H H 1.9 1.5 ≥ 3.0 
6.2 Me OAc H H 2.0 1.0 ≥ 10.0 
6.3 Et OH H H 1.6 3.0 ≥ 3.0 
6.4 iPr OH H H 1.0 10 > 10 
6.5 C≡CH OH H H 1.7 3.0 ≥ 3.0 
6.6 CH2CH2CO2Et OH H H 1.6 3.0 ≥ 3.0 
6.7 CH2CO2Me OH H H 2.0 1.0 ≥1.0 
6.8 CH2CO2Me OH Cl Cl 2.0 1.0 ≥ 3.0 
6.9 CH2CO2Me OAc H H 1.8 1.5 ≥ 10.0 
6.10 CH2CO2Me OCO2Me H H 2.0 1.0 ≥ 3.0 
6.11 CH2CO2Et OH H H 1.8 3.0 ≥ 3.0 
6.12 CH2CO2Et OH F H 1.5 - b ≥ 3.0 
6.13 CH2CO2Et OH Cl Cl 1.7 - b ≥ 1.0 
6.14 CH2CO2Et OH Br Br 1.8 - b ≥ 3.0 
6.15 CH2CH2CH2CO2H OH H H 1.9 3.0 ≥ 3.0 
6.16 CH2CH2CH2CO2Et OH H H 1.3 - b ≥ 3.0 
6.17 CH2CH2OAc OH H H 1.8 1.5 ≥ 10 
6.18 R1-CH2CH2CO2-R2  H H 1.5 - b ≥ 3.0 
6.19 CH2CH2OH OMe H H 1.3 -b - b  
6.20 CH2CH2O 
(glucopyranos-1β-yl) OMe H H 1.0 - b - b 
6.21 Me NHAc H H 1.0 10 > 10 
6.22 Et NHAc H H 1.1 - b - b 
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6.23 iPr NHAc H H 1.1 - b - b 
6.24 CH2CO2Me NHAc H H 1.1 - b - b 
6.25 CH2CO2Et NHAc H H 1.5 - b - b 
6.26 CH2CH2CO2Et NHAc H H 1.2 - b - b 
6.27 CH3 F H H 1.4 - b - b 
6.28 CH2CO2Et F H H 1.3 - b ≥ 3.0 
6.29 C6H5 OH H H 2.0 1.0 ≥ 1.0 
6.30 4-methoxyphenyl OH H H 2.3 0.6 ≥ 3.0 
6.31 C6H5 OMe H H 1.6 2.0 ≥ 30.0 
6.32 C6H5 OCH2CH2OH H H 1.2 10 ≥ 30.0 
6.33 Me Me CO2Me H 1.9 1.2 ≥ 30.0 
6.34 Me Me COMe H 1.6 2.0 ≥ 30.0 
6.35 Me Me CN H 2.3 0.5 ≥ 10 
6.36 Et Me CO2Me H 1.2 - b - b 
6.37 Et Me COMe H 1.4 - b - b 
6.38 Pr Me CO2Me H 1.2 - b - b 
6.39 Pr Me COMe H 1.4 - b - b 
6.40 R1-[CH2]5-R2  CO2Me H 1.3 - b - b 
6.41 R1-[CH2]5-R2  COMe H 1.6 4.0 ≥ 30.0 
6.42 C6H5 C6H5 CO2Me H 1.1 - b - b 
6.43 C6H5 C6H5 COMe H 1.3 - b - b 
6.44 C6H5 Me H H 1.0 10 > 100 
6.45 C6H5 Me CO2Me H 1.4 - b - b 
6.46 C6H5 Me COMe H 1.7 1.5 ≥ 30.0 
6.47 4-chlorophenyl Me COMe H 1.7 1.5 ≥ 10.0 
6.48 4-cyanophenyl Me COMe H 2.0 1.7 ≥ 10.0 
6.49 3-chlorophenyl Me COMe H 2.1 1.0 ≥ 10.0 
6.50 3,4-dichlorophenyl Me COMe H 1.5 1.5 ≥ 10.0 
6.51 4-methoxyphenyl Me COMe H 1.4 2.5 ≥ 30.0 
6.52 4-methylphenyl Me COMe H 1.4 3.5 ≥ 30.0 
6.53 4-isopropylphenyl Me COMe H 1.1 5.0 ≥ 30.0 
6.54 4-tert-butylphenyl Me COMe H 1.0 - b ≥ 10.0 
6.55 - - - - 0.9 - b ≥ 10.0 
Notes: a. Fold induction at 1 µM; b. Not determined.Compounds (Cpds). 
 
The structures in Table 6.2 and 6.3 ranged from inactive to weakly active without a 
doubling of NQO1 activity at the tested concentration range.  
The compounds in group 2a-c represent derivatives of the natural plant product 
rengyolone. The structures in group 2a and b contain one single Michael acceptor, 
whereas the structure in group 2c contains two Michael acceptor groups. However, 









Table 6.2a: NQO1 (in the Hepa1c1c7 cell line) results for group 2a-c of the cyclohexadienone 
analogues. 










6.56 2a MeO 1.4 -b -b 
6.57 2a OH 1.0 -b > 10 
6.58 2b MeO 1.4 -b -b 
6.59 2b C6H5 1.3 -b -b 
6.60 2c OH 0.9 -b ≥ 30.0 
Notes: a. Fold induction at 1 µM; b. Not determined. Compounds (Cpds). 
 
The compounds in group 3 are related to the benzylidenemalononitriles, which were 
found to induce the phase II enzyme HO-1; a property that was associated with the 
reactivity of the Michael acceptor 62. However, none of the related structures in 
Table 6.3 were able to double NQO1 activity at the test concentration of 1 µM.  
 








6.61 OMe CN CN 1.0 -b > 100 
6.62 Cl CN CN 1.0 -b ≥ 30.0 
6.63 CN CN CN 1.0 -b ≥ 30.0 
6.64 OMe CONH2 CN 1.0 -b > 100 
6.65 NO2 CN CN 1.0 -b > 100 
6.66 Cl CONH2 CN 1.0 -b > 100 
6.67 CN CONH2 CN 1.0 -b > 100 
6.68 NO2 CONH2 CN 1.0 -b > 100 
6.69 H CN CN 1.1 -b > 100 
6.70 CN CONMe2 CN 1.0 -b > 100 
6.71 NO2 CONMe2 CN 1.0 -b > 100 
Notes: a. Fold induction at 1 µM; b. Not determined. Compounds (Cpds). 
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Compound selection for further characterisation 
Although compounds 6.33 and 6.46 presented interesting therapeutic index values, 
they were not chosen for further characterisation in this study but warrant further 
investigation in the future. 
 
Compounds 6.48, 6.49 and 6.54 from group 1, carried an additional electron-
withdrawing group at the R3-position of the cyclohexadienone, but different 
substituents at the 4-position of the R1-phenyl substituent (6.48 -Cl, 6.49–CN and 
6.54 t-Bu) and presented dissimilar activity in the NQO1 assay. Therefore, they 
were selected for further characterisation. As the compounds contain reactive 
Michael acceptor groups, they were thought to induce NQO1 enzyme activity via the 
Keap1-Nrf2 pathway. Nevertheless, the compounds may have the potential to be 
ligands for the AhR as the structures contain aryl moieties. Hence, the NQO1 
induction activity of compounds 6.48, 6.49 and 6.54 was additionally examined in 
the ARNT-defective BpRc1 cell line. Dose response profiles were generated in both 
Hepa1c1c7 and BpRc1 cell lines (Figure 6.8 A and B). All structures were able to 
up-regulate NQO1 in both the Hepa1c1c7 and the ARNT-defective BpRc1 cell line 
with comparable induction potencies. 
 
 
Figure 6.8: Dose response curves for the NQO1 assays of compounds 6.48(●), 6.49 (○) and 
6.54 (▼) in Hepa1c1c7 (A) and BpRc1 (B) cells after 24 h stimulation. The error bars 
represent the standard deviation of (A) n = 3 independent experiments and (B) n = 4 
replicates in a representative experiment.  
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An important class of indirect inducers are compounds that contain Michael 
acceptors. Michael acceptors are reactive towards sulfhydryl groups and are 
thought to interact with key cysteine residues in Keap1, thereby causing 
conformational changes and as a result induce the Keap1-Nrf2 pathway. The 
indirect Nrf2 inducers described here are quinol-derived (cyclohexadienone) 
analogues containing Michael acceptor group(s).  
 
Various structures were screened for their ability to up-regulate the downstream 
Nrf2 target enzyme, NQO1. The compounds showed a wide range of NQO1 
induction potential and cytotoxicity in Hepa1c1c7 cells. Although, the most active 
compounds up-regulate NQO1 at relatively low concentrations (CD ~ 0.5 – 1.0 µM), 
they also demonstrate cytotoxicity at higher concentrations (≥ 10 µM). This is likely 
to be due to the compounds interacting with thiols (with a low pKa) other than those 
in Keap1 at higher concentrations. The most promising molecules were structures 
containing two Michael acceptor groups. This observation is in agreement with the 
hypothesis that the addition of an extra Michael acceptor group increases the 
structures reactivity towards thiol groups 35 52. Moreover, NMR studies 62 confirmed 
the reversibility of the compounds reaction with thiol groups 224, which may 
contribute to lower cytotoxicity levels. Three representative compounds containing 
two Michael acceptors (two active; 6.48 and 6.49 and one moderately active; 6.54) 
were further evaluated. A differential NQO1 induction pattern was observed for the 
three compounds in both Hepa1c1c7 and BpRc1 cells. The cell lines showed 
matching dose response profiles, which supports the proposition that the 
compounds up-regulate the NQO1 enzyme through the Keap1-Nrf2 pathway and is 
not suggestive of AhR pathway involvement. Moreover, exposure of Hepa1c1c7 
cells to compounds 6.49 or 6.54 demonstrated Nrf2 nuclear accumulation using 
both western blotting and flow cytometry techniques. The quantitative difference in 
Nrf2 up-regulation between 6.49 and 6.54 was best demonstrated using the flow 
cytometry assay; the moderately active NQO1 inducer 6.54 demonstrated a 
reduced Nrf2 protein expression compared to the more active NQO1 inducer 6.49. 
These matching data suggests that the colourimetric NQO1 assay is a good initial 
screening tool for ranking the indirect Nrf2 inducers. Although both sulforaphane 
and the cyclohexadienone analogues are believed to induce Nrf2 via reactivity 
169 
 
towards thiol residues in Keap1, the cyclohexadienone analogues show a different 
time-dependent Nrf2 induction to sulforaphane; Nrf2 showed a peak induction after 
1-3 h with 6.49 and after 3-6 h with 6.54 in Hepa1c1c7 cells, whereas cellular 
exposure to sulforaphane resulted in a maximal nuclear accumulation of Nrf2 after 
only 1 hour.  
 
The cyclohexadienone analogues are a group that includes members with strong 
Nrf2-inducing capabilities. In particular, structures containing two Michael acceptor 
groups and additional electron-withdrawing substituents showed an increased 
potency towards the up-regulation of NQO1. Further optimisation of the lead 
structure 6.49 should be targeted at maximizing potency and reducing overall 
cytotoxicity levels. Although induction of NQO1 enzyme activity in the ARNT 
deficient BpRc1 cell line is not suggestive of AhR involvement, additional future 








NMR, crystallography, mutagenesis and isothermal calorimetry studies have 
provided structural insight into the Keap1 – Nrf2 PPI 30. The Nrf2 Neh2 domain (KD 
= 5 – 9 nM) binds to the Keap1 Kelch domain using both a low affinity motif 29DLG31 
(KD = 1000 nM) and a high affinity motif 79ETGE82 (KD = 5 nM) (hinge and latch, two 
binding-sites mechanism) 47. Both motifs interact with the Keap1 Kelch domain 
electrostatically via salt bridges between negatively charged Asp and Glu residues 
in Nrf2 and positively charged Arg residues in the Kelch domain. Figure 7.1 shows 
the five binding sub-pockets of the Keap1 Kelch domain (P1 - P5) with an Nrf2-
ETGE peptide bound. Both P1 and P2 are positively charged and bind the peptide 
via electrostatic interactions (residues E79 and E82 from Nrf2 respectively). P3 is 
polar (interacts with the Nrf2-ETGE peptide backbone) and the sub-pockets P4 and 
P5 are hydrophobic (interacts with residues L76, E78 and F83 from Nrf2). This 
structural information can be used to design highly specific inhibitors of the Keap1-
Nrf2 PPI and offers an alternative strategy to thiol reactive compounds and their 
associated off-target effects for up-regulation of Nrf2 and downstream phase II 
enzymes.  
 
The aim of this chapter is to screen a group of Nrf2 derived peptides and 
small molecules for their ability to directly disrupt the Keap1-Nrf2 PPI and to 
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7.1.1 Peptides  
 
A study from 2006 demonstrated that a 16-mer Nrf2 derived peptide can bind to the 
Keap1 Kelch domain with high affinity (KD = 20 nM) when the central 77DEETGE82 
motif is conserved 46. Moreover, Chen et al. 226 synthesised several ETGE 
containing Nrf2 peptides and found that the minimal Keap1 binding sequence was a 
9-mer Nrf2 peptide 76LDEETGEFL84 (KD = 352 nM). A range of 7-mer Nrf2 derived 
synthetic peptides based on the high-affinity ETGE motif were previously designed 
in our research group and evaluated for their ability to disrupt the Keap1-Nrf2 PPI 
using a fluorescence polarisation (FP) assay 143, 170. Peptides derived from the 
binding sequences of sequestosome-1 (p62) (residues 347 - 353), which was found 
to interact with Keap1, were also synthesised. A series of peptide conjugates were 
also synthesised to improve cell permeability, i.e. peptides were coupled at their N-
terminus to the C18 fatty acid stearic acid to promote cellular penetration. In order to 
quantify the binding activity of the peptides, a previously developed competitive FP 
assay was applied that utilised an FITC labelled 7-mer Nrf2 peptide (FITC-β-
DEETGEF-OH) as the fluorescent probe and Keap1 Kelch domain as the target 
protein 143. FP results revealed that peptides based on the Keap1 binding 
sequences of both Nrf2 and sequestosome-1 presented the highest binding affinity 
to Keap1 143. In this chapter, several of these 7-mer Nrf2 derived peptides were 
evaluated further. A FRET based competition assay was developed to screen direct 
inhibitors of the Keap1-Nrf2 PPI (Chapter 3) and was used as an additional in vitro 
tool to verify the inhibition potential of the peptides. Their ability to penetrate the cell 
membrane and to induce the Nrf2 downstream target NQO1 was examined in the 
colourimetric cell-based NQO1 assay in Hepa1c1c7 cells. A promising Nrf2 derived 
peptide that was able to induce NQO1 enzyme activity was conjugated to a FITC 




7.1.2 Small molecules 
 
The use of non-reactive small molecules to inhibit the Keap1-Nrf2 PPI presents a 
novel approach to directly induce Nrf2 activity. Structural data enabled the design of 
specific inhibitor molecules that demonstrate high affinity. Most of these structures 
are designed to mimic the Nrf2 high affinity ETGE peptide motif in order to compete 
with Nrf2 for Keap1 binding sites. The use of small molecules for inhibiting PPIs 
presents certain advantages over peptides i.e. oral bioavailability and improved 
stability 129. An example is described by Hu et al. 119, who performed high-
throughput screening of the MLPCN library of 337,116 compounds using an FP-
based assay. They found eight promising molecules that were evaluated further. 
The ‘Hit 1’ compound was the most active inhibitor of the Keap1-Nrf2 PPI and 




Figure 7.2: Small molecule inhibitor of the Keap1-Nrf2 PPI as described by Hu et al. 119.  
 
In this chapter, various other putative small molecule inhibitor groups were 
evaluated. The in vitro FRET assay developed in Chapter 3 was used to screen the 
molecules inhibitory properties. Cellular techniques, i.e. a cellular NQO1 screening 
assay, western blotting and flow cytometry, were employed to explore the molecules 
ability to induce Nrf2 and its downstream target enzymes. Finally, the pathway 
specificity of potent Nrf2 inducers was examined using various cell based methods.  
 
Initially, a group of previous identified compounds, 7A1 – 7A10 115, 119, 227-228, were 
studied. Marcotte et al. 227 developed the bis-sulphonamide derivative ‘compound 
16’, a potent inhibitor of the Keap1-Nrf2 PPI (Figure 7.3 A).  
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A close analogue of ‘compound 16’, 7A4, was further evaluated in our group (Figure 
7.3 B). Moreover, Jiang et al. 129 used ‘compound 16’ as a scaffold to design a 
series of more potent analogues, including ‘compound 2’ 129 (Figure 7.3 C). Our 
group designed a close analog series of 7B compounds related to ‘compound 2’ 129. 
The compound 7B1 represents ‘compound 2’. In addition, a group of 7C compounds 
were synthesised by our group based upon a 1,4-diaryl-1,2,3-triazole scaffold. The 
small molecules were screened for their ability to disrupt the Keap1-Nrf2 PPI and 




                           
 
Figure 7.3: Chemical structures of A: ‘compound 16’, a small molecule inhibitor of the 
Keap1-Nrf2 PPI as described by Marcotte et al. 227, B: 7A4, a close analogue of ‘compound 
16’ and C: the ‘compound 2’/7B1 small molecule inhibitor of the Keap1-Nrf2 PPI as 
described by Jiang et al. 129.   
 
7A compounds 
The 7A compounds present a range of putative Keap1-Nrf2 PPI inhibitors with 
distinct (chemical) properties. A library of 47,000 compounds (Microsource, 
Prestwick, and Chembridge Libraries) were screened with a luciferase reporter gene 
assay by Wu et al. 115. Compounds 7A1, 7A3 and 7A6 were amongst the top 4 
molecules with the lowest EC50 values for Nrf2-ARE activation (EC50 = 0.9 µM, EC50 
= 1.0 µM and EC50 = 0.9 µM respectively). Marcotte et al. 227 screened 267,551 
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improve binding potency and cell penetration. They are thought to occupy the same 
space in the Keap1 binding pocket as ‘compound 2’/7B1 129. The structures in group 
2 contain substituents that should mimic the naphthalene rings and are predicted to 
bind in a similar manner to ‘compound 2’/7B1 and the structures in group 1. 
Moreover, docking studies suggest that these compounds bind deeper in the Keap1 
binding pocket than the compounds containing a naphthalene ring system. 
Previously obtained FP results by our group showed promising inhibitory properties 
of the developed 7B compound series.   
 
7C compounds 
An in silico fragment-based approach was used to dock ~ 178,000 compounds (a 
subset of the ZINC virtual screening database) into the Keap1 Kelch binding pocket 
where the Nrf2 ETGE motif binds. From this docking study, 360 promising 
molecules were selected for further evaluation. Figure 7.6 shows three core 
scaffolds (A: oxotetrahydrothiazole, B: 1, 2, 4-triazole and C: 1, 2, 3-triazole) that 
were identified for development by structural modification and introduction of various 
functional groups, i.e. carboxylic acid, carboxamide and nitro groups (R, R’). These 
groups function as hydrogen bond acceptors that can form salt bridges or hydrogen 
bonding interactions with the Keap1 Kelch domain, hence mimicking the binding of 
the high-affinity Nrf2-ETGE motif. Scaffolds A and B were derived from structures 
that frequently appeared as potent Keap1-Nrf2 PPI inhibitors in the virtual screen 
(submitted and in the press 229), whereas scaffold C was designed to mimic the 





Figure 7.6: Core scaffolds used for the development of small molecule inhibitors of the 
Keap1-Nrf2 PPI. A: oxotetrahydrothiazole, B: 1, 2, 4-triazole and C: 1, 2, 3-triazole.  
A C B 
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The oxotetrahydrothiazole derivatives presented high levels of fluorescence 
interference in FP assays performed by our group 143, hence they were not 
evaluated further. Although the 1,2,4-triazoles derivatives were not very active in the 
FP based assay, their ability to induce phase II enzymes was examined in a cellular 
NQO1 induction assay. The 1,2,3-triazoles derivatives showed the most promising 
results in the FP based assay and were subjected to further examination in various 




7.2 Results – Evaluation of peptides (7P) 
 
7.2.1 FRET assay 
 
The Keap1-Nrf2 PPI inhibition potential of several of 7-mer Nrf2-derived peptides 
was examined using a FRET competition assay (assay development described in 
Chapter 3). Increasing concentrations of the Nrf2 derived peptides (0.001 – 100 µM) 
were added to a mixture of the eCFP-TEV-Nrf2 and eYFP-TEV-Kelch proteins (0.11 
µM and 0.20 µM respectively) and IC50 values were determined using the reduction 
in FRET efficiency. Figure 7.7 shows the dose-dependent competitive inhibition of 
FRET between eCFP-TEV-Nrf2 and eYFP-TEV-Kelch proteins and Table 7.1 shows 
the corresponding IC50 values. The IC50 values obtained using the FP assay were 
included as a comparison. The 7-mer 7P1 peptide is a truncated version of the 16-
mer Nrf2 WT peptide (Section 3.2.11) and showed a 30-fold higher IC50 value (3.34 
µM vs. 0.11 µM). Peptides 7P2, 7P3 and 7P4 contain a hybrid binding sequence 
derived from both Nrf2 and sequestosome-1. They all contained an E78P 
substitution, which improved activity considerably. Substitution of the N-terminal 
acetyl for a stearic acid increased inhibition potencies of peptides 7P5 and 7P4 (the 
stearic acid versions of 7P1 and 7P3 respectively). The peptide 7P6 is a scrambled 
version of peptide 7P5 and showed a marked reduction in inhibition of the Keap1-
Nrf2 PPI indicating the importance and specificity of the correct peptide sequence. 

























Figure 7.7: Competitive inhibition of FRET between 0.11 µM eCFP-TEV-Nrf2 and 0.20 µM 
eYFP-TEV-Kelch by increasing concentrations (0.001 – 100 µM) of unlabelled Nrf2-derived 
peptides (●: 7P1, ○: 7P5, ▼: 7P2, ∆: 7P3, ■: 7P4 and □: 7P6). The data were fitted to a 
standard four-parameter logistic function. The error bars represent the standard deviation of 
n = 3 independent assays. Adapted from 142.  
 
Table 7.1: FRET and FP assay results for the 7P peptide range.  
 
Peptides Sequence FRET IC50 ± SE (µM) FP IC50 ± SE (µM) 
7P1 Ac-DEETGEF-OH 3.34 ± 0.44 5.39 ± 0.58 
7P2 Ac-DPETGEF-OH 0.33 ± 0.03 0.25 ± 0.04 
7P3 Bz-DPETGEL-OH 0.26 ± 0.03 0.16 ± 0.02 
7P4 St-DPETGEL-OH 0.12 ± 0.01   0.02 ± 0.003 
7P5 St-DEETGEF-OH 0.45 ± 0.05 0.18 ± 0.04 
7P6 St-DEGEETF-OH 14.5 ± 1.60 11.8 ± 2.67 
Notes: FP assays performed by Rowena Hancock, UCL School of Pharmacy 
 
7.2.2 NQO1 assay 
 
Several 7-mer Nrf2 derived peptides were examined for their ability to induce NQO1 
expression in Hepa1c1c7 cells (Table 7.2). Included are the IC50 values from the FP 






Table 7.2: NQO1 (in the Hepa1c1c7 cell line) results for the 7P peptide range. 
 






7P1 Ac-DEETGEF-OH 5.39 ± 0.58 1.0 -b > 100 
7P7 Ac-DPETGEL-OH 0.12 ± 0.01 1.0 - b > 100 
7P4 St-DPETGEL-OH   0.02 ± 0.003 1.0 100 > 100 
7P3 Bz-DPETGEL-OH 0.16 ± 0.02 1.0 - b > 100 
7P8 Ac-DPGEETL-OH -b 1.0 - b > 100 
7P9 St-DPGEETL-OH 73.91 ± 38.57 1.0 - b > 100 
7P10 St-NPETGEL-NH2 3.71 ± 1.14 1.0 - b > 100 
7P11 St-NPETGEL-OH 0.27 ± 0.03 1.0 100 > 100 
7P5 St-DEETGEF-OH 0.18 ± 0.04 1.2 20 > 100 
7P6 St-DEGEETF-OH 11.8 ± 2.67 1.0 40 > 100 
Notes: FP assays performed by Rowena Hancock, UCL School of Pharmacy; a. Fold induction at 10 
µM; b. Not determined. 
 
The FP data obtained previously (Table 7.1) 143 and the FRET 142 data show that 
peptide 7P1, containing the original Nrf2 sequence, was a good inhibitor of the 
Keap1-Nrf2 PPI. Peptides 7P7 and 7P3 are proline-substituted versions of peptide 
7P1 and dramatically improved the inhibition potential in the FP and FRET assay 143 
170 142. The peptide 7P8 is a scrambled version of peptide 7P1 and demonstrated to 
be inactive in the FP assay 170. None of the above mentioned peptides 
demonstrated up-regulation of NQO1 gene expression in the cellular NQO1 assay. 
The introduction of a stearic acid group to the peptides 7P5 (version of 7P1) and 
7P4 (version of 7P3) increased the inhibition potential in the FP and FRET assay 170 
142. Both these peptides showed NQO1 induction potencies (CD ~ 20 and 100 µM 
respectively) (Figure 7.8). Scrambled stearic acid conjugates 7P9 and 7P6 showed 
increased inhibition of the Keap1-Nrf2 PPI compared to their native sequences (7P8 
and ‘peptide 17’ 170 respectively) in the FP and FRET assay 170, 142. No increase in 
NQO1 activity was found with peptide 7P9, but a CD value of 40 µM was obtained 
with the 7P6 peptide (Figure 7.8). Reduction of the negative charge by introducing 
the substitution of D76N reduced the activity of peptides 7P10 and 7P11 in the FP 
assay 170, but peptide 7P11 maintained cellular activity in the NQO1 assay that was 

























Figure 7.8: Dose response curves for the NQO1 assays of compounds 7P4 (●), 7P5 (○) and 
7P6 (▼) 7P11 (∆) in Hepa1c1c7 after 24 h stimulation. The error bars represent the 
standard deviation of n = 3 independent experiments.  
 
7.2.3 Cellular uptake  
 
Several stearic-acid conjugated Nrf2-derived peptides were shown to have 
promising cellular activity in the colourimetric cell-based NQO1 assay. To study their 
cellular uptake, the peptide 7P11 was modified to incorporate an FITC fluorophore 
conjugated to the side chain of a lysine residue introduced at the N-terminus of the 
peptide sequence; this resulted in peptide 7P12 (Table 7.3). Flow cytometry was 
used to quantify the cellular uptake of the peptide and confocal microscopy 
facilitated mapping of the intracellular distribution of 7P12. TAT is a well-known cell-
penetrating peptide (CPP) that is derived from the HIV viral protein 230. TAT was 
conjugated to FITC and used as a positive control peptide in both flow cytometry 
and confocal analysis (AnaSpec) (Table 7.3). CPPs are short peptide sequences 
(< 30 amino acids) that are mostly positively charged 231. They are thought to 
interact electrostatically with the plasma membrane then enter the cell by a process 
of endocytosis 232. The FITC labelled 7-mer peptide 7P13 (Table 7.3) was designed 
to match the high-affinity ETGE motif to be used in previous FP assays 101. The 
7P13 peptide (which lacks a conjugated fatty acid) was used as a negative control 




Table 7.3: Sequences of peptides studied. The LC in the TAT peptide sequence represents 
a long chain that prevents FITC from degradation. 




TAT FITC - LC - 47YGRKKRRQRRR57 
 
To measure cellular uptake of the peptides, Hepa1c1c7 cells were incubated with a 
final concentration of 1 µM peptide at 37 °C for 5, 10, 30, 60 and 120 min before 
removing surface-bound peptide with trypsin. Cells were subsequently washed with 
PBS before the internalisation process was measured using flow cytometry. Figure 
7.9 shows the cellular uptake of the peptides by plotting FITC - median fluorescence 
intensity (MFI) vs. time. The data were fitted by non-linear regression using an 
equation for ligand binding: 
 Ligand binding = Bmax* abs (x) Kd + abs (x) +  Ns * x 
Where Bmax represents the FITC – MFI, the Kd represents the time in min, abs is the 
absorbance and Ns is the slope of the non-specific binding line: 
Time (min)

















Figure 7.9: Kinetics of cellular uptake of 7P13 (●), TAT (○) and 7P12 (▼) peptides in 




The FITC fluorescence signal for the 7P12 peptide increased rapidly after only 5 
min and continued to increase after 120 min without having reached a plateau, 
which demonstrates a progressively increasing cell entry over time. Although low 
FITC background signals were observed with the negative control 7P13 peptide, no 
significant cellular uptake was detected with the positive control FITC-TAT peptide.   
 
The cellular distribution of the FITC conjugated 7P12 and TAT peptides were 
examined in both living and fixed Hepa1c1c7 cells. Hepa1c1c7 cells were incubated 
with a final concentration of either 10 µM FITC - 7P12 or 1 µM FITC-TAT peptide at 
37°C for 1 h. Fixed cells (2% PFA) were stained with CellMask (Life Technologies), 
a cellmembrane dye, before they were mounted on glass slides using mounting 
medium containing the fluorescent dye DAPI that stains nuclei. Living cells were 
washed with PBS before staining the cells with the nuclear Hoechst 33342 dye and 
the cell membrane with CellMask dye. The Hoechst 33342 dye was used for living 
cells since DAPI is less efficient at penetrating the cell membrane of living cells. 
Commonly used cell membrane markers include fluorophore conjugated lectins. 
These markers depend on cell-specific surface sugars for staining, which may result 
in inconsistencies. The CellMask stain consists of an amphipathic probe that 
enables anchoring of the dye in the plasma membrane. Moreover, its staining 
efficiency is not dependent on a specific cell type. A predominant cytoplasmic 
distribution of the 7P12 peptide was observed in both living and fixed cells (Figure 
7.10 A and B respectively), although to a lesser extent in living cells. In contrast, the 
TAT peptide could not be detected in living cells (Figure 7.10 A), but was present in 
both the cytoplasm and the nucleus in fixed cells (7.10 C). The 7P12 peptide was 
visible as small intense green vesicles inside the cells, whereas the TAT peptide 



















 for 1 h wit
ere imaged




n of FITC la
10) using a 6
h either 10 µ







M 7P12 (A 




 and TAT pe
rsion object
& B) or 1 µM





















7.3 Results – Evaluation of small molecules (7A) 
 
7.3.1 FRET assay 
 
Screening of compounds 
A FRET competition assay was employed to evaluate the ability of the different 7A 
compounds (Figure 7.11) to inhibit the Keap1-Nrf2 PPI. The inhibition potential was 
determined by measuring the decrease in FRET efficiency at a fixed dose 
concentration of 25 µM. A second read-out counter assay was performed in the 
absence of both eCFP-TEV-Nrf2 and eYFP-TEV-Kelch proteins to determine any 
potential auto-fluorescence properties of the compounds. Table 7.4 shows the fixed 
dose (25 µM) inhibition of the Keap1-Nrf2 PPI by 7A compounds using the FRET 
assay. FRET inhibition percentages were corrected for potential fluorescence 
interference by subtracting the compounds fluorescence emission values upon 
excitation in the absence of the fluorescent proteins. As a comparison, uncorrected 
percentages of inhibition at concentrations of 10 µM and 100 µM that were obtained 





























Table 7.4: FRET and FP assay results for the 7A compound range.  
 
Cpds FRETa FPb1 FPb2 
7A1 12.7 13 9.0 
7A2 0.3* 110* 110* 
7A3 3.2 0.9 -32.9 
7A4 76.2 -116.6* 110.3* 
7A5 58.4 51.1 51.3 
7A6 8.4 1.0* -45.7* 
7A7 18.4 28.9 13.5 
7A8 0.3* 102.2* 102.2* 
7A9 -27.5* 1.0 42.3 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Auto-fluorescence 
corrected percentage inhibition at 25 µM; b1 Percentage inhibition at 10 µM; b2. Percentage inhibition 
at 100 µM; *large amounts of observed auto-fluorescence. Compounds (Cpds). 
 
Compound selection for further characterisation 
The most promising inhibition potential in the FRET experiments was observed with 
compounds 7A4 and 7A5, which were selected for further evaluation in dose-
response experiments. The obtained dose-response profiles revealed that 7A4 
binds with an apparent IC50 of 2.84 µM and 7A5 with an apparent IC50 of 12.20 µM 
(Figure 7.12). 
Compound (µM)

















Figure 7.12: Competitive inhibition of FRET between 0.11 µM eCFP-TEV-Nrf2 and 0.20 µM 
eYFP-TEV-Kelch by increasing concentrations (0.001 – 100 µM) of ●: 7A4 and ○: 7A5. IC50 
values of 2.84 µM and 12.20 µM were obtained for 7A4 and 7A5 respectively. The data 
were fitted to a standard four-parameter logistic function. The error bars represent the 
standard deviation of n = 3 independent assays.  
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7.3.2 NQO1 assay 
 
Screening of compounds 
To verify whether the Keap1-Nrf2 PPI inhibition potential of the various 7A 
compounds is accompanied by an up-regulation of the NQO1 enzyme in 
Hepa1c1c7 cells, the compounds were screened at a fixed dose concentration of 25 
µM. The fold induction at this concentration is displayed in Figure 7.13 and Table 
7.5. The majority of the compounds were able to up-regulate NQO1 in cells at a 
concentration of 25 µM (fold induction > 1.0), except for 7A2, 7A5 and 7A7 (fold 
induction ≤ 1.0).  





















Figure 7.13: NQO1 induction in Hepa1c1c7 cells after 24 h of stimulation with 7A1-9 at a 
fixed concentration of 25 µM. The red line indicates a doubling of NQO1 activity (CD value). 
Error bars are based on n = 4 replicates in a representative experiment. 
 
Table 7.5: NQO1 enzymatic activity induction by the 7A compounds in the Hepa1c1c7 cell 
line. 
 






7A1 1.9 -b ≥ 30 
7A2 0.9 - b - b 
7A3 1.6 - b > 100 
7A4 4.8 8 > 25  
7A5 1.0 - b - b 
7A6 2.1 0.8 > 25 
7A7 1.1 - b - b 
7A8 1.7 30 > 100  
7A9 1.7 30 > 100  
Notes: a. Fold induction at 25 µM; b Not determined. Compounds (Cpds). 
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Compound selection for further characterisation 
To examine the active compounds further, dose-response curves were created for 
7A1, 7A3, 7A4, 7A6, 7A8 and 7A9 in both Hepa1c1c7 and ARNT-defective BpRc1 
cell lines (Figure 7.14). 7A4 and 7A6 were the most potent NQO1 inducer 
compounds in the Hepa1c1c7 cell line; 7A4: CD ~ 8 µM and max fold induction ~ 
5.0 at 25 µM, 7A6: CD ~ 0.8 µM and max fold induction ~ 2.6 µM at 25 µM. Only 
7A4 was able to slightly increase NQO1 activity in the BpRc1 cell line and was 
selected for further characterisation.   
 
 
Figure 7.14: Dose response curves for the NQO1 assays of compounds 7A1 (●), 7A3 (○), 
7A4 (▼), 7A6 (∆), 7A8 (■) and 7A9 (□) in Hepa1c1c7 (A) and BpRc1 (B) cells after 24 h 
stimulation. The red line indicates a doubling of NQO1 activity (CD value). The error bars 
represent the standard deviation of n = 3 independent experiments. 
 
7.3.3 SRB assay 
 
The 7A4 compound appeared not to be toxic at concentrations up to 25 µM in the 
cellular NQO1 assay as the NQO1 enzyme activity didn’t show a decline at this 
dose. An SRB assay was performed to verify the cytotoxicity of 7A4 at 
concentrations up to 250 µM (in 1% DMSO final concentration) after 24 and 48 h of 
stimulation of Hepa1c1c7, BpRc1 and HeLa cells (Figure 7.15 A and B 
respectively). In agreement with the NQO1 assay results, 7A4 was not cytotoxic in 
either of the cell lines at concentrations up to 25 µM after 24 and 48 h.  
Compound (µM)












































Though, cell viability was reduced by ~ 50 - 60% at a concentration of ~ 80 µM and 
decreased by ~ 60 - 70% at a concentration of 250 µM in the mouse hepatoma cell 
lines after 24 h. The cytotoxic effect of 7A4 in HeLa cells was reduced compared to 
the other two cell lines (~ 10% decrease of cell viability at 250 µM after 48 h). As 
cell viability started to reduce at concentrations > 25 µM, a 7A4 dose of 25 µM was 
used in all following experiments.   
 
 
Figure 7.15: Dose response curves for the SRB assays of 7A4 in Hepa1c1c7 (●), BpRc1 (○) 
and HeLa cells (▼) after 24 h (A) and 48 h (B) stimulation. Cell viability is calculated as a 





































7.3.4 Western blotting 
 
To examine whether the 7A4 compound is able to activate nuclear Nrf2 
accumulation and the up-regulation of downstream target enzymes HO-1 and 
NQO1 in Hepa1c1c7 and BpRc1 cells, protein levels were measured by Western 
blot analysis. Following treatment of the cells with 25 µM 7A4, samples were taken 
after 1, 3, 6 and 24 h of exposure and divided into cytoplasmic and nuclear protein 
fractions. A maximal induction of nuclear Nrf2 was observed after 1 h in Hepa1c1c7 
cells (fold induction ~ 5), but only a weak induction was promoted in BpRc1 cells 
(fold induction < 2) (Figure 7.16 A, C and E). Expression of NQO1 by 7A4 was only 
detected after 24 h in the Hepa1c1c7 cell line (Figure 7.16 B and D). A time 
dependent induction of HO-1 was also observed with a peak induction after 6 h (fold 
induction ~ 5) in Hepa1c1c7 cells (Figure 7.16 B and E). HO-1 protein levels were 
only slightly induced in the BpRc1 cell line with a maximal increase detected after 3 
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7.3.5 Pathway evaluation 
 
ARNT-AhR 
The inability of 7A4 to significantly up-regulate NQO1 (and Nrf2 and HO-1) in the 
ARNT-deficient BpRc1 cell line is suggestive of the involvement of other pathways 
(i.e. ARNT-AhR) in the induction of this phase II enzyme. As a result, 7A4 treated 
Hepa1c1c7 cells were examined by western blot analysis for the expression of 
nuclear AhR and cytoplasmic CYP1A1 proteins. The cells were stimulated with 25 
µM 7A4 over a 24 h time period with nuclear and cytoplasmic protein samples taken 
at 0, 1, 3, 6 and 24 h time intervals. Following 7A4 exposure, Hepa1c1c7 cells 
demonstrated an increase in AhR nuclear accumulation, which peaked after 1 h 
(fold induction ~ 4.5) (Figure 7.17 A and C). After 6 h, CYP1A1 expression was 
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CYP1A1 induction value after 6 h (fold induction ~ 3.9) compared to 24 h and (fold 
induction ~ 1.9). These results confirm western blot observations. Though, the fold-
changes detected with the AhR ligand BaP (fold induction ~ 42 after 6 h and ~ 51 
after 24 h) are substantially higher than with 7A4.       
 
 
Figure 7.18: CYP1A1 induction measured using the P450 Glo Assay (Promega) following 
exposure of Hepa1c1c7 cells to vehicle (C), 25 µM 7A4 or 3 µM BaP (P). (A): the quantity of 
luciferin (RLU) detected is proportional to the extent of CYP1A1 enzyme activity. The error 
bars represent the standard deviation of n = 8 replicates in a representative experiment. (B): 
fold changes of 7A4 and BaP versus vehicle control. Data indicated with an * are previously 








































A flow cytometry based ROS assay was employed to examine whether ROS 
production occurs in Hepa1c1c7 cells following exposure to 7A4, which possibly 
contributes to the nuclear accumulation of Nrf2 and up-regulation of the phase II 
enzymes HO-1 and NQO1. Cells were treated with 25 µM of 7A4 for 1 h and 
subsequently stained with CellROX Deep Red reagent (Life Technologies). The 
fluorescence detected from the CellROX (MFI) probe is proportional to the ROS 
concentration and is shown in Figure 7.19. The previous described fluorescence 
values for the blank and negative controls: DMSO (C1) and acetonitrile (C2) and 
positive control: menadione (M), are included in the graph. As can be observed from 
Figure 7.19, cellular treatment with 7A4 did not result in an induction of ROS 
production.  
















* * * *  
 
Figure 7.19: ROS production measured using the CellROX Deep Red dye after exposure of 
Hepa1c1c7 cells) to 25 µM 7A4 or 50 µM menadione (M) for 1 h. As controls, cells were 
exposed to the 7A4 vehicle, DMSO (C1) and the menadione vehicle, acetonitrile (C2). The 
amount of fluorescence (APC MFI) detected is proportional to the extent of ROS production. 
The error bars represent the standard deviation of n = 3 independent experiments. Data 









7.4 Results – Evaluation of small molecules (7B) 
 
7.4.1 NQO1 assay 
 
Screening of compounds 
Initially, the 7B structures (n = 14) were examined in an in vitro FP assay 101 to 
evaluate their Keap1-Nrf2 PPI inhibition potencies (performed by Nikolaos 
Georgakopoulos, UCL School of Pharmacy). Subsequently, the NQO1 induction 
potency was tested in a cellular NQO1 assay in which Hepa1c1c7 cells were 
exposed to a fixed dose concentration of 10 µM of each compound. In the fixed 
dose screen three compounds from group 1 (Table 7.6); 7B1, 7B8 and 7B9, and 
three compounds from group 2 (Table 7.7); 7B11, 7B13 and 7B14, were found to 
up-regulate NQO1 enzyme activity.  
 
Compound selection for further characterisation 
As the active molecules from group 2 were poorly soluble, dose response profiles 
were only created for the compounds from group 1 (Figure 7.20). FP results 
obtained by our group revealed that 7B1, 7B8 and 7B9 were potent inhibitors of the 
Keap1-Nrf2 PPI; IC50 = 59 nM, IC50 = 143 nM and IC50 = 76 nM respectively. The 
compound 7B1 represents ‘compound 2’ as developed by Jiang et al. 129. In the 
cellular NQO1 assay, 7B1 was shown to double the NQO1 induction at a 
concentration of 4 µM with no detected cytotoxicity up to 10 µM. Compound 7B9 
contains two tetrazole substituents in place of the carboxylic acids, and the 7B8 
compound contains an amide substituent in place of one of the carboxylate groups. 
These groups have a lower acidity and higher lipophilicity compared to the 
carboxylic acid-substituted 7B1, which should reduce the structure’s negative 
charge at physiological pH and may improve cellular penetration properties. 
However, 7B9 and 7B8 only showed moderate activity in the NQO1 assay (fold 
induction ~ 1.8 at 10 µM). Compounds 7B11, 7B13 and 7B14 were slightly less 
potent in the FP assay; IC50 = 575 nM, IC50 = 815 nM and IC50 = 677 nM. 
Nevertheless, NQO1 results suggest that they largely retain their cellular potency; a 
fold induction of 1.7 for 7B11 and a fold induction of ~ 1.9 for 7B13 and 7B14 were 
observed at the test concentration of 10 µM.  
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Table 7.6: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 1 of the 7B compound 
range. 
 






7B1 CH2CO2H CH2CO2H 0.059 ± 0.006 2.9 4.0 > 10 
7B2 CH2CO2Et CH2CO2H - b 1.1 - b > 10 
7B3 CH2CO2Et CH2CO2Et -b 0.9 - b ≥ 10 
7B4 CH2CO2Et CH2CO2tBu - b 0.8 - b ≥ 10 
7B5 CH2CO2Et CH2CONH2 - b 1.2 - b > 10 
7B6 CH2CO2Et CH2CN - b 0.6 - b ≥ 10 
7B7 CH2CO2H CH2CN - b 0.8 - b ≥ 10 
7B8 CH2CONH2 CH2CO2H 0.143 ± 0.018 1.8 - b > 10 
7B9 CH2CN4H CH2CN4H 0.076 ± 0.003 1.8 - b > 10 
Notes: FP assays performed by Nikolaos Georgakopoulos, UCL School of Pharmacy; a. Fold induction 
at 10 µM; b. Not determined. Compounds (Cpds). 
 
Table 7.7: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 2 of the 7B compound 
range. 
 






7B10 CH2CO2Et CH2CO2Et C6H5 -b 1.0 - b - b 
7B11 CH2CO2H CH2CO2H C6H5 0.575 ± 0.072 1.7 - b - b 
7B12 CH2CO2Et CH2CO2Et Me - b 0.9 - b ≥ 10 
7B13 CH2CO2H CH2CO2H Me 0.815 ± 0.06 1.9 - b - b 
7B14 CH2CO2H CH2CO2H Pr 0.677 ± 0.059 1.95 - b - b 
Notes: FP assays performed by Nikolaos Georgakopoulos, UCL School of Pharmacy; a. Fold induction 



























Figure 7.20: Dose response curves for the NQO1 assays of compounds 7B1 (●), 7B8 (▼) 
and 7B9 (○) in Hepa1c1c7 after 24 h stimulation. The red line indicates a doubling of NQO1 






7.5 Results – Evaluation of small molecules (7C) 
 
7.5.1 NQO1 assay 
 
First, 7C compounds were screened in vitro using an FP assay 101 to examine their 
ability to disrupt the Keap1-Nrf2 PPI (performed by Helene Bertrand and Adrian 
Fowkes, UCL School of Pharmacy). Next, the structures were subjected to a cellular 
screen in which their induction capabilities for the Nrf2 dependent NQO1 enzyme 
were evaluated. Initially, the compounds were tested at a fixed concentration of 10 
µM. Dose response profiles were created for compounds that demonstrated a good 
NQO1 induction potency. Tables 7.8 – 7.24 list the tested compounds and their 
corresponding FP and NQO1 results.  
 
Screening of compounds 
The first group to be screened in the NQO1 assay were the 1,2,4-triazole 
derivatives (n = 7) (Table 7.8). These compounds were poor inhibitors of the Keap1-
Nrf2 PPI in the FP assay and were not able to up-regulate the NQO1 enzyme.   
 
Table 7.8: NQO1 (in the Hepa1c1c7 cell line) and FP results for the 1,2,4 – triazole 
derivatives.   
 






7C1 NO2 NO2   CH3 C 14.6 1.0 -c > 10 
7C2 CO2H NO2   CH3 C 13.4 1.0 - c - c 
7C3 NO2 CO2H   CH3 C 14.9 1.0 - c - c 
7C4 NO2 NO2 C6H5 C 12.7 1.0 - c - c 
7C5 CO2H NO2   C6H5 C 10.5 1.0 - c - c 
7C6 NO2 H H S 6.3 1.0 - c > 10 
7C7 CO2H H H S 9.6 1.0 - c - c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 10 µM; c. Not determined. Compounds (Cpds). 
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Subsequently, a first library of 1,2,3-triazole derivatives (n = 36) was studied, which 
was synthesised from a series of ethynyl- and azido-benzene intermediates with 
nitro, carboxylic acid or carboxamide functional groups (Table 7.9, group 1.1). This 
library presented a diverse range in activity in both the FP and NQO1 assay. The 
most promising activities were observed with molecules containing an R1/R2 – NO2 
and R3/R4 – NO2 or R1/R2 – NO2 and R3/R4 – CONH2 or R1/R2 – CONH2 and 
R3/R4 – NO2 groups. However, some carboxamide substituents demonstrated 
fluorescence interference in the FP assay. Several structures containing carboxyl 
substituents were active in the FP assay, but not in the NQO1 assay possibly due to 





















Table 7.9: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 1.1 of the 1,2,3-
triazole derivatives.   
 
Cpds R1/R2 R3/R4 FPa  FP  
IC50 (µM) 




7C8 R1 - NO2   R4 - NO2 72.6 8.7 1.0 - c - c 
7C9 R2 - NO2   R4 - NO2 46.5 -c 1.8 - c - c 
7C10 R1 - NO2   R3 - NO2 74.8 8.8 3.4 0.2 > 10  
7C11 R2 - NO2 R3 - NO2 81 11.5 2.3 ~ 10 > 10  
7C12 R1 - CO2H   R4 - NO2   81.3 50.1 1.0 - c - c 
7C13 R2 - CO2H   R4 - NO2   61 - c 0.7 - c ≥ 10 
7C14 R1 - CO2H   R3 - NO2   39.4 - c 1.0 - c - c 
7C15 R2 - CO2H   R3 - NO2   80.1 - c 0.8 - c ≥ 10 
7C16 R1 - NO2   R4 - CO2H   83.8 16.7 0.9 - c ≥ 10 
7C17 R2 - NO2   R4 - CO2H   87.5 21.1 1.1 - c - c 
7C18 R1 - NO2   R3 - CO2H   82.3 62.7 1.1 - c - c 
7C19 R2 - NO2   R3 - CO2H   63.8 - c 0.8 - c ≥ 10 
7C20 R1 - CONH2   R4 - NO2   46.1 - c 1.1 - c - c 
7C21 R2 - CONH2   R4 - NO2   62.2 - c 1.0 - c - c 
7C22 R1 - CONH2   R3 - NO2   64.5 - c 2.1 10 > 10  
7C23 R2 - CONH2   R3 - NO2   65.3 - c 2.1 7.7 ≥ 30 
7C24 R1 - NO2   R4 - CONH2   -23.3 - c 1.0 -
 c - c 
7C25 R2 - NO2   R4 - CONH2   2.34 - c 1.3 -
 c - c 
7C26 R1 - NO2   R3 - CONH2   48 - c 1.1 -
 c - c 
7C27 R2 - NO2   R3 - CONH2   32 - c 2.1 10 ≥10 
7C28 R1 - CONH2   R4 - CO2H   76.5 182.4 1.0 - c - c 
7C29 R1 - CONH2 R3 - CO2H   87.9 16 1.0 - c - c 
7C30 R1 - CONH2   R4 - CONH2   -159.1 - c 1.0 -
 c - c 
7C31 R2 - CONH2   R3 - CO2H   96.3 45.6 1.0 - c - c 
7C32 R2 - CONH2   R4 - CONH2   43.7 - c 1.0 -
 c - c 
7C33 R2 - CONH2  R4 - CO2H   15.4 - c 1.0 - c - c 
7C34 R1 - CONH2   R3 - CONH2   -44.7 - c 1.0 -
 c - c 
7C35 R2 - CONH2   R3 - CONH2   53.3 - c 1.0 -
 c - c 
7C36 R1 - CO2H   R4 - CO2H   77.3 23.6 1.0 - c - c 
7C37 R1 - CO2H   R4 - CONH2 -20.4 - c 1.0 -
 c - c 
7C38 R1 - CO2H   R3 - CO2H   92.8 50 1.0 - c - c 
7C39 R1 - CO2H   R3 - CONH2   70.7 14.6 1.0 -
 c - c 
7C40 R2 - CO2H   R4 - CO2H   89.6 49.1 1.0 - c - c 
7C41 R2 - CO2H   R4 - CONH2   -23.4 - c 1.0 -
 c - c 
7C42 R2 - CO2H   R3 - CO2H   82.3 51 1.0 - c - c 
7C43 R2 - CO2H   R3 - CONH2   78.6 18.6 1.0 -
 c - c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 10 µM; c. Not determined. Compounds (Cpds).  
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The second library containing 16 compounds (Table 7.10, group 1.2) was designed 
based on these findings; the R3 NO2 group was fixed and the R1 and R2 groups 
were varied (Table 7.9, group 1.1). Most compounds were active in both assays, 
apart from the fluorine substituted 7C52 and cyano substituted 7C57 that were less 
active in the FP assay. The iodine containing compound 7C55 was one of the most 
potent compounds in this series, demonstrating a low IC50 value in the FP assay 
and a CD value of 0.6 µM in the NQO1 assay.  
 
Table 7.10: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 1.2 of the 1,2,3-
triazole derivatives.   
                        
 






7C44 H 66.9 20.6 2.0 10 > 10  
7C45 R2 – CH3 68.9 10 2.2 1.3 > 10  
7C46 R2 – tBu 69.8 37.8 1.9 - c - c 
7C47 R2 – OCH3 68.2 15 2.6 4.7 > 100 
7C48 R2 – OCH2CH3 69.3 11.3 2.5 - c - c 
7C49 R1/2 -OCH2O- 67.2 15 2.2 - c - c 
7C50 R2 – SCH3 77.7 38.5 3.0 - c - c 
7C51 R2 – N[CH3]2 65.4 12.7 2.9 2.0 ≥ 10 
7C52 R2 – F 42.6 -c 2.3 - c - c 
7C53 R2 – Cl 60.4 8.8 2.5 0.8 > 10  
7C54 R2 - Br 68.2 24.5 2.9 1.2 > 100 
7C55 R2 – I 67.2 7.1 4.0 0.6 > 10  
7C56 R2 – CF3 66.9 22.6 2.5 - c - c 
7C57 R2 – CN 36.8 - c 2.0 10 > 10  
7C58  16.5 - c 1.8 - c - c 
7C59  -16.5 - c 1.7 - c - c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 10 µM; c. Not determined. Compounds (Cpds). 
 
A small third library of compounds with a tetrazole substituent (n = 8) at the R3 
position was developed as an alternative to the carboxylic acid or nitro group in that 
position, which previous showed promising activity in the FP assay but not in the 
cellular assay (Table 7.12, group 1.3b). It was hypothesised that the less acidic and 
more lipophilic tetrazole groups would favour cell penetration. The synthesis of the 
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tetrazole compounds was performed from a cyano group; hence this series of 
compounds with a cyano group at the R3 position (n = 5) were also tested (Table 
7.11 group 1.3a). However, neither of the two compound groups exhibited an 
improvement in cellular activity.   
 
Table 7.11: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 1.3a of the 1,2,3-
triazole derivatives.   
 






7C60 R2 – OCH2CH3 24.5 - c 1.3 - c - c 
7C61 R2 – Cl 19.9 - c 2.0 10 ≥ 10 
7C62 R2 – I    21.9 -c 1.5 - c - c 
7C63 R1 - CO2H   52.8 1.6 1.0 - c - c 
7C64 R2 – CN 58.8 46.2 1.9 - c - c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 





Table 7.12: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 1.3b of the 1,2,3-
triazole derivatives.   
 






7C65 R2 – CH3 30.4 - c 0.9 - c - c 
7C66 R2 – OCH2CH3 39.6 - c 1.3 - c - c 
7C67 R2 – Cl 40.7 - c 1.2 - c - c 
7C68 R2 – I 51.5 - c 0.4 - c ≥ 10 
7C69 R2 - NO2  71.1 51.4 1.8 - c - c 
7C70 R1 - CO2H 70 63.7 1.0 - c - c 
7C71 R2 –  CHN4 13.7 -c 0.8 - c ≥ 10 
7C72 R1 - * 74.2 15.8 1.0 - c - c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 10 µM; c. Not determined; * R1/R3 – CO2CH2CH2-(N-morpholine). 
Compounds (Cpds). 
 
The structures in Table 7.13 contain an additional R5 group compared to the 
structures described in Table 7.9. Compounds 7C77, 7C78 and 7C79 have a similar 
core structure but differ from each other by their R5 group; 7C78 and 7C79 contain 
a CH=CHCH2OCH3 and a C≡CCH2OH R5 group respectively, whereas 7C77 has 
an iodide at this position. Their cellular activity appears to be related to the size of 
their R5 group; 7C77 displays a CD value of 0.9 µM, whereas 7C79 and 7C78 
demonstrate CD values of 4 µM and 40 µM respectively. Moreover, FP results 
reveal a high level of inhibition at 10 µM for 7C77, but 7C78 caused fluorescence 
interference in the assay. It is possible that the bulky R5 groups of 7C79 and 7C78 
may cause stearic hindrance in the Keap1 binding pocket and decrease the 
inhibition potential of the compounds. The sulphonamide/sulphone-containing 
compounds 7C81-7C85 generally showed reasonable inhibitory activity in the fixed 






Table 7.13: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 1.4 of the 1,2,3-
triazole derivatives.   
 






7C73 NO2 H  H * H 22 -d 3.2 1.5 > 10 
7C74 Br H  NO2 CH2OH H 43.1 - d 1.0 - d - d 
7C75 Br CH2OH NO2 H H 40 1.4 2.2 10 > 100 
7C76 CN H  NO2 H I 62.1 1.1 - d - d - d 
7C77 CN H H NO2 I 97a1 2.1 2.2 0.9 > 10 
7C78 CN H H NO2 ** a2 1.1 1.6 40 > 100 
7C79 CN H H NO2 *** -d 1.5 2.7 4.0 > 10 
7C80 CN H H * H 24.2 1.0 - d - d ≥ 3.0 
7C81 CN  H  H SO2NH2 H 52.0 - d 1.0 - d - d 
7C82 SO2NH2 H  H SO2NH2 H 52 1.0 1.0 - d - d 
7C83 SO2NH2 H H CO2H H -d - d 1.0 - d - d 
7C84 SO2NH2 H H CN H 54.6 - d 1.0 - d - d 
7C85 SO2CH3 H  H CN H 50.3 - d 1.1 - d - d 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; a1. Percentage inhibition at 10 µM; a2.fluorescence interference; b. Fold induction at 1 µM; c. 
Fold induction at 10 µM; d. Not determined; *CO2CH2CH2 N-morpholino. ** CH=CHCH2OCH3 *** 
C≡CCH2OH. Compounds (Cpds). 
 
The structures in Table 7.14 are dimers of the core structure in Table 7.10. 
Although, these compounds showed promising inhibition potencies in the FP assay, 











Table 7.14: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 1.5 of the 1,2,3-
triazole derivatives.   
 






7C86 OCH3 H 66 1.0 - d - d - d 
7C87  I H 69 1.0 - d - d - d 
7C88 CO2H H 74  1.0 -d - d - d 
7C89 CONH2 H 70 1.0 - d - d - d 
7C90 H CONH2 66 1.0 - d - d - d 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 1 µM; c. Fold induction at 10 µM; d. Not determined. Compounds (Cpds). 
 
Group 2 (n = 20) contains a range of 1,2,3-triazole derived structures that 
incorporate a spacer between the triazole and one of the phenyl rings (Table 7.15 – 
7.19, group 2.1 – 2.5). Compounds 7C91 and 7C92, 7C93 and 7C94 have a 
methylene spacer at the 1-position of the triazole, whereas the compounds in Table 
7.17 – 7.19 incorporate a spacer unit at the triazole 4-position. These molecules 
were designed to evaluate the positioning of the functional groups that form 
hydrogen bonds with amino acid residues in the binding pocket of the Keap1 
protein. Although some compounds showed moderate potency in either or both FP 
and NQO1 assays, the overall activity was not improved from the structures in 










Table 7.15: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 2.1 of the 1,2,3-
triazole derivatives.   
 






7C91 R1 - NO2   R3 - NO2 47.2 1.0 -c -c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 10 µM; c. Not determined. Compounds (Cpds). 
 
Table 7.16: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 2.2 of the 1,2,3-
triazole derivatives.   
 






7C92 H NO2 NO2 C 69 1.0 -d - d - d 
7C93 H SO2 CO2H N 77.6 1.0 1.1 - d - d 
7C94 H SO2 CO2CH2O2CCH3 N - d 1.0 1.0 - d - d 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 









Table 7.17: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 2.3 of the 1,2,3-




R1 R2/R3 FPa FP 
IC50 
(µM) 






7C95 1 NO2 R2 - NO2 40.3 -c - d 2.2 1.0 > 3.0 
7C96 1 NO2 R2 - CO2H 74.8 8.1 - d 1.0 - d - d 
7C97 1 CO2H R2 - CO2H 78.8 9.6 - d 1.0 - d - d 
7C98 1 CONH2 R2 - 
CO2Me 
10.0 - c - d 1.2 - d - d 
7C99 1 CN R2 - 
CO2Me 
-5.9 - c - d 1.1 - d - d 
7C100 1 NO2 R2 - 
CO2Me 
-51.3 - c - d 2 10 > 10 
7C101 2 (X = CH2) CO2H H       
7C102 2 (X = CH2) NO2 R2 - NO2 -0.2 - c - d 1.8 - d - d 
7C103 2 (X = CH2) NO2 R3 - Cl -21.4 - c - d 1.7 - d - d 
7C104 2 (X =S) NO2 R3 - CH3O 54.4 11.1 1.0 1.3 - d - d 
7C105 3 NO2 H -9.8 - c - d 1.0 - d - d 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 1 µM; c. Fold induction at 10 µM; d. Not determined. Compounds (Cpds). 
 
Table 7.18: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 2.4 of the 1,2,3-
triazole derivatives.   
 






7C106 CO2H 56.9 1.34 1.0 -d - d - d 
7C107 CO2CH2O2CCH3 - d - d 1.0 1.0 - d - d 
7C108 NO2 62.3 10 1.0 1.0 - d - d 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 







Table 7.19: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 2.5 of the 1,2,3-
triazole derivatives.   
 






7C109 NO2 a1 -d 1.0 - d - d 
7C110 SO2Me 16.6 - d 1.0 - d - d 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; a1. Fluorescence interference; b. Fold induction at 1 µM; c. Fold induction at 10 µM; d. Not 
determined. Compounds (Cpds). 
 
The structures in group 3 (n = 12) contain an imidazole heterocycle, which was not 
particularly active in either FP or NQO1 assays (Table 7.20 – 7.23, group 3.1 – 3.4). 
An exception to the poor activity is demonstrated by compound 7C116, which 
showed negative values in the FP assay (possibly due to fluorescence interference), 
but was highly potent in the NQO1 assay, CD ~ 0.6 µM.  
 
Table 7.20: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 3.1 of the 1,2,3-
triazole derivatives.   
 






7C111 H NO2   8.6 1.9 -c - c 
7C112 CH3 NO2   19.7 2.2 10 > 10 
7C113 C6H5 NO2   -14.1 2.0 10 > 10 
7C114 H CO2Me 18.4 1.5 - c - c 
7C115 CH3 CO2Me 8.5 1.0 - c - c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 





Table 7.21: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 3.2 of the 1,2,3-
triazole derivatives.   
 






7C116 C6H5NO2   R2 - NO2   -53.1 2.4 0.6 ≥ 10 
7C117 H R3 - NO2   8.6 1.2 -c -c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 10 µM; c. Not determined. Compounds (Cpds). 
 
Table 7.22: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 3.3 of the 1,2,3-
triazole derivatives.   
 






7C118 R1 - Cl NO2 a1 -d 1.0 - d - d 
7C119 R1 - Cl Cl a1 1.1 - d - d - d 
7C120 R1 - CN NO2 a1 - d 1.2 - d - d 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; a1. Fluorescence interference; b. Fold induction at 1 µM; c. Fold induction at 10 µM; d. Not 





Table 7.23: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 3.4 of the 1,2,3 – 
triazole derivatives.   
 






7C121 Cl NO2 a1 1.2 - c - c 
7C122 NO2 Cl a1 1.0 - c - c 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; a1. Fluorescence interference; b. Fold induction at 10 µM; c. Not determined. Compounds 
(Cpds). 
 
The quinolone-based structures in group 4 (n = 8) (Table 7.24) showed generally a 
large amount of fluorescence interference in the FP assay, but revealed high 
potency in the NQO1 assay. However, the compounds are structurally similar to 
AhR ligands 233 and tyrosine kinase inhibitors 234. Hence, it may be unlikely that the 
molecules induced the NQO1 enzyme via the Keap1-Nrf2 pathway.  
 
Table 7.24: NQO1 (in the Hepa1c1c7 cell line) and FP results for group 4 of the 1,2,3-
triazole derivatives.   
 






7C123 NO2 H R5 - NO2   -0.7 1.0 -c - c 
7C124 NO2 H R3 - NO2   11.2 3.9 0.3 > 100 
7C125 NO2 H R4 - NO2   100.2 3.5 1.0 > 10 
7C126 NO2 C2H5O R5 – NO2   5.2 1.5 - c - c 
7C127 NO2 C2H5O R3 – NO2   5.0 3.5 1.0 > 100 
7C128 NO2 C2H5O R4 – NO2   0.6 3.6 -c -c 
7C129 CO2Me H R3 - NO2   -26.6 3.8 -c -c 
7C130 CO2H H R4 - NO2   -10.1 1.9 - c - c 
Notes: FP assays performed by Helene Bertrand, UCL School of Pharmacy; a. Percentage inhibition at 




Compound selection for further characterisation 
Four compounds from group 1.1 and 1.2 demonstrating different activity in the FP 
and NQO1 assays were selected for further evaluation (Figure 7.21 A). 7C33 
showed only a low inhibition in the FP assay (~ 15% inhibition at 100 µM) and no 
NQO1 induction in the cellular assay. 7C46 was able to displace the fluorescent 
Nrf2 peptide with an IC50 of 37.8 µM and revealed a slight NQO1 induction (fold 
change ~ 1.9 at 10 µM). 7C45 demonstrated an improved IC50 of 10 µM in the FP 
assay and a moderate activity in the NQO1 assay (CD ~ 1.3 µM). 7C55 was the 
most promising molecule; presenting an IC50 of 7.1 µM in the FP assay and a 
doubling of NQO1 activity at 0.6 µM. Dose response profiles were created in both 
Hepa1c1c7 and BpRc1 cells for the two most potent compounds 7C45 and 7C55 
(Figure 7.21 B and C respectively). Neither of the two structures was able to up-









Figure 7.21: Chemical structures of compounds 7C33, 7C46, 7C45 and 7C55 (A) and dose 
response curves for the NQO1 assays of compounds 7C45 (●) and 7C55 (○) in Hepa1c1c7 
(B) and BpRc1 (C) after 24 h stimulation. The red line indicates a doubling of NQO1 activity 


















































7.5.2 SRB assay 
 
No decrease in NQO1 induction was observed at concentrations up to 10 µM of the 
7C55 compound in the cell-based NQO1 induction assay, which therefore indicates 
no cytotoxicity. Hepa1c1c7, BpRc1 and HeLa cells were exposed for 24 and 48 h to 
7C55 at concentrations up to 250 µM (in 1% DMSO final concentration) to evaluate 
potential cytotoxicity in an SRB assay. No cytotoxicity was detected up to 250 µM 
after 24 and 48 h in either of the cell lines (Figure 7.22 A and B respectively). For 
consistency purposes, all subsequent experiments with 7C55 were carried out at a 
concentration of 10 µM.   
 
 
Figure 7.22: Dose response curves for the SRB assays of 7C55 in Hepa1c1c7 (●), BpRc1 
(○) and HeLa cells (▼) after 24 h (A) and 48 h (B) stimulation. Cell viability is calculated as a 






































7.5.3 Western blotting 
 
Western blot analysis was used to verify whether 7C55 can activate the nuclear 
accumulation of Nrf2 and expression of Nrf2 regulated proteins HO-1 and NQO1 in 
Hepa1c1c7 and BpRc1 cells. Cells were exposed to 10 µM 7C55 over 24 h before 
samples were extracted after 1, 3, 6 and 24 h and separated into cytoplasmic and 
nuclear protein fractions. Treatment with 7C55 resulted in an increase of Nrf2 
accumulation in Hepa1c1c7 cells that was time dependent; the protein induction 
was maximal between 3 – 6 h (fold induction ~ 3 and 5 respectively) (Figure 7.23 A 
and E). However, Nrf2 induction in BpRc1 cells was barely detected (fold induction 
< 1.5) (Figure 7.23 C and E). Up-regulation of the expression of downstream target 
protein HO-1 was also promoted by 7C55; showing a peak HO-1 induction after 6 h 
in Hepa1c1c7 cells (fold induction ~ 9) (Figure 7.23 B and E), but a reduced 
maximum induction after 3 h in BpRc1 cells (fold induction ~ 2) (Figure 7.23 D and 
E). Induction of the other phase II enzyme, NQO1, was only observed after 24 h in 











































: A - D: We
se II enzym















sed as a 
ot results of 
bars respec
duction leve
R ratio of 
deviation of 
3 h 6 h
218
alysis of nu


































iments.   
 
 and its dow
 B respectiv














 The Nrf2 i
cells was
cellular NQ











































5 B for 7C
dependen
western b






































ith 10 µM 






























e shown in 
old change
tion for 7










5. No Nrf2 
lation in Hep
0 µM of 7C








nd E); a p
ively).  
p 1) in Hep
reviously o
5 (fold indu













 A for 7C5






























































































































 of n = 3 
221 
 
7.5.5 Pathway evaluation 
 
ARNT – AhR 
Cellular NQO1 induction assays and western blotting experiments indicated that 
7C55 was not able to induce NQO1 in the ARNT-deficient BpRc1 cell line (Figure 
7.21 C and Figure 7.23 D respectively). Moreover, no significant nuclear 
accumulation of Nrf2 was observed in BpRc1 cells following 7C55 treatment (Figure 
7.23 C). To verify whether the ARNT-AhR pathway is involved in the up-regulation 
of NQO1 in Hepa1c1c7 cells, western blot experiments were performed to examine 
the expression of nuclear AhR and cytoplasmic CYP1A1 proteins. Hepa1c1c7 cells 
were exposed to 10 µM 7C55 and cytoplasmic and nuclear samples were obtained 
over a time period of 24 h. Up to 1 h, 7C55 treatment resulted in an induction of 
nuclear AhR (fold induction ~ 1.7) that returned to baseline levels after 1 – 24 h 
(Figure 7.26 A and C). An induction of CYP1A1 protein was visible after 6 h (fold 
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The induction of the CYP1A1 enzyme detected by western blotting was further 
assessed by a luciferase CYP1A1 enzyme activity assay. Following 6 and 24 h of 
cellular exposure to 10 µM of 7C55, the amount of converted luciferin CYP1A1-
specific substrate was measured by detection of produced luminescence (Figure 
7.27 A). Subsequently, absolute luminescence values were converted into fold 
changes compared to the control (Figure 7.27 B). Previously reported data for the 
controls (Section 5.2.5): cells treated with vehicle only (C) and cells treated with 3 
µM BaP (P), were also displayed in Figure 7.27 to provide context for the test 
compound. After 6 and 24 h of 7C55 stimulation, Hepa1c1c7 cells show a small 
increase in CYP1A1 activity (fold induction ~ 1.4 and ~ 1.6 respectively). This 
finding is not in complete agreement with earlier described western blotting results, 
which showed a peak induction after 6 h (fold induction ~ 2.0).    
 
      
Figure 7.27: CYP1A1 induction measured using the P450 Glo Assay (Promega) following 
exposure of Hepa1c1c7 cells to vehicle (C), 10 µM 7C55 or 3 µM BaP (P). (A): the quantity 
of luciferin (RLU) detected is proportional to the extent of CYP1A1 enzyme activity. The error 
bars represent the standard deviation of n = 8 replicates in a representative experiment. (B): 
fold changes of 7C55 and BaP versus vehicle control. Data indicated with an * are 








































To verify whether ROS is produced after exposure of Hepa1c1c7 cells to 7C55, a 
flow cytometry based assay was performed. ROS production may promote the 
nuclear translocation of Nrf2 by reacting with thiol groups of Keap1. After treatment 
of Hepa1c1c7 cells with 10 µM 7C55 for 1 h, cells were stained with CellROX Deep 
Red reagent (Life Technologies) and fluorescence was measured on a flow 
cytometer (Figure 7.28). The results of the blank and previously described controls 
were also shown in Figure 7.28: negative controls DMSO (C1) and acetonitrile (C2) 
and positive control: menadione (M). No ROS production was evident after cellular 
exposure to 7C55.  
 
















* * * *  
 
Figure 7.28: ROS production measured using the CellROX Deep Red dye after exposure of 
Hepa1c1c7 cells to 10 µM 7C55 or 50 µM menadione (M) for 1 h. As controls, cells were 
exposed to the 7C55 vehicle, DMSO (C1) and the menadione vehicle, acetonitrile (C2). The 
amount of fluorescence (APC MFI) detected is proportional to the extent of ROS production. 
The error bars represent the standard deviation of n = 3 independent experiments. Data 








Although there are some disadvantages associated with the use of peptides as 
drugs, such as rapid degradation and poor cell permeability, they are highly suited 
to inhibit protein-protein interactions 235. Moreover, peptides are highly specific and 
are straightforward to synthesise and modify, which is especially useful in the earlier 
stages of drug development. In this respect, peptidomimetics are powerful tools to 
enhance the pharmacological properties of peptides and present a development 
route for highly active Nrf2 peptide-derived inducer molecules 235.  
 
Previous synthesised 7-mer peptides and derivatives were designed to include or 
mimic the high affinity ETGE interaction. Initial FP results 143 suggested that the 
minimal binding motif is 77DEETGEF83 (7P1) (IC50 ~ 5.39 µM), but that the inhibition 
potential of the peptide structure was improved by introducing an E78P substitution. 
This substitution is derived from the binding sequence of Keap1 interactor, 
sequestosome-1. The original sequestosome-1 binding sequence demonstrated 
moderate inhibition potency in the FP assay (IC50 ~ 34.4 µM) 143, but modifying the 
peptide structure to become more ETGE-like (7P2) improved the activity drastically 
(IC50 ~ 0.25 µM) 143. Both peptides 7P1 and 7P2 exhibited matching inhibition 
potencies in the FRET assay that was developed in Chapter 3 (IC50 ~ 3.34 µM and 
IC50 ~ 0.33 µM respectively). However, they were not found to be active in a cell-
based NQO1 assay. The modification of the peptide structure with an N-terminal 
stearic acid group (peptides 7P4 and 7P5) improved not only cellular penetration 
properties as demonstrated in the NQO1 assay, but also enhanced binding affinities 
in both FP 170 and FRET assays. Scrambled versions of the peptide (peptides 7P8, 
7P9 and 7P6) were not active in any of the assays and demonstrated the 
importance of the ETGE motif for binding. However, scrambled stearic acid 
conjugates (i.e. peptides 7P8 and 7P6) appeared to have a non-specific 
advantageous effect on binding, which should be further explored. The designed 
peptides have an overall net negative charge at physiological pH. This is an 
unfavourable physical property for cell penetration as the plasma membrane is a 
non-polar environment. In an attempt to reduce this charge, a D76N substitution 
was introduced, resulting in peptides 7P10 and 7P11.  
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This charge reduction was detrimental for the binding properties of the peptide as 
the D76 residue is essential for maintaining the peptide secondary structure (a β-
turn-like structure) when bound to Keap1. However, induction of NQO1 activity in 
the cell-based assay was similar for both 7P4 and 7P11. Although the overall net 
charge of peptide 7P11 remained negative, the peptide has improved cell 
penetrating properties and was therefore conjugated to a FITC fluorophore to study 
its uptake in cells. The FITC conjugated peptide 7P12 (10 µM) showed a time-
dependent cell penetration in Hepa1c1c7 cells measured up to 2 h using flow 
cytometry analysis. Moreover, a cytoplasmic distribution in both living and fixed cells 
was observed after 1 h of cellular incubation with 10 µM 7P12. Only a minimal 
amount of the peptide co-localised with the CellMask cell membrane marker, 
suggesting that the peptide does not associate strongly with the cell membrane. The 
peptides may form micelles or vesicles within the cell (visible as small, intensely 
green areas), which is enabled by the conjugated stearic acid group. Nevertheless, 
this hypothesis needs to be verified in further experiments. The TAT peptide is a 
widely used CPP; hence an FITC conjugated version was used as a positive control 
in the cellular uptake study. The TAT peptide has a positive net charge at 
physiological pH and is thought to bind to the highly negative charged plasma 
membrane and enter the cell via endocytosis, within the cell the TAT peptide 
accumulates within the nucleus in the vicinity of the negatively charged DNA. The 
FITC conjugated TAT peptide (1 µM) demonstrated a cytoplasmic and nuclear 
distribution in fixed cells, but no cellular uptake was detected in living cells (flow and 
confocal analysis). Some studies have suggested that the TAT peptide has to reach 
a certain threshold concentration to translocate to the cytoplasm and nucleus via 
endocytosis 236 237. The concentration used here, 1 µM, might be too low, which is 
surprising considering the cellular distribution in fixed cells at the same 
concentration. However, the fixation process causes disruption of the membrane 
and may facilitate influx of the peptide. Future work may include studying the 
peptide uptake and distribution in different cell types.  
 
Recently, a series of TAT-conjugated ETGE peptides has been reported to induce 
the expression of Nrf2 and its downstream target gene HO-1 in THP-1 cells in a 
similar concentration range to those required for peptides 7P4, 7P5 and 7P11 to 
induce NQO1 up-regulation in Hepa1c1c7 cells 238. These and our findings suggest 
that peptides and peptide conjugates may contribute to finding potent inducers of 
Nrf2 activity via inhibition of the Keap1-Nrf2 PPI.  
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In particular, stearic acid conjugated peptides showed promising cell penetrating 
capabilities in both an NQO1 induction assay and cellular uptake studies.  
 
7.6.2 Small molecules 
 
Similar to peptidomimetic compounds, small molecule inhibitors of protein-protein 
interactions bind target sites in a highly specific and non-covalent manner and 
generally possess better cellular penetrating properties than peptides. Moreover, 
identification of small molecule inhibitors benefited from the ability to screen large 
compound libraries using in silico methods, without the need for synthesizing every 
molecule 239.  
 
A selection of different small molecule inhibitors (7A range) was tested to examine 
their ability to disrupt the Keap1-Nrf2 PPI and up-regulate Nrf2 and its downstream 
target genes. These small molecules were previously identified from a wide range of 
compound libraries. Initial screening using an in vitro FP and FRET screening and a 
cellular NQO1 assay was performed to establish the biological activity profiles of the 
molecules. Compound 7A4 possessed the best pharmacological properties of the 
series; the compound inhibited the PPI with an IC50 of 2.84 µM obtained with the 
FRET assay, which is similar to a previously found IC50 of 2.7 µM with close 
analogue ‘compound 16’ 227 using a confocal fluorescence anisotropy assay. 
However, 7A4 showed a significant amount of fluorescence interference in the FP 
assay. This could be due to specific spectral overlap with the FITC fluorophore used 
in the FP assay. The fluorescence properties of the eCFP and eYFP conjugated 
proteins used in the FRET assay may have less potential for fluorescence overlap 
or interference in this assay system. 7A4 demonstrated a CD value of 8 µM in the 
cellular NQO1 induction assay in Hepa1c1c7 cells. Further western blotting analysis 
in this cell line revealed an Nrf2 dependent up-regulation of the phase II enzymes 
HO-1 and NQO1. 7A4 showed a similar protein induction pattern to the reference 
compound sulforaphane in Hepa1c1c7 cells; a peak Nrf2, HO-1 and NQO1 
induction occurred after 1, 6 and 24 h respectively. Indeed, Marcotte et al. 227 found 
an induction of Nrf2 and NQO1 in a DLD1-ARE reporter cell line upon exposure to 
close analogue ‘compound 16’. The Nrf2 dependency of the NQO1 induction was 
confirmed by activity in an Nrf2 specific ARE-driven luciferase cell-based assay and 
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by a detected decrease in NQO1 expression upon Nrf2 gene knockdown 227. 
However, 7A4 failed to induce NQO1 expression in the ARNT-defective BpRc1 cell 
line, which was observed alongside a significant reduced induction of Nrf2 and 
HO-1 protein levels. This is in contrast to the unaltered induction profile of Nrf2 and 
phase II enzymes that was observed with sulforaphane. A modest up-regulation of 
the AhR transcription factor and target enzyme CYP1A1 was found in the 
Hepa1c1c7 cells after 1 h and 6 h of 7A4 exposure respectively. Sulforaphane did 
not show a significant nuclear accumulation of the AhR transcription factor, but the 
CYP1A1 protein and enzyme activity was modestly induced after 24 h. 
Nevertheless, the CYP1A1 induction with 7A4 or sulforaphane was small compared 
to enzyme activity levels detected with cellular exposure to AhR ligand BaP. 
Although the mutant cell line, BpRc1, should only differ from its wild-type cell line, 
Hepa1c1c7, by a defective ARNT, evidence has emerged that other significant 
differences exist. Seidel and Denison 110 used the approach of differential display to 
verify the gene expression in both wild-type and mutant cell lines and found an 
ARNT-independent modified gene expression between Hepa1c1c7 and BpRc1 
cells. In addition, differential growth profiles were observed between wild-type and 
mutant cells and between two different ARNT deficient mutant cell lines (BpRc1 and 
c4). More recently, Wang et al. 240 re-introduced ARNT into the ARNT deficient c4 
cells and subjected the cells to DNA microarray analysis. Twenty-seven genes other 
than AhR were found to be induced following re-introduction of ARNT and represent 
target genes for ARNT. These findings suggest that the inability of 7A4 to induce 
NQO1 in the BpRc1 cell line is not necessarily (only) due to ARNT-AhR 
dependence, but could also be related to other factors. 7A4 demonstrated no 
evidence of ROS production upon exposure to Hepa1c1c7 cells. Hence, ROS 
production is an unlikely factor to have contributed to the up-regulation of phase II 
enzymes. This is consistent with the direct disruption of the interaction between 
Keap1 and Nrf2. Moreover, close analogue ‘compound 16’ was not found to be 
cysteine reactive 227. Further characterisation of 7A4 revealed no cytotoxicity up to 
25 µM in Hepa1c1c7, BpRc1 and HeLa cells after 24 and 48 h of compound 
exposure, but cell viability started to decline at higher concentrations. Future 
experiments should include the assessment of the long-term toxicity of 7A4 on 
diverse cell lines. Co-crystal structure data obtained by Marcotte et al. 227 revealed 
that ‘compound 16’ binds in subpockets P3, P4 and P5 of Keap1, but is unable to 
occupy the highly positive charged P1 and P2 subpockets. The latter Keap1 binding 
sites are of high importance for the binding of the Nrf2 ETGE motif; the two side 
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chain carboxylic acids from the residues E79 and E82 mainly interact 
electrostatically with arginine residues in Keap1.  
Jiang et al. 129 designed ‘compound 2’ based on the co-crystal structure of 
‘compound 16’ bound in the Keap1 binding pocket. The two carboxylic acids linked 
to the nitrogen of the sulfonamide groups, enabled occupancy of the P1 and P2 
subpockets. Moreover, Jiang et al. 129 found ‘compound 2’ to inhibit the Keap1-Nrf2 
PPI with an improved IC50 of 28.6 nM in a FP assay (IC50 2.7 µM for ‘compound 16’ 
227). Our group developed a compound series based on this ligand design. 
Compound 7B1 was synthesised and identical in structure to ‘compound 2’. The 
activity of 7B1 was very similar to the quoted activity of ‘compound 2’, with an FP 
IC50 59 nM in our assay system. 7B1 was also able to up-regulate the NQO1 
enzyme in Hepa1c1c7 cells, demonstrating a higher potency than 7A4 (CD ~ 4 µM 
versus 8 µM). This is in agreement with earlier reported findings were the compound 
showed activity in an Nrf2 ARE-luciferase reporter assay and Nrf2-associated gene 
expression was up-regulated. Although no cytotoxicity tests were performed, 7B1 
did not affect cell viability at concentrations up to 10 µM under the conditions of the 
NQO1 assay in Hepa1c1c7 cells. According to docking studies and FP assays, this 
compound is suggested to bind with higher affinity and specificity in the Keap1 
binding pocket compared to ‘compound 16’ 227 or 7A4. However, the added 
carboxylic acid groups introduce a net negative charge to the compound at 
physiological pH. This could be detrimental for the cell penetrating properties of the 
compound. Consequently, 7B compounds were developed containing less acidic 
side chains, e.g. tetrazole and amide groups. However, these structures did not 
show an improvement in the cellular NQO1 induction assay. Another strategy 
involved mimicking the naphthalene ring to improve binding potency, yet FP results 
showed increased IC50 values and the NQO1 induction potency remained similar to 
naphthalene ring equivalents. Ongoing work is conducted to improve Keap1 binding 
properties and cellular potency of these promising small molecule inhibitors.        
 
In an attempt to discover other potent small molecule inhibitors of the Keap1-Nrf2 
PPI, a docking screen was performed with a fragment library of 178,000 
compounds. An FP screen revealed that 1,2,3-triazole derivatives (7C range) 
demonstrated the most promising results. These structures were based on a 1,4-
diaryl-1,2,3-triazole scaffold that was designed to mimic the distance between the 
glutamate side chains of the Nrf2 – ETGE motif. Additional cellular screening with a 
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NQO1 induction assay revealed a range of different activities using various 
functional group substituents. The main findings included: carboxylic acid 
substituents were good for binding in vitro, but less so for cellular potency as 
negatively charged molecules do not favour cell penetration. Carboxamide and nitro 
groups showed better NQO1 inducing abilities, but carboxamide substituents 
caused some fluorescence FP interference. However, generally, compounds 
containing nitro groups should be avoided in drug development as their metabolism 
can generate reactive species that may induce cytotoxicity 241. The introduction of 
linkers or alterations to the heterocycle of the core structure didn’t improve in vitro or 
cellular potency significantly. Quinoline-containing structures were active in cell-
based assays, but may not up-regulate NQO1 via disruption of the Keap1-Nrf2 PPI 
as they share structural similarity with some known AhR ligands, including 9,10-
dimethyl-1.2-benzanthracene (DMBA), benzo(a)pyrene (BaP) and 3,4,5,3’,4’-
pentachlorobiphenyl (PCB 126) 242. These compounds also showed FP interference, 
which could be due to their large aromatic planar rings. The most promising 
compound tested was the nitro and iodine substituted compound 7C55, which was 
not cytotoxic at concentrations up to 250 µM in Hepa1c1c7, BpRc1 and HeLa cells 
after 24 and 48 h of compound exposure. Future experiments should include the 
assessment of the long-term toxicity of 7C55 on diverse cell lines. This small 
molecule inhibited the Keap1-Nrf2 PPI with an IC50 of 7.1 µM in the FP assay and 
induced the downstream enzyme NQO1 by 4-fold at 10 µM with a CD value of 0.6 
µM in Hepa1c1c7 cells. Western blotting analysis confirmed the up-regulation of the 
NQO1 protein. This induction was observed alongside the expression of other 
phase II enzyme HO-1 and nuclear accumulation of Nrf2 in Hepa1c1c7 cells. A 
reduced performance in the FP assay and a decreased NQO1 induction of related 
compounds 7C33, 7C45 and 7C46 was consistent with a diminished nuclear 
accumulation of Nrf2. Flow cytometry analysis quantitatively confirmed the 
differential expression of Nrf2 upon cellular exposure to 7C55 or the non-active 
compound 7C33. Compared to the reference compound sulforaphane, 7C55 
showed a later peak induction of Nrf2 (3 - 6 h versus 1 h). However, a similar time 
dependent up-regulation of HO-1 was observed for both compounds (max induction 
after 6 h). Nevertheless, 7C55 was not able to induce NQO1 expression in the 
ARNT-deficient BpRc1 cell line. Similar to 7A4, Nrf2 and HO-1 protein induction was 
substantially decreased in this mutant Hepa1c1c7 cell line. In addition, 7C55 
showed an induction of AhR after 1 h and CYP1A1 after 6 h, which was also 
observed with 7A4. However, the AhR induction was slightly lower compared to 7A4 
(fold difference of 1.7 vs. 4.5). 7C55 induced the nuclear accumulation of Nrf2 with 
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The group of Albena Dinkova-Kostova developed a FRET-based method combined 
with multi-photon fluorescence lifetime imaging microscopy (FLIM) (submitted and in 
the press 229). The hinge and latch theory describes an open confirmation of the 
Keap1-Nrf2 complex when Keap1 is only bound by the high affinity motif Nrf2-ETGE 
and a closed conformation of the complex when Keap1 is bound by both high 
affinity ETGE and low affinity DLG motifs. The results from Dinkova-Kostova 
indicate that sulforaphane and other electrophilic inducers cause an accumulation of 
the closed confirmation, where Nrf2 is not ubiquinated by the covalently modified 
Keap1 and de novo Nrf2 can accumulate in the nucleus. However, 7C55 causes an 
accumulation of the open complex confirmation and suggests that the small 
molecule disrupts the interaction of Keap1 with low affinity DLG motif. These 
observations are supportive of the 7C55-Keap1 docking studies.  
 
In the process of mitophagy, damaged mitochondria are degraded and recycled by 
autophagosomes and lysosomes 243. The expression of P62 or sequestosome-1 is 
partly regulated by Nrf2 and plays a crucial role in mitophagy by targeting 
autophagy. A defective mitophagy process is related to cancer and several 
neurodegenerative diseases. East et al. 244 showed that unlike sulforaphane, 7C55 
is able to induce mitophagy in MEF cells in an Nrf2 and p62-mediated manner and 
thus demonstrates potential as a tool compound in mitochondrial quality control. 
Overall, the 7C55 compound shows promising inhibitory and cellular activity towards 
the disruption of the Keap1-Nrf2 PPI. Hence, the relative simple chemical structure 
can be used as a tool compound for further development.  
 
The small molecule inhibitors discussed here present powerful examples of an 
alternative to thiol-reactive compounds for the induction of Nrf2. However, 
evaluation of pathway specificity demonstrates the potential involvement of other 
pathways than Keap-Nrf2 in the up-regulation of phase II enzymes i.e. NQO1. 
Future work, including Nrf2 and AhR knock-out experiments would be essential to 








In this chapter, Nrf2 inducer compounds that cannot yet be classified as direct or 
indirect Nrf2 inducers are discussed. Several of these compounds showed 
promising activity in a cellular NQO1 enzyme activity assay. However, the exact 
mode of action for most of the structures described is unknown.  
 
The aim of this chapter is to screen Nrf2 inducers with an unknown 
mechanism of action for their ability to induce Nrf2 target genes. 
 
8.1.1 8A compounds 
 
These compounds, which were developed by our group 62, were synthetic 
intermediates for the synthesis of a series of p-quinol derivatives via oxidation 
reactions (described in Chapter 6). They were evaluated as potential Nrf2-inducing 
agents in order to compare their activity with their oxidised counterparts and 
because various phenolic compounds have been shown to induce NQO1 activity in 
previous studies. In some cases bio-oxidation can convert phenols into electrophilic 
quinones containing Michael acceptor groups e.g. tBHQ (tert-butyl-p-hydroquinone) 
84-85. Michael acceptors are able to up-regulate phase II enzymes i.e. NQO1 by their 
reactivity towards thiol residues.  
 
8.1.2 8B compounds 
 
Chalcones are naturally occurring compounds that are biological and synthetic 
precursors of flavonoids and isoflavonoids; they consist of two phenyl rings linked 
by a three-carbon α,β-unsaturated carbonyl group (Figure 8.1 A) 245. This compound 
group has been shown to exhibit multiple biological properties, including anti-
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inhibition of NF-kB may affect the promotion and progression of cancer cells via the 
induction of apoptosis 251. Inhibition of the aromatase enzyme, which is responsible 
for estrogen production, is a well-known strategy in the treatment and prevention of 
oestrogen receptor-positive breast cancer. Figure 8.2 B shows the 3,5-diaryl-1,2,4 – 
thiadiazole core scaffold that was used to develop analogues 251. This structure 
presents a high level of similarity with the lead compound from the 7C range, 7C55 
(Figure 8.2 C). Hence, the 8C compound series was developed by our group based 





Figure 8.2: Chemical structures of A: trans-resveratrol, B: 3,5-diaryl-1,2,4 – thiadiazole core 
scaffold 251 and C: 7C55. 
  
A C B 
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8.2 NQO1 results  
 
8.2.1 8A compounds  
 
This group of phenolic compounds (n = 7) exhibited weak NQO1 induction potency 
in the Hepa1c1c7 cell line; fixed dose studies at a concentration of 1 µM, resulting in 
a fold induction of < 1.5 for the most potent structures, 8A2 and 8A4 (Table 8.1). No 
cytotoxicity was observed at this concentration.  
 
Table 8.1: NQO1 (in the Hepa1c1c7 cell line) results for phenolic 8A compounds.  
 






8A1 CH2CH2OAc H 1.0 - b - b 
8A2 CH2CO2Et H < 1.5 - b - b 
8A3 CH2CO2Et F 1.0 - b - b 
8A4 CH2CH2CO2Et H < 1.5 -b - b 
8A5 CH=CHCOMe H 1.1 - b - b 
8A6 CH2CH2CH2CO2Et H 1.0 - b - b 
8A7 4-Methoxyphenyl H 1.0 - b - b 
Notes: a. Fold induction at 1 µM; b. Not determined. Compounds (Cpds). 
 
8.2.2 8B compounds 
 
The series of compounds (n = 18), which was divided over two groups, was 
examined for their ability to induce NQO1 enzyme activity in a cellular assay in the 
Hepa1c1c7 cell line. A fixed dose study at a concentration of 10 µM was performed 






The group 1 core structure (Table 8.2) is similar to ‘compound 2b’ (Figure 8.1 B) as 
described by Kumar et al. 247. Chloro and trifluoromethyl groups in the R1 and/or R2 
positions appear to be favourable for NQO1 activity; three structures in group 1, 
8B6, 8B8 and 8B9, demonstrated a moderate NQO1 induction potency with CD 
values ranging from 3 – 6 µM and were not cytotoxic up to 10 µM. Compound 8B10 
also exhibited the ability to up-regulate NQO1 in the fixed dose study (fold induction 
~ 3.5 at 10 µM), but was not examined further.   
 
Table 8.2: NQO1 (in the Hepa1c1c7 cell line) results for group 1 of the 8B compound range. 
 






8B1 H H 1.9 - b - b 
8B2 CH3 H 1.4 - b - b 
8B3 OMe H 1.7 -b - b 
8B4 OMe OMe 1.8 - b - b 
8B5 SCH3 H 1.7 - b - b 
8B6 H Cl 2.5 6.0 > 10 
8B7 Cl H 1.2 - b - b 
8B8 Cl Cl 2.9 5.0 > 10 
8B9 CF3 H 6.8 3.0 > 10 
8B10 Cl CF3 3.5 - b - b 
Notes: a. Fold induction at 10 µM; b. Not determined. Compounds (Cpds). 
 
The compounds in group 2 (Table 8.3) vary in activity; ranging from inactive (8B14, 
fold induction ~ 1.0 at 10 µM) to highly active (8B17 and 8B18, CD ~ 0.04 µM). No 
cytotoxicity was detected up to 10 µM. Again, the Cl and CF3 groups at the R1 









Table 8.3: NQO1 (in the Hepa1c1c7 cell line) results for group 2 of the 8B compound range. 
 






8B11 H H 1.3 -b - b 
8B12 CH3 H 2.0 - b - b 
8B13 OMe H 1.3 - b - b 
8B14 OMe OMe 1.0 - b - b 
8B15 SCH3 H 2.3 8.0 > 10 
8B16 Cl H 3.0 6.0 > 10 
8B17 Cl Cl 4.2 0.04 > 10 
8B18 CF3 H 3.6 0.04 > 10 
Notes: a. Fold induction at 10 µM; b. Not determined. Compounds (Cpds). 
 
Figure 8.3 shows the dose response profiles that were created for the three most 
active compounds in group 1 (8B9) and group 2 (8B17 and 8B18).  
Compound (µM)





















Figure 8.3: Dose response curves for the NQO1 assays of compounds 8B9 (●), 8B17 (○) 
and 8B18 (▼) in Hepa1c1c7 after 24 h stimulation. The error bars represent the standard 




8.2.3 8C compounds 
 
The NQO1 induction potential of 8C compounds (n = 9) was studied in Hepa1c1c7 
cells. The compounds were subdivided into four separate groups based on their 
chemical structures. Initially, all compounds were examined at a fixed dose 
concentration of 10 µM. Several compounds were screened in an in vitro FP assay 
101 for their ability to interfere with the interaction between Keap1 and Nrf2 
(performed by Adrian Fowkes, UCL School of Pharmacy).  
 
The compounds in group 1 (Table 8.4) are thiadiazole derivatives and are based on 
the structures of 8C1 and 8C3, which represent compound ‘3ii’ and ‘3hh’ 
respectively, as described by Mayhoub et al. 251 (Figure 8.4 A and B respectively). 
These structures were found to range from not active (8C2, fold induction ~ 1.0 at 
10 µM) to highly active (8C4, CD ~ 0.2 µM) with varying cytotoxicity levels. 
Changing the R1 and R2 groups from OMe (8C1) to NO2 (8C4) improved the activity 
considerably (CD ~ 2 µM versus 0.2 µM). Moreover, FP results revealed slight 
inhibition activity by 8C1 (17.5% inhibition at 100 µM). None of the other compounds 




















Table 8.4: NQO1 (in the Hepa1c1c7 cell line) results for group 1 of the 8C compound range. 
 






8C1 OMe OMe 17.5 2.8 2.0 > 10  
8C2 NH2 CN - 0.3 1.0 -c -c 
8C3 CN CN a1 1.8 -c -c 
8C4 NO2 NO2 - 0.7 3.6 0.2 > 3.0 
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; a1. Fluorescence interference b. Fold induction at 10 µM; c. Not determined. Compounds 
(Cpds). 
 
The two structures in group 2 (Table 8.5) containing a linker group (X) were 
moderately active with CD values ranging from 3 – 10 µM and no cytotoxicity up to 
10 µM. A weak inhibition was observed for 8C6 in the FP assay. 
 
Table 8.5: NQO1 (in the Hepa1c1c7 cell line) results for group 2 of the 8C compound range. 
 






8C5 NH 0.7 2.0 10 > 10 
8C6 NMe 8.7 2.3 3.0 > 10  
Notes: FP assays performed by Adrian Fowkes, UCL School of Pharmacy; a. Percentage inhibition at 
100 µM; b. Fold induction at 10 µM. Compounds (Cpds). 
 
The 8C7 compound (Table 8.6) contains a NH-linker group and an altered 
heterocycle. This compound was highly active in the cell-based assay (CD ~ 0.6 







Table 8.6: NQO1 (in the Hepa1c1c7 cell line) results for group 3 of the 8C compound range. 
 






8C7 2.8 0.6 ≥ 30 
Notes: a. Fold induction at 10 µM. Compounds (Cpds). 
 
The compounds in group 4 (Table 8.7) are succinimide derivatives and were not 
active at a fixed dose of 10 µM.  
 
Table 8.7: NQO1 (in the Hepa1c1c7 cell line) results for group 4 of the 8C compound range. 
 






8C8 CN 1.0 - b - b 
8C9 NO2 1.0 -b - b 
Notes: a. Fold induction at 10 µM; b. Not determined. Compounds (Cpds). 
 
The two most active compounds (8C4 and 8C7) (CD < 1.0 µM) and one moderately 




























Figure 8.5: Dose response curves for the NQO1 assays of compounds 8C4 (●), 8C7 (○) and 
8C5 (▼) in Hepa1c1c7 after 24 h stimulation. The error bars represent the standard 





Although the phenolic 8A compounds may exert their NQO1 inducing ability after 
oxidation similarly to compounds containing Michael acceptors, they only showed 
modest activity in the cellular NQO1 assay. It is possible that their bio-oxidation 
might not be as effective as some other potent phenolic compounds such as t-BHQ.  
 
The 8B compounds are chalcone based structures, similar to those developed by 
Kumar et al. 247. Chloro and trifluoromethyl substituted derivatives of 8B groups 1 
and 2 demonstrated promising activity in the cellular NQO1 assay. The NQO1 
induction potencies of the group 1 structures were similar to activities found with 
‘compound 2b’-related structures (Figure 8.1 B) 247. Moreover, the 8B compounds 
based on the group 2 core structure were highly active presenting CD values of 0.04 
µM for the most potent 8B17 and 8B18 compounds. Group 2 compounds present a 
level of structural similarity with the 1,2,3-triazole derivatives (7C range group 4) and 
might be equally able to disrupt the interaction between Keap1 and Nrf2. However, 
these structures were not active in an FP-based assay. Nevertheless, 8B 
compounds ability to induce NQO1 activity may also be a result of an interaction 
with the AhR, as flavonoids and related structures are thought to act as AhR ligands 
246. Consequently, the compounds should additionally be examined in the ARNT-
deficient BpRc1 cell line.       
 
As the 8C compounds display structural similarity with the direct Nrf2 inducers 
described previously in Chapter 7 (7C range group 1), they were expected to be 
able to disrupt the Keap1-Nrf2 PPI to some extent and in this manner up-regulate 
the expression of NQO1. However, only weak inhibition potencies were observed in 
the FP assay; the highest inhibition percentage was observed with 8C1, 17.5 % at 
100 µM. The 8C1 compound demonstrated a similar NQO1 induction potency to 
that observed by Mayhoub et al. 251 (CD ~ 2 µM versus 4 µM). This activity improved 
considerably by substitution of the OMe groups to NO2 (8C4) groups (CD ~ 0.2 µM). 
This is in agreement with observed NQO1 potencies for 1,2,3-triazole derivatives 
containing nitro substituents (group 1.1 7C compounds, Chapter 7). Moreover, the 
highly active lead compound 7C55 contains one nitro group and inhibited the 
Keap1-Nrf2 PPI in an FP based assay. However, 8C4 was cytotoxic at 
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concentration ≥ 3 µM. Compounds containing nitro groups are often associated with 
cytotoxicity as they can be bio-activated by cytochrome p450 enzymes to generate 
reactive products 241. These reactive species can cause carcinogenicity, 
hepatotoxicity, mutagenicity and bone marrow suppression 241. Compound 8C2 and 
8C3 are structurally similar to the compounds in group 1.3a from the 7C compound 
range and present similar weak to moderate NQO1 activity in the cellular induction 
assay. The two 8C structures 8C5, 8C6 and 8C7 share some level of structural 
similarity with structures in group 2.3 from the 7C compound range. However, none 
of the 7C structures were as potent as 8C7 in the NQO1 assay. The core scaffold of 
this compound has been reported as a component of a FLT3 kinase inhibitor 252; 
hence, 8C7 may demonstrate off-target effects. The succinimide derivatives (8C8 
and 8C9) were not active. As the 8C compounds were not highly active in the FP 




9 Final discussion  
 
The focus of this thesis is chemoprevention as an alternative strategy to current 
cancer treatments. Both natural and synthetic compounds have the potential to be 
developed into chemopreventive drugs. Here, several biological methods have been 
specifically optimised or developed to evaluate diverse libraries of small molecules 
and peptides for their ability to induce cytoprotective mechanisms by manipulating 
the Keap1-Nrf2 pathway. The main methods utilised included a cellular NQO1 
induction assay that was optimised for screening purposes, an in vitro fluorescence 
polarisation (FP) screening assay that was previously developed in our group 143 
and western blotting analysis. In addition to these optimised methods, two novel 
assays were developed: the in-vitro steady-state Förster resonance energy transfer 
(FRET) assay can be used to screen direct inhibitors of the Keap1-Nrf2 complex 
and the intracellular Nrf2 staining method for flow cytometry enables the 
quantification of Nrf2 protein levels and supports western blotting analysis.    
 
Potential direct inhibitors of the Keap1-Nrf2 PPI were initially screened using an FP 
assay 143. However, complex polarizing optics are necessary for FP based 
screening. The FRET technique requires only simple excitation and emission filters 
and is at present successfully applied to study diverse PPIs 140-141. Here, a steady 
state FRET assay was developed to quantify protein-protein binding and to screen 
direct inhibitors of the Keap1-Nrf2 PPI. FRET was observed between the fusion 
proteins eCFP-TEV-Nrf2 and eYFP-TEV-Kelch due to a specific protein-protein 
interaction between the Keap1 Kelch domain and a 16-mer Nrf2 derived peptide. 
Subsequently, binding affinities were determined of both wild-type and (point) 
mutated Nrf2 derived peptides for the Keap1 Kelch domain. Competition was 
measured by monitoring the efficiency of energy transfer of the fluorescent labelled 
FRET pair during the addition of an unlabelled peptide or small molecule. IC50 
values were determined from the observed reduction in FRET efficiency. Moreover, 
the FRET assay was adapted to a multi-well plate format and was found suitable for 





During the project, western blotting was used as an approach to determine the level 
of protein expression. However, in this method one data point (stained protein band) 
is obtained by generating an average value for the protein expressed in an entire 
cell population (population analysis). As a consequence, datasets might differ from 
each other due to a range of responses within (multiple) cell populations. Flow 
cytometry applies the principle of single-cell analysis, which measures events in 
individual cells. The determination of protein induction levels using this technique 
improves the reliability and reproducibility of the obtained data. Here, a flow 
cytometry based method was developed to detect Nrf2 protein induction levels in 
both whole cells and isolated nuclei in a quantitative manner to support the more 
qualitative western blotting analysis. The application of the intracellular Nrf2 staining 
technique was verified using various Nrf2 inducing compounds in multiple cell lines. 
A specific primary antibody was found to be essential to ensure efficient staining.   
 
For the biological evaluation of compound libraries, the thiol reactive natural product 
sulforaphane was shown to be a good reference compound with good Nrf2 and 
phase II enzyme induction potency in both Hepa1c1c7 and ARNT-deficient BpRc1 
cells (NQO1 CD value ~ 0.4 µM and ~ 0.6 µM respectively). Subsequently, a library 
of quinol (cyclohexadienone) analogues, containing Michael acceptors, were 
evaluated for their ability to up-regulate the phase II enzyme NQO1. Structures that 
contained two Michael acceptors were found to be the most active. Especially, a 
series of optimised p-phenyl compounds demonstrated high potency and relatively 
low cytotoxicity levels (Table 6.1). The most promising structure was 6.49, a 3-
chlorophenyl compound. This molecule was able to up-regulate NQO1 enzyme 
activity in both Hepa1c1c7 and ARNT-deficient BpRc1 cells (CD values ~ 1 µM), 
which is indicative of a monofunctional inducer of Nrf2 107. Moreover, 6.49 
stimulated nuclear Nrf2 accumulation in Hepa1c1c7 cells. Overall, 6.49 has 
potential to be developed as an effective indirect Nrf2 inducer molecule by reducing 
its cytotoxicity and by investigating its effect on other (related) pathways.    
 
Direct Nrf2 inducers activate Nrf2 nuclear accumulation in a different way to 
cysteine reactive compounds. These structures are designed to interfere directly 
with the Keap1-Nrf2 PPI. In this inducer category several compound libraries have 
been examined. Peptides based on the high affinity 77DEETGE82 sequence from 
Nrf2 demonstrated promising inhibitory properties.  
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In particular, peptides containing an E78P substitution, derived from the binding 
sequence of sequestosome-1, performed well in both FP and FRET competition 
assays. Although, these peptides were not active in the cell-based NQO1 induction 
assay, stearic acid (C18) fatty acid conjugation promoted cellular penetration. 
Conjugation to a FITC fluorophore enabled the observation of peptide uptake and 
cellular distribution. Peptides and peptide conjugates are useful tools to identify and 
study the key binding sites in a PPI. Moreover, they can be used to develop small 
molecules with (enhanced) inhibitory properties.    
 
The 7A series of small molecules is a selection of previously identified compounds 
with Keap1-Nrf2 PPI specific inhibitory properties. 7A4, a bis-sulphonamide 
derivative, was one of the most potent molecules and demonstrated an IC50 of 2.84 
µM in the developed FRET assay and a CD value of 8 µM in the cellular NQO1 
induction assay in Hepa1c1c7 cells. Moreover, Nrf2 and downstream target 
enzymes HO-1 and NQO1 were up-regulated in a time dependent manner in 
Hepa1c1c7 cells. However, the induction of these proteins was significantly reduced 
in the ARNT-deficient BpRc1 cell line. Although a modest induction of the AhR 
transcription factor and downstream target CYP1A1 enzyme was found, other 
pathways may be affected by the 7A4 compound. Analysis of the closely related 
‘compound 16’ described by Marcotte et al. 227 revealed the interaction of the 
compound with subpockets P3, P4 and P5 of Keap1 (Figure 7.4). The binding of this 
structure in the Keap1 subpockets was improved by Jiang et al. 129 who developed 
‘compound 2’. This structure contains two acetic acid side chains conjugated to the 
sulphonamide nitrogen from ‘compound 16’ and demonstrated additional 
interactions with the Keap1 P1 and P2 subpockets. Since the structure appears to 
make contact with all five subpockets of Keap1, ‘compound 2’ has the ability to 
disrupt the Keap1-Nrf2 PPI with high affinity. Studies performed here with the 
identical compound 7B1, showed an IC50 value of 59 nM in an FP assay and a CD ~ 
4 µM for NQO1 induction in Hepa1c1c7 cells. Although, attempts were made to 
optimise the cell-penetrating properties by reducing the compounds overall acidity 






As part of a docking screen, compound 7C55, a 1,2,3-triazole derivative, was one of 
the most promising early molecules. The distance between the glutamate side 
chains of the Nrf2 high affinity motif ETGE was used to develop the scaffold of this 
structure. A 7C55 – Keap1 docking study revealed interactions of the compound 
with the P3 and P5 subpockets of Keap1. This virtual prediction was supported by 
promising FP results; IC50 ~ 7.1 µM and a FRET-FLIM study in which 7C55 was 
able to disrupt the Keap1-Nrf2 DLG motif interaction (submitted and in the press 
229). In addition, 7C55 was shown to be highly active in the cellular NQO1 induction 
assay; CD ~ 0.6 µM in Hepa1c1c7 cells. This induction was accompanied by 
nuclear Nrf2 accumulation and up-regulation of HO-1. Nevertheless, 7C55 was 
unable to induce the expression of Nrf2 and phase II enzymes in the ARNT-deficient 
BpRc1 cell line whilst modestly up-regulating the expression of AhR and CYP1A1 in 
the Hepa1c1c7 cell line. Moreover, 7C55 was found to induce mitophagy in MEF 
cells 244. These data demonstrates 7C55’s wide range of (cellular) activity and 
potential for further development.  
 
The 8C compounds were of a similar design to 7C55 and evaluated as Keap1-Nrf2 
PPI inhibitors. However, FP results demonstrated only low inhibition percentages. 
Nevertheless, these structures were able to induce the expression of NQO1 via an 
as yet unknown mechanism. 8B compounds represent a group of chalcone and 
flavanone derivatives with a very high potency for NQO1 up-regulation (CD values ~ 
40 nM). Although these compounds also share some level of structural similarity 
with 7C55, they were barely active in the FP assay (data not shown). In future 
studies, both compound groups should be evaluated in the ARNT-deficient BpRc1 
cell line to verify potential cross-talk with the AhR.  
 
Results of the biological evaluation of diverse direct and indirect Nrf2 inducer 
compounds aid in the future development of drugs targeted at the disruption of the 
Keap1-Nrf2 pathway. This is of vital importance as inhibitors of the Keap1-Nrf2 PPI 
may have additional effects on other pathways. In particular, potential AhR-XRE 
cross-talk may be responsible for cellular activity. For cross-talk activity it is 
desirable to include assays which generate additional data beyond enzyme 
induction, to provide a coherent drug discovery approach and to get a better 
impression of compounds selective behaviour.  
249 
 
10 Future perspectives 
 
The work described in this thesis has developed a number of research themes that 
warrant further study in the future. Some of these topics and experiments are 
described in more detail in the sections below. 
 
10.1 In vitro steady-state FRET based assay 
 
Future work may be targeted at improvement of the observed FRET between the 
interacting proteins by using a different fluorescent FRET pair or by altering the 
position or orientation of the fluorophores. In addition, the binding efficiencies of 
other Keap1 or Nrf2 interacting proteins may be studied by fusing them to 
appropriate fluorophores.  
 
The anti-apoptotic protein Bcl2 is reported to interact with the Keap1 – Kelch 
domain through its BH2 domain 253. It has been proposed that Bcl2 can escape 
Keap1 mediated ubiquitination and degradation through oxidative stress or 
electrophilic compounds that modify key cysteine residues in Keap1 254. As a result, 
apoptosis reduces whilst cell survival increases. To examine whether Bcl2 directly 
competes with Nrf2 for Keap1 binding sites, preliminary FRET experiments were 
performed using a 16-mer Bcl2 - BH2 domain peptide. No change in FRET 
efficiency was observed upon addition of BH2 peptide (100 µM, final concentration) 
to the eCFP-TEV-Nrf2 and eYFP-TEV-Kelch protein mixture (0.11 µM and 0.20 µM 
respectively). However, in vitro, the BH2 peptide may not fold into a conformation 
that is recognised by the Keap1 Kelch domain. The Keap1 binding affinity of the 
Bcl2 protein may be determined by future FRET experiments in which the anti-
apoptotic protein is conjugated to an eCFP fluorophore and the Keap1 Kelch protein 






10.2  Crystal structure determination eYFP-TEV-Kelch protein 
 
In 2004, Li et al. 255 determined the crystal structure of the Kelch domain of human 
Keap1. Two years later Lo et al. 46 published the crystal structure of Keap1-Kelch in 
complex with a 16-mer Nrf2 based peptide. In this project an eYFP conjugated 
Kelch protein was expressed and purified for the development of a steady-state 
FRET based assay to identify inhibitors of the Keap1-Nrf2 PPI. To obtain structural 
information regarding the eYFP fusion protein binding properties of peptides and 
small molecules, preliminary experiments were performed to determine the crystal 
structure for the eYFP-TEV-Kelch protein alone and in complex with an Nrf2 based 
7-mer peptide. Following immobilised metal affinity chromatography (IMAC), the 
fluorophore fusion protein was additionally purified using size exclusion 
chromatography. Crystallisation screens with diverse conditions were set up using 
the hanging drop vapour diffusion method. Although the eYFP-TEV-Kelch protein 
benefits from enhanced protein stability due to fluorophore conjugation, no crystals 
were obtained. Future determination of the crystal structure of the eYFP conjugated 
Kelch protein may allow further optimisation of the steady-state FRET based assay 
by providing information regarding the position and orientation of the fluorophore. 
 
10.3 Nrf2 intracellular staining method for flow cytometry 
 
Further assay improvements may be made by including the fluorescent labelling of 
other relevant proteins (phase II enzymes) to enable the measurement of multiple 
parameters in an individual sample and by adapting the assay to a multi-well plate 
format using suitable instruments and further method development to facilitate HTS 
screening.   
 
10.4 Compound combination effect 
 
The combined effect (synergism, additive or antagonism) of direct and indirect 
inducers on the up-regulation of the Nrf2 target gene NQO1 in Hepa1c1c7 cells was 
examined in preliminary experiments to gain better understanding on the disruption 
of the interaction between Keap1 and Nrf2 (data not shown). The hypothesis was 
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that when two compounds target the same site the combined effect may plateau at 
a particular concentration due to occupation of the binding site by either or both 
compounds. Alternatively, combining two mechanistically different molecules could 
result in either an additive or synergistic effect as the target site is dissimilar. 
However, results were inconclusive and follow-up experiments are needed to 
observe possible different effects at a wide dose range. This may aid in the 
development of Nrf2 inducer molecules with multiple mode of actions, hence 
maximizing potency.  
 
10.5 Gene silencing of AhR and Nrf2 
 
Preliminary gene silencing experiments with short hairpin RNA (shRNA) were 
performed to examine the effect of AhR and Nrf2 protein knockdown on Nrf2 
inducer dependent NQO1 induction (Figure 10.1). Transfection of cells with shRNA 
enables long-term gene silencing through stable integration of shRNA 256. Moreover, 
transfection efficiency can be monitored with a co-expressed reporter gene e.g a 
fluorophore. Hepa1c1c7 cells were transfected with an AhR or Nrf2-specific shRNA 
plasmid containing a coding sequence for a Green Fluorescent Protein (GFP) 
(Figure 10.1). Although flow cytometry analysis demonstrated an increase in GFP 
fluorescence in transfected cells, western blots using antibodies against AhR and 
Nrf2 presented no evidence of protein knockdown. Successful protein knockdown 
experiments could aid in the evaluation of a compound’s potential AhR-XRE cross-
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Streptavidin-HRP is used to detect the bound probes. Although this array would 
provide important information regarding the activation of other transcription factors 
upon induction of the Keap1-Nrf2 pathway, the results were inconclusive. Hence, re-
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